<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Comprehensive Drug Reference Guide</title>
    <style>
        * { box-sizing: border-box; }
        
        :root {
            --primary: #2563eb;
            --primary-dark: #1d4ed8;
            --secondary: #059669;
            --warning: #d97706;
            --danger: #dc2626;
            --purple: #7c3aed;
            --bg-light: #f8fafc;
            --border: #e2e8f0;
            --text: #1e293b;
            --text-muted: #64748b;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
            font-size: 10pt;
            line-height: 1.5;
            margin: 0;
            padding: 0;
            color: var(--text);
            background: var(--bg-light);
        }
        
        /* Header */
        .main-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--purple) 100%);
            color: white;
            padding: 25px 30px;
            position: sticky;
            top: 0;
            z-index: 1000;
            box-shadow: 0 2px 10px rgba(0,0,0,0.15);
        }
        
        .main-header h1 {
            margin: 0;
            font-size: 22pt;
            font-weight: 700;
        }
        
        .main-header .subtitle {
            margin: 5px 0 0 0;
            opacity: 0.9;
            font-size: 11pt;
        }
        
        .header-stats {
            display: flex;
            gap: 20px;
            margin-top: 12px;
            flex-wrap: wrap;
        }
        
        .stat-badge {
            background: rgba(255,255,255,0.2);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 10pt;
        }
        
        /* Search */
        .search-container {
            background: white;
            padding: 15px 30px;
            border-bottom: 1px solid var(--border);
            position: sticky;
            top: 95px;
            z-index: 999;
        }
        
        .search-wrapper {
            max-width: 600px;
            position: relative;
        }
        
        .search-input {
            width: 100%;
            padding: 12px 45px 12px 15px;
            border: 2px solid var(--border);
            border-radius: 10px;
            font-size: 14px;
            background: var(--bg-light);
            -webkit-appearance: none;
        }
        
        .search-input:focus {
            outline: none;
            border-color: var(--primary);
            box-shadow: 0 0 0 3px rgba(37, 99, 235, 0.1);
        }
        
        .search-clear {
            position: absolute;
            right: 12px;
            top: 50%;
            transform: translateY(-50%);
            background: var(--border);
            border: none;
            width: 24px;
            height: 24px;
            border-radius: 50%;
            cursor: pointer;
            display: none;
            align-items: center;
            justify-content: center;
            font-size: 12px;
        }
        
        .search-results-count {
            margin-top: 8px;
            font-size: 12px;
            color: var(--text-muted);
        }
        
        /* Container */
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: 20px;
        }
        
        /* Navigation */
        .nav-section {
            background: white;
            border-radius: 12px;
            padding: 20px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.08);
        }
        
        .nav-title {
            font-size: 14pt;
            font-weight: 700;
            color: var(--primary);
            margin: 0 0 15px 0;
            border-bottom: 2px solid var(--primary);
            padding-bottom: 8px;
        }
        
        .category-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(280px, 1fr));
            gap: 10px;
        }
        
        .category-link {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 10px 12px;
            background: var(--bg-light);
            border: 1px solid var(--border);
            border-radius: 8px;
            text-decoration: none;
            color: var(--text);
            transition: all 0.2s;
        }
        
        .category-link:hover {
            background: var(--primary);
            color: white;
            border-color: var(--primary);
        }
        
        .category-icon {
            font-size: 16px;
        }
        
        .category-name {
            font-weight: 600;
            font-size: 11pt;
        }
        
        .category-count {
            margin-left: auto;
            background: white;
            padding: 2px 8px;
            border-radius: 10px;
            font-size: 10px;
            font-weight: 600;
            color: var(--text-muted);
        }
        
        /* Drug Category Sections */
        .drug-category {
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.08);
            overflow: hidden;
        }
        
        .category-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 15px 20px;
            cursor: pointer;
            display: flex;
            align-items: center;
            justify-content: space-between;
        }
        
        .category-header h2 {
            margin: 0;
            font-size: 14pt;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        
        .category-header .toggle {
            font-size: 16px;
            transition: transform 0.3s;
        }
        
        .category-header.collapsed .toggle {
            transform: rotate(-90deg);
        }
        
        .category-content {
            padding: 15px 20px;
        }
        
        .category-content.collapsed {
            display: none;
        }
        
        /* Drug Cards */
        .drug-card {
            border: 1px solid var(--border);
            border-radius: 10px;
            margin-bottom: 15px;
            overflow: hidden;
            transition: box-shadow 0.2s;
        }
        
        .drug-card:hover {
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
        }
        
        .drug-card.hidden {
            display: none;
        }
        
        .drug-header {
            background: var(--bg-light);
            padding: 12px 15px;
            border-bottom: 1px solid var(--border);
            cursor: pointer;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        
        .drug-name {
            font-weight: 700;
            font-size: 12pt;
            color: var(--primary-dark);
        }
        
        .drug-brand {
            font-size: 10pt;
            color: var(--text-muted);
            font-style: italic;
        }
        
        .drug-class-badge {
            margin-left: auto;
            background: var(--primary);
            color: white;
            padding: 3px 10px;
            border-radius: 15px;
            font-size: 9pt;
            font-weight: 600;
        }
        
        .drug-toggle {
            color: var(--text-muted);
            font-size: 14px;
        }
        
        .drug-body {
            padding: 15px;
            display: none;
        }
        
        .drug-body.expanded {
            display: block;
        }
        
        .drug-section {
            margin-bottom: 12px;
        }
        
        .drug-section:last-child {
            margin-bottom: 0;
        }
        
        .drug-section-title {
            font-weight: 700;
            font-size: 10pt;
            color: var(--secondary);
            margin-bottom: 4px;
            display: flex;
            align-items: center;
            gap: 6px;
        }
        
        .drug-section-content {
            font-size: 10pt;
            color: var(--text);
        }
        
        .drug-section-content ul {
            margin: 4px 0;
            padding-left: 18px;
        }
        
        .drug-section-content li {
            margin: 3px 0;
        }
        
        /* Special boxes */
        .warning-box {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 6px;
            padding: 10px;
            margin: 10px 0;
            font-size: 9.5pt;
        }
        
        .warning-box::before {
            content: "‚ö†Ô∏è ";
        }
        
        .black-box {
            background: #1f2937;
            color: white;
            border-radius: 6px;
            padding: 10px;
            margin: 10px 0;
            font-size: 9.5pt;
        }
        
        .black-box::before {
            content: "‚ò†Ô∏è BLACK BOX: ";
            font-weight: bold;
        }
        
        .pearl-box {
            background: #dbeafe;
            border: 1px solid var(--primary);
            border-radius: 6px;
            padding: 10px;
            margin: 10px 0;
            font-size: 9.5pt;
        }
        
        .pearl-box::before {
            content: "üíé ";
        }
        
        /* Cross-links */
        .cross-links {
            margin-top: 10px;
            padding-top: 10px;
            border-top: 1px dashed var(--border);
        }
        
        .cross-links-title {
            font-size: 9pt;
            color: var(--text-muted);
            margin-bottom: 5px;
        }
        
        .guide-link {
            display: inline-block;
            background: var(--bg-light);
            border: 1px solid var(--border);
            padding: 3px 8px;
            border-radius: 4px;
            font-size: 9pt;
            text-decoration: none;
            color: var(--primary);
            margin-right: 5px;
            margin-bottom: 5px;
        }
        
        .guide-link:hover {
            background: var(--primary);
            color: white;
        }
        
        /* Dosing table */
        .dosing-table {
            width: 100%;
            border-collapse: collapse;
            font-size: 9.5pt;
            margin: 8px 0;
        }
        
        .dosing-table th, .dosing-table td {
            border: 1px solid var(--border);
            padding: 6px 10px;
            text-align: left;
        }
        
        .dosing-table th {
            background: var(--bg-light);
            font-weight: 600;
        }
        
        /* Footer */
        .footer {
            background: #1e293b;
            color: white;
            padding: 30px;
            text-align: center;
            margin-top: 30px;
        }
        
        .footer p {
            margin: 5px 0;
            opacity: 0.8;
            font-size: 10pt;
        }
        
        .back-to-top {
            display: inline-block;
            background: var(--primary);
            color: white;
            padding: 8px 16px;
            border-radius: 6px;
            text-decoration: none;
            font-size: 10pt;
            margin-top: 10px;
        }
        
        /* Responsive */
        @media (max-width: 1024px) {
            .specialty-container {
                grid-template-columns: repeat(2, 1fr);
            }
        }
        
        @media (max-width: 768px) {
            .category-grid,
            .specialty-container {
                grid-template-columns: 1fr;
            }
            
            .main-header h1 {
                font-size: 18pt;
            }
            
            .search-container {
                top: 85px;
            }
        }
        
        /* Print */
        @media print {
            .main-header, .search-container, .nav-section {
                display: none;
            }
            
            .drug-body {
                display: block !important;
            }
            
            .drug-card {
                page-break-inside: avoid;
            }
        }
        
        /* Category-specific colors */
        .cat-antibiotics { --cat-color: #dc2626; }
        .cat-cardiac { --cat-color: #e11d48; }
        .cat-anticoag { --cat-color: #9333ea; }
        .cat-neuro { --cat-color: #2563eb; }
        .cat-pulm { --cat-color: #0891b2; }
        .cat-gi { --cat-color: #059669; }
        .cat-endo { --cat-color: #ca8a04; }
        .cat-rheum { --cat-color: #7c3aed; }
        .cat-renal { --cat-color: #0d9488; }
        .cat-tox { --cat-color: #dc2626; }
        .cat-pain { --cat-color: #ea580c; }
        .cat-psych { --cat-color: #6366f1; }
        .cat-other { --cat-color: #64748b; }

        /* Specialty Navigation */
        .specialty-container {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(280px, 1fr));
            gap: 15px;
        }
        
        .specialty-card {
            background: linear-gradient(135deg, #f8f9fa 0%, #ffffff 100%);
            border: 1px solid var(--border);
            border-radius: 12px;
            overflow: hidden;
            transition: all 0.2s;
        }
        
        .specialty-card:hover {
            box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            transform: translateY(-2px);
        }
        
        .specialty-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 12px 15px;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        
        .specialty-icon {
            font-size: 20px;
        }
        
        .specialty-name {
            font-weight: 700;
            font-size: 12pt;
        }
        
        .specialty-links {
            padding: 12px 15px;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }
        
        .specialty-links a {
            display: inline-block;
            padding: 5px 10px;
            background: var(--bg-light);
            border: 1px solid var(--border);
            border-radius: 15px;
            font-size: 10pt;
            color: var(--text);
            text-decoration: none;
            transition: all 0.2s;
        }
        
        .specialty-links a:hover {
            background: var(--primary);
            color: white;
            border-color: var(--primary);
        }
        
        /* Collapsible specialty sections */
        .nav-section h2 {
            cursor: pointer;
            user-select: none;
        }
        
        .nav-section h2::after {
            content: ' ‚ñº';
            font-size: 10pt;
            opacity: 0.5;
        }
        
        .nav-section.collapsed .category-grid,
        .nav-section.collapsed .specialty-container {
            display: none;
        }
        
        .nav-section.collapsed h2::after {
            content: ' ‚ñ∂';
        }

    </style>
</head>
<body>

<div class="main-header">
    <h1>üíä Comprehensive Drug Reference Guide</h1>
    <p class="subtitle">Clinical Pharmacology for Hospital Medicine ‚Ä¢ Cross-linked to IMCRG, Nephrology, Rheumatology & ID Guides</p>
    <div class="header-stats">
        <span class="stat-badge">üìä 172 Medications</span>
        <span class="stat-badge">üè• 12 Specialties ‚Ä¢ üìÅ 42 Categories</span>
        <span class="stat-badge">üîó Cross-Referenced</span>
        <span class="stat-badge">üì± iPad Optimized</span>
    </div>
</div>

<div class="search-container">
    <div class="search-wrapper">
        <input type="text" class="search-input" id="drugSearch" placeholder="Search by drug name, class, or indication..." autocomplete="off" autocorrect="off" autocapitalize="off" spellcheck="false">
        <button class="search-clear" id="searchClear" type="button">‚úï</button>
    </div>
    <div class="search-results-count" id="searchResults"></div>
</div>

<div class="container">

<!-- NAVIGATION -->
<!-- SPECIALTY NAVIGATION -->
<div class="nav-section" id="specialty-nav">
    <h2 class="nav-title">üè• Browse by Medical Specialty</h2>
    <div class="specialty-container">
        
        <div class="specialty-card" id="spec-id">
            <div class="specialty-header">
                <span class="specialty-icon">ü¶†</span>
                <span class="specialty-name">Infectious Disease</span>
            </div>
            <div class="specialty-links">
                <a href="#antibiotics-penicillins">Penicillins</a>
                <a href="#antibiotics-cephalosporins">Cephalosporins</a>
                <a href="#antibiotics-carbapenems">Carbapenems</a>
                <a href="#antibiotics-glycopeptides">Glycopeptides</a>
                <a href="#antibiotics-fluoroquinolones">Fluoroquinolones</a>
                <a href="#antibiotics-other">Other Antibiotics</a>
                <a href="#antibiotics-additional">Additional Abx</a>
                <a href="#antifungals">Antifungals</a>
                <a href="#antivirals">Antivirals</a>
                <a href="#antiparasitics">Antiparasitics</a>
            </div>
        </div>

        <div class="specialty-card" id="spec-cards">
            <div class="specialty-header">
                <span class="specialty-icon">‚ù§Ô∏è</span>
                <span class="specialty-name">Cardiology</span>
            </div>
            <div class="specialty-links">
                <a href="#cardiac-antihypertensives">Antihypertensives</a>
                <a href="#cardiac-antiarrhythmics">Antiarrhythmics</a>
                <a href="#cardiac-additional">Nitrates/Statins/ARNI</a>
                <a href="#anticoagulants">Anticoagulants</a>
                <a href="#anticoag-additional">DTIs/Fondaparinux</a>
                <a href="#hematology">Antiplatelets/TXA</a>
            </div>
        </div>

        <div class="specialty-card" id="spec-pulm-cc">
            <div class="specialty-header">
                <span class="specialty-icon">ü´Å</span>
                <span class="specialty-name">Pulm / Critical Care</span>
            </div>
            <div class="specialty-links">
                <a href="#pulmonary">Bronchodilators/ICS</a>
                <a href="#cardiac-vasopressors">Vasopressors/Inotropes</a>
                <a href="#icu-sedation">ICU Sedation</a>
                <a href="#anesthesia">Paralytics/Induction</a>
                <a href="#pain-sedation">Opioids/Sedatives</a>
                <a href="#electrolytes">Electrolyte Replacement</a>
                <a href="#reversal">Reversal Agents</a>
            </div>
        </div>

        <div class="specialty-card" id="spec-gi">
            <div class="specialty-header">
                <span class="specialty-icon">ü´É</span>
                <span class="specialty-name">Gastroenterology</span>
            </div>
            <div class="specialty-links">
                <a href="#gi-meds">PPIs/Lactulose/Octreotide</a>
                <a href="#bowel-regimen">Bowel Regimen</a>
                <a href="#antiemetics">Antiemetics</a>
            </div>
        </div>

        <div class="specialty-card" id="spec-nephro">
            <div class="specialty-header">
                <span class="specialty-icon">ü´ò</span>
                <span class="specialty-name">Nephrology</span>
            </div>
            <div class="specialty-links">
                <a href="#electrolytes">Electrolyte Replacement</a>
                <a href="#k-binders">Potassium Binders</a>
                <a href="#phosphate">Phosphate Replacement</a>
                <a href="#heme-nephro">EPO/Iron/Sevelamer</a>
                <a href="#cardiac-antihypertensives">ACEi/ARB/Diuretics</a>
            </div>
        </div>

        <div class="specialty-card" id="spec-endo">
            <div class="specialty-header">
                <span class="specialty-icon">ü¶ã</span>
                <span class="specialty-name">Endocrinology</span>
            </div>
            <div class="specialty-links">
                <a href="#diabetes">Diabetes Medications</a>
                <a href="#endocrine">Thyroid/Insulin/D50</a>
                <a href="#corticosteroids">Corticosteroids</a>
            </div>
        </div>

        <div class="specialty-card" id="spec-rheum">
            <div class="specialty-header">
                <span class="specialty-icon">ü¶¥</span>
                <span class="specialty-name">Rheumatology</span>
            </div>
            <div class="specialty-links">
                <a href="#dmards-biologics">DMARDs & Biologics</a>
                <a href="#gout">Gout Medications</a>
                <a href="#corticosteroids">Corticosteroids</a>
                <a href="#immunosuppressants">Immunosuppressants</a>
                <a href="#pain-additional">NSAIDs/Colchicine</a>
            </div>
        </div>

        <div class="specialty-card" id="spec-neuro">
            <div class="specialty-header">
                <span class="specialty-icon">üß†</span>
                <span class="specialty-name">Neurology / Psychiatry</span>
            </div>
            <div class="specialty-links">
                <a href="#anticonvulsants">Anticonvulsants</a>
                <a href="#neuro-psych">Antipsychotics/tPA</a>
                <a href="#psych-additional">Antidepressants/Sleep</a>
                <a href="#pain-additional">Gabapentinoids</a>
            </div>
        </div>

        <div class="specialty-card" id="spec-heme">
            <div class="specialty-header">
                <span class="specialty-icon">ü©∏</span>
                <span class="specialty-name">Hematology / Oncology</span>
            </div>
            <div class="specialty-links">
                <a href="#anticoagulants">Anticoagulants</a>
                <a href="#anticoag-additional">HIT Treatment</a>
                <a href="#hematology">G-CSF/TXA/Vit K/PCC</a>
                <a href="#heme-nephro">EPO/Iron/DDAVP</a>
                <a href="#reversal">Reversal Agents</a>
                <a href="#immunosuppressants">Immunosuppressants</a>
            </div>
        </div>

        <div class="specialty-card" id="spec-tox">
            <div class="specialty-header">
                <span class="specialty-icon">‚ò†Ô∏è</span>
                <span class="specialty-name">Toxicology / Emergency</span>
            </div>
            <div class="specialty-links">
                <a href="#toxicology">Antidotes</a>
                <a href="#reversal">Reversal Agents</a>
                <a href="#misc">Epinephrine/Glucagon</a>
                <a href="#anesthesia">RSI Agents</a>
            </div>
        </div>

        <div class="specialty-card" id="spec-pain">
            <div class="specialty-header">
                <span class="specialty-icon">üíä</span>
                <span class="specialty-name">Pain / Palliative</span>
            </div>
            <div class="specialty-links">
                <a href="#pain-sedation">Opioids/Benzos</a>
                <a href="#pain-additional">Dilaudid/Toradol/Gabapentin</a>
                <a href="#antiemetics">Antiemetics</a>
                <a href="#bowel-regimen">Bowel Regimen</a>
            </div>
        </div>

        <div class="specialty-card" id="spec-general">
            <div class="specialty-header">
                <span class="specialty-icon">üè†</span>
                <span class="specialty-name">General / Primary Care</span>
            </div>
            <div class="specialty-links">
                <a href="#vitamins">Vitamins B1/B9/B12</a>
                <a href="#misc">IV Fluids/Albumin</a>
                <a href="#antiemetics">Antiemetics</a>
                <a href="#bowel-regimen">Laxatives</a>
            </div>
        </div>

    </div>
</div>

<div class="nav-section" id="toc">
    <h2 class="nav-title">üìö Quick Navigation by Category</h2>
    <div class="category-grid">
        <a href="#antibiotics-penicillins" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Antibiotics - Penicillins</span>
        </a>
        <a href="#antibiotics-cephalosporins" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Antibiotics - Cephalosporins</span>
        </a>
        <a href="#antibiotics-carbapenems" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Antibiotics - Carbapenems</span>
        </a>
        <a href="#antibiotics-glycopeptides" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Antibiotics - Glycopeptides</span>
        </a>
        <a href="#antibiotics-fluoroquinolones" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Antibiotics - Fluoroquinolones</span>
        </a>
        <a href="#antibiotics-other" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Antibiotics - Other Classes</span>
        </a>
        <a href="#antibiotics-additional" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Additional Antibiotics</span>
        </a>
        <a href="#anticoagulants" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Anticoagulants</span>
        </a>
        <a href="#anticoag-additional" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Additional Anticoagulants</span>
        </a>
        <a href="#cardiac-vasopressors" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Vasopressors & Inotropes</span>
        </a>
        <a href="#cardiac-antihypertensives" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Antihypertensives</span>
        </a>
        <a href="#cardiac-antiarrhythmics" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Antiarrhythmics</span>
        </a>
        <a href="#cardiac-additional" class="category-link">
            <span class="category-icon">‚ù§Ô∏è</span>
            <span class="category-name">Additional Cardiac</span>
        </a>
        <a href="#antifungals" class="category-link">
            <span class="category-icon">üçÑ</span>
            <span class="category-name">Antifungals</span>
        </a>
        <a href="#antivirals" class="category-link">
            <span class="category-icon">ü¶†</span>
            <span class="category-name">Antivirals</span>
        </a>
        <a href="#antiparasitics" class="category-link">
            <span class="category-icon">ü¶ü</span>
            <span class="category-name">Antiparasitics</span>
        </a>
        <a href="#corticosteroids" class="category-link">
            <span class="category-icon">üíâ</span>
            <span class="category-name">Corticosteroids</span>
        </a>
        <a href="#diabetes" class="category-link">
            <span class="category-icon">üç¨</span>
            <span class="category-name">Diabetes Medications</span>
        </a>
        <a href="#gi-meds" class="category-link">
            <span class="category-icon">ü´Å</span>
            <span class="category-name">GI / Hepatic</span>
        </a>
        <a href="#bowel-regimen" class="category-link">
            <span class="category-icon">üöΩ</span>
            <span class="category-name">Bowel Regimen / GI</span>
        </a>
        <a href="#immunosuppressants" class="category-link">
            <span class="category-icon">üõ°Ô∏è</span>
            <span class="category-name">Immunosuppressants</span>
        </a>
        <a href="#dmards-biologics" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">DMARDs & Biologics</span>
        </a>
        <a href="#pain-sedation" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Pain & Sedation</span>
        </a>
        <a href="#pain-additional" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Additional Pain Meds</span>
        </a>
        <a href="#icu-sedation" class="category-link">
            <span class="category-icon">üè•</span>
            <span class="category-name">ICU Sedation</span>
        </a>
        <a href="#anticonvulsants" class="category-link">
            <span class="category-icon">üß†</span>
            <span class="category-name">Anticonvulsants</span>
        </a>
        <a href="#neuro-psych" class="category-link">
            <span class="category-icon">üß†</span>
            <span class="category-name">Neurology / Psychiatry</span>
        </a>
        <a href="#psych-additional" class="category-link">
            <span class="category-icon">üß†</span>
            <span class="category-name">Additional Psychiatry</span>
        </a>
        <a href="#antiemetics" class="category-link">
            <span class="category-icon">ü§¢</span>
            <span class="category-name">Antiemetics</span>
        </a>
        <a href="#pulmonary" class="category-link">
            <span class="category-icon">ü´Å</span>
            <span class="category-name">Pulmonary Medications</span>
        </a>
        <a href="#hematology" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Hematology Agents</span>
        </a>
        <a href="#heme-nephro" class="category-link">
            <span class="category-icon">ü©∏</span>
            <span class="category-name">Heme/Nephrology Agents</span>
        </a>
        <a href="#endocrine" class="category-link">
            <span class="category-icon">ü¶ã</span>
            <span class="category-name">Endocrine Medications</span>
        </a>
        <a href="#gout" class="category-link">
            <span class="category-icon">üíé</span>
            <span class="category-name">Gout Medications</span>
        </a>
        <a href="#electrolytes" class="category-link">
            <span class="category-icon">‚öóÔ∏è</span>
            <span class="category-name">Electrolyte Replacement</span>
        </a>
        <a href="#k-binders" class="category-link">
            <span class="category-icon">‚öóÔ∏è</span>
            <span class="category-name">Potassium Binders</span>
        </a>
        <a href="#phosphate" class="category-link">
            <span class="category-icon">‚öóÔ∏è</span>
            <span class="category-name">Phosphate Replacement</span>
        </a>
        <a href="#toxicology" class="category-link">
            <span class="category-icon">‚ò†Ô∏è</span>
            <span class="category-name">Toxicology & Antidotes</span>
        </a>
        <a href="#anesthesia" class="category-link">
            <span class="category-icon">üí®</span>
            <span class="category-name">Anesthesia / Paralytics</span>
        </a>
        <a href="#reversal" class="category-link">
            <span class="category-icon">‚Ü©Ô∏è</span>
            <span class="category-name">Reversal Agents</span>
        </a>
        <a href="#vitamins" class="category-link">
            <span class="category-icon">üíä</span>
            <span class="category-name">Vitamins & Supplements</span>
        </a>
        <a href="#misc" class="category-link">
            <span class="category-icon">üì¶</span>
            <span class="category-name">Miscellaneous</span>
        </a>
    </div>
</div>

<!-- ======================= ANTIBIOTICS - PENICILLINS ======================= -->
<div class="drug-category" id="antibiotics-penicillins">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Penicillins</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">
        
        <!-- PENICILLIN G -->
        <div class="drug-card" data-search="penicillin g benzylpenicillin streptococcal pharyngitis syphilis endocarditis beta-lactam cell wall">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Penicillin G</span>
                <span class="drug-brand">(Benzylpenicillin)</span>
                <span class="drug-class-badge">Œ≤-Lactam</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds penicillin-binding proteins (PBPs), inhibiting cell wall synthesis ‚Üí bactericidal</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Streptococci (GAS, GBS, viridans), <em>Treponema pallidum</em></li>
                            <li><strong>Key uses:</strong> Strep pharyngitis, syphilis (all stages), native valve endocarditis (strep), neurosyphilis</li>
                            <li><strong>Not active:</strong> Staph aureus (penicillinase producers), most gram-negatives</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Strep pharyngitis</td><td>Pen VK 500mg PO BID-TID √ó 10 days</td></tr>
                            <tr><td>Syphilis (primary/secondary)</td><td>Benzathine PCN G 2.4 MU IM √ó 1</td></tr>
                            <tr><td>Neurosyphilis</td><td>Aqueous PCN G 3-4 MU IV q4h √ó 10-14 days</td></tr>
                            <tr><td>Strep endocarditis</td><td>PCN G 12-18 MU/day IV divided q4h √ó 4 weeks</td></tr>
                        </table>
                        <p><strong>Renal adjustment:</strong> CrCl &lt;10: reduce dose 25-50%</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypersensitivity reactions (rash, anaphylaxis ~0.01%)</li>
                            <li>Jarisch-Herxheimer reaction (syphilis treatment)</li>
                            <li>High-dose: seizures, interstitial nephritis, hyperkalemia (K+ in PCN G potassium)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Cross-reactivity with cephalosporins ~1-2% (much lower than previously thought). Safe to use cephalosporins in most PCN allergies unless severe IgE-mediated reaction.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Syphilis</a>
                </div>
            </div>
        </div>

        <!-- AMPICILLIN -->
        <div class="drug-card" data-search="ampicillin aminopenicillin listeria enterococcus meningitis beta-lactam cell wall">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ampicillin</span>
                <span class="drug-brand">(Principen)</span>
                <span class="drug-class-badge">Aminopenicillin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤-lactam; broader gram-negative coverage than PCN G due to enhanced outer membrane penetration</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Key coverage:</strong> <em>Listeria monocytogenes</em>, <em>Enterococcus faecalis</em>, <em>E. coli</em> (some), <em>H. influenzae</em> (non-Œ≤-lactamase)</li>
                            <li><strong>Primary uses:</strong> Listeria meningitis, enterococcal endocarditis, GBS prophylaxis</li>
                            <li><strong>Combination therapy:</strong> + gentamicin for enterococcal endocarditis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Listeria meningitis</td><td>2g IV q4h √ó 21 days</td></tr>
                            <tr><td>Enterococcal endocarditis</td><td>2g IV q4h + gentamicin √ó 4-6 weeks</td></tr>
                            <tr><td>GBS prophylaxis (labor)</td><td>2g IV then 1g q4h until delivery</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Maculopapular rash (especially in EBV infection - NOT true allergy)</li>
                            <li>Diarrhea, <em>C. difficile</em></li>
                            <li>Allergic interstitial nephritis</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">High incidence of rash if given to patients with mononucleosis (EBV) - this is NOT a true penicillin allergy</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Listeria</a>
                </div>
            </div>
        </div>

        <!-- AMPICILLIN-SULBACTAM -->
        <div class="drug-card" data-search="ampicillin sulbactam unasyn aspiration pneumonia diabetic foot beta-lactamase inhibitor">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ampicillin-Sulbactam</span>
                <span class="drug-brand">(Unasyn)</span>
                <span class="drug-class-badge">Œ≤-Lactam/BLI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Sulbactam inhibits Œ≤-lactamases ‚Üí restores ampicillin activity. Sulbactam itself has activity against <em>Acinetobacter</em></div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Extended coverage:</strong> MSSA, anaerobes (Bacteroides), Œ≤-lactamase producing organisms</li>
                            <li><strong>Key uses:</strong> Aspiration pneumonia, diabetic foot infections (mild-moderate), skin/soft tissue, intra-abdominal</li>
                            <li><strong>Unique:</strong> <em>Acinetobacter baumannii</em> (due to sulbactam)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>3g IV q6h</td></tr>
                            <tr><td>Acinetobacter</td><td>3g IV q4h or 9g/day continuous</td></tr>
                            <tr><td>CrCl 15-29</td><td>1.5g IV q12h</td></tr>
                            <tr><td>CrCl &lt;15</td><td>1.5g IV q24h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Diarrhea, GI upset</li>
                            <li>Rash, hypersensitivity</li>
                            <li>C. diff colitis</li>
                            <li>Seizures (high doses, renal impairment)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Sulbactam component has intrinsic activity against Acinetobacter - use high-dose sulbactam (9g/day) for MDR Acinetobacter infections</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#diabetic-foot-infection" class="guide-link">IMCRG: Diabetic Foot</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Aspiration PNA</a>
                </div>
            </div>
        </div>

        <!-- PIPERACILLIN-TAZOBACTAM -->
        <div class="drug-card" data-search="piperacillin tazobactam zosyn pip-tazo pseudomonas nosocomial pneumonia neutropenic fever broad spectrum">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Piperacillin-Tazobactam</span>
                <span class="drug-brand">(Zosyn)</span>
                <span class="drug-class-badge">Extended-Spectrum PCN/BLI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Piperacillin: extended-spectrum penicillin with anti-pseudomonal activity. Tazobactam: Œ≤-lactamase inhibitor restoring activity against ESBL producers (variable)</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Strep, enterococci (not VRE), MSSA</li>
                            <li><strong>Gram-negative:</strong> <em>Pseudomonas aeruginosa</em>, Enterobacterales, <em>H. influenzae</em></li>
                            <li><strong>Anaerobes:</strong> Excellent (Bacteroides, etc.)</li>
                            <li><strong>Key uses:</strong> Nosocomial pneumonia, neutropenic fever, intra-abdominal infections, diabetic foot</li>
                            <li><strong>Gaps:</strong> MRSA, Stenotrophomonas, atypicals, some ESBL producers</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>3.375g IV q6h</td></tr>
                            <tr><td>Pseudomonas/severe</td><td>4.5g IV q6h (or 3.375g q6h extended infusion 4hr)</td></tr>
                            <tr><td>CrCl 20-40</td><td>2.25g IV q6h</td></tr>
                            <tr><td>CrCl &lt;20</td><td>2.25g IV q8h</td></tr>
                            <tr><td>HD</td><td>2.25g IV q8h + 0.75g after HD</td></tr>
                        </table>
                        <p><strong>Extended infusion:</strong> Infuse over 4 hours to maximize time above MIC - superior PK/PD</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypokalemia (monitor K+)</li>
                            <li>Leukopenia, thrombocytopenia (prolonged use >14 days)</li>
                            <li>Nephrotoxicity when combined with vancomycin (controversial - likely AIN)</li>
                            <li>Seizures (high doses, renal impairment)</li>
                            <li><em>C. difficile</em> colitis</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Pip-tazo + vancomycin associated with increased AKI compared to cefepime + vancomycin. Consider alternatives if possible.</div>
                <div class="pearl-box">Extended infusion (4hr) is pharmacokinetically superior for serious infections - increases time above MIC</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                    <a href="im_guidev3B20.html#hap" class="guide-link">IMCRG: HAP/VAP</a>
                    <a href="id_guide5_5_integrated.html#empiric-therapy" class="guide-link">ID Guide: Empiric Therapy</a>
                </div>
            </div>
        </div>

        <!-- NAFCILLIN -->
        <div class="drug-card" data-search="nafcillin antistaphylococcal mssa endocarditis osteomyelitis penicillinase-resistant">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Nafcillin</span>
                <span class="drug-brand">(Nallpen)</span>
                <span class="drug-class-badge">Anti-Staph PCN</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Penicillinase-resistant penicillin; resists staph Œ≤-lactamase (not MRSA mecA)</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Primary target:</strong> MSSA - drug of choice for serious MSSA infections</li>
                            <li><strong>Key uses:</strong> MSSA bacteremia, endocarditis, osteomyelitis, septic arthritis</li>
                            <li><strong>NOT for:</strong> MRSA, enterococci, gram-negatives</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>MSSA endocarditis</td><td>2g IV q4h √ó 6 weeks</td></tr>
                            <tr><td>MSSA bacteremia</td><td>2g IV q4h √ó 2-4 weeks</td></tr>
                            <tr><td>Osteomyelitis</td><td>2g IV q4h √ó 4-6 weeks</td></tr>
                        </table>
                        <p><strong>No renal adjustment needed</strong> - hepatic metabolism</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Phlebitis (use central line for prolonged therapy)</li>
                            <li>Interstitial nephritis (AIN)</li>
                            <li>Neutropenia (with prolonged use - check CBC weekly)</li>
                            <li>Hepatotoxicity</li>
                            <li>Drug-induced fever</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Nafcillin/oxacillin are preferred over vancomycin for serious MSSA infections - better outcomes, faster clearance of bacteremia</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="im_guidev3B20.html#osteomyelitis" class="guide-link">IMCRG: Osteomyelitis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: MSSA</a>
                </div>
            </div>
        </div>

        <!-- OXACILLIN -->
        <div class="drug-card" data-search="oxacillin antistaphylococcal mssa penicillinase-resistant">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Oxacillin</span>
                <span class="drug-brand">(Bactocill)</span>
                <span class="drug-class-badge">Anti-Staph PCN</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Penicillinase-resistant penicillin; equivalent to nafcillin for MSSA</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Same as nafcillin - MSSA coverage</li>
                            <li>Alternative to nafcillin with similar efficacy</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>2g IV q4h (same as nafcillin)</p>
                        <p>Requires renal adjustment (unlike nafcillin)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Similar to nafcillin</li>
                            <li>Higher rate of hepatotoxicity than nafcillin</li>
                        </ul>
                    </div>
                </div>
            </div>
        </div>

        <!-- DICLOXACILLIN -->
        <div class="drug-card" data-search="dicloxacillin oral mssa cellulitis skin soft tissue">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dicloxacillin</span>
                <span class="drug-brand">(Dynapen)</span>
                <span class="drug-class-badge">Oral Anti-Staph PCN</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Oral penicillinase-resistant penicillin for MSSA</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>MSSA skin/soft tissue infections</li>
                            <li>Step-down therapy from IV nafcillin/oxacillin</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>500mg PO QID (take on empty stomach)</p>
                        <p>Duration: 5-10 days for uncomplicated SSTI</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GI upset, nausea, diarrhea</li>
                            <li>Hypersensitivity reactions (rash, anaphylaxis rare)</li>
                            <li>Hepatotoxicity (rare, cholestatic)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Must take on empty stomach (1hr before or 2hr after meals) - food significantly reduces absorption. QID dosing limits adherence.</div>
            </div>
        </div>

        <!-- AMOXICILLIN -->
        <div class="drug-card" data-search="amoxicillin aminopenicillin sinusitis otitis pharyngitis helicobacter">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amoxicillin</span>
                <span class="drug-brand">(Amoxil)</span>
                <span class="drug-class-badge">Aminopenicillin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Oral aminopenicillin; better absorbed than ampicillin</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Strep pharyngitis, sinusitis, otitis media</li>
                            <li>Community-acquired pneumonia (in combination)</li>
                            <li><em>H. pylori</em> triple therapy component</li>
                            <li>Endocarditis prophylaxis (dental procedures)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Strep pharyngitis</td><td>500mg PO BID or 1g PO daily √ó 10 days</td></tr>
                            <tr><td>Sinusitis</td><td>500mg PO TID or 875mg PO BID √ó 5-10 days</td></tr>
                            <tr><td>H. pylori (triple)</td><td>1g PO BID √ó 14 days</td></tr>
                            <tr><td>Endocarditis prophylaxis</td><td>2g PO 30-60 min before procedure</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Diarrhea, GI upset</li>
                            <li>Rash (common; "amox rash" in EBV infection)</li>
                            <li>Hypersensitivity reactions</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Maculopapular rash occurs in 70-100% of patients with EBV (mono) given amoxicillin - this is NOT a true allergy (type IV reaction). Avoid unnecessary penicillin allergy labels.</div>
            </div>
        </div>

        <!-- AMOXICILLIN-CLAVULANATE -->
        <div class="drug-card" data-search="amoxicillin clavulanate augmentin bite wounds sinusitis diabetic foot beta-lactamase inhibitor">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amoxicillin-Clavulanate</span>
                <span class="drug-brand">(Augmentin)</span>
                <span class="drug-class-badge">Aminopenicillin/BLI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Clavulanate inhibits Œ≤-lactamases ‚Üí extends amoxicillin spectrum</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Extended coverage:</strong> MSSA, Œ≤-lactamase producing H. influenzae, M. catarrhalis, anaerobes</li>
                            <li><strong>Key uses:</strong> Bite wounds (human/animal), acute sinusitis, UTI, mild diabetic foot, aspiration PNA</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>875/125mg PO BID</td></tr>
                            <tr><td>Severe/respiratory</td><td>2000/125mg (XR) PO BID</td></tr>
                            <tr><td>Bite wounds</td><td>875/125mg PO BID √ó 3-5 days (prophylaxis) or 5-10 days (treatment)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Diarrhea</strong> (clavulanate dose-dependent - use BID formulations)</li>
                            <li>Hepatotoxicity (cholestatic - "Augmentin hepatitis")</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Bite wounds (cat, dog, human) - Augmentin is first-line. Cat bites have highest infection rate. Cover Pasteurella, oral anaerobes, and staph/strep.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#ssti" class="guide-link">IMCRG: Skin/Soft Tissue</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Bite Wounds</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTIBIOTICS - CEPHALOSPORINS ======================= -->
<div class="drug-category" id="antibiotics-cephalosporins">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Cephalosporins</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- CEFAZOLIN -->
        <div class="drug-card" data-search="cefazolin ancef first generation surgical prophylaxis mssa cellulitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cefazolin</span>
                <span class="drug-brand">(Ancef, Kefzol)</span>
                <span class="drug-class-badge">1st Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤-lactam; binds PBPs, inhibits cell wall synthesis. Best gram-positive coverage of cephalosporins.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> MSSA (excellent), Streptococci</li>
                            <li><strong>Gram-negative:</strong> E. coli, Klebsiella, Proteus (limited)</li>
                            <li><strong>Key uses:</strong> Surgical prophylaxis (#1), MSSA infections, UTI, SSTI</li>
                            <li><strong>Alternative to nafcillin</strong> for MSSA with slightly less efficacy but better tolerability</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Surgical prophylaxis</td><td>2g IV within 60 min of incision (redose q4h if prolonged)</td></tr>
                            <tr><td>MSSA bacteremia</td><td>2g IV q8h</td></tr>
                            <tr><td>Skin/soft tissue</td><td>1-2g IV q8h</td></tr>
                            <tr><td>CrCl 35-54</td><td>1g IV q8h</td></tr>
                            <tr><td>CrCl 11-34</td><td>500mg IV q12h</td></tr>
                            <tr><td>CrCl ‚â§10</td><td>500mg IV q24h</td></tr>
                        </table>
                        <p><strong>Weight-based surgical prophylaxis:</strong> 2g if &lt;120kg, 3g if ‚â•120kg</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Generally well-tolerated</li>
                            <li>Cross-reactivity with penicillins ~1-2%</li>
                            <li>Interstitial nephritis (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Cefazolin can be used for most MSSA infections as alternative to nafcillin. Data for MSSA endocarditis is emerging but nafcillin remains standard.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#ssti" class="guide-link">IMCRG: SSTI</a>
                    <a href="id_guide5_5_integrated.html#surgical-prophylaxis" class="guide-link">ID Guide: Surgical Prophylaxis</a>
                </div>
            </div>
        </div>

        <!-- CEPHALEXIN -->
        <div class="drug-card" data-search="cephalexin keflex oral first generation cellulitis uti skin">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cephalexin</span>
                <span class="drug-brand">(Keflex)</span>
                <span class="drug-class-badge">1st Gen (Oral)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds PBPs, inhibits cell wall synthesis. 1st gen = excellent gram-positive (MSSA, strep), limited gram-negative.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Oral equivalent of cefazolin</li>
                            <li><strong>Key uses:</strong> Non-purulent cellulitis, uncomplicated UTI, strep pharyngitis (PCN allergy)</li>
                            <li>Step-down from IV cefazolin</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Cellulitis</td><td>500mg PO QID √ó 5-10 days</td></tr>
                            <tr><td>UTI (uncomplicated)</td><td>500mg PO BID √ó 3-7 days</td></tr>
                            <tr><td>Strep pharyngitis</td><td>500mg PO BID √ó 10 days</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GI upset, diarrhea</li>
                            <li>Hypersensitivity (cross-reactivity with PCN ~1-2%)</li>
                            <li>C. diff (like all antibiotics)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Non-purulent cellulitis (no abscess) = strep > staph ‚Üí cephalexin is appropriate. Purulent cellulitis (abscess, pus) = staph likely ‚Üí needs MRSA coverage (TMP-SMX, doxy)</div>
            </div>
        </div>

        <!-- CEFTRIAXONE -->
        <div class="drug-card" data-search="ceftriaxone rocephin third generation meningitis pneumonia gonorrhea once daily long half-life">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ceftriaxone</span>
                <span class="drug-brand">(Rocephin)</span>
                <span class="drug-class-badge">3rd Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">3rd generation cephalosporin with excellent gram-negative coverage and CSF penetration. Long half-life allows once-daily dosing.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Strep (including S. pneumoniae), but NOT MSSA (poor coverage)</li>
                            <li><strong>Gram-negative:</strong> Excellent - E. coli, Klebsiella, Proteus, H. influenzae, N. meningitidis, N. gonorrhoeae</li>
                            <li><strong>Key uses:</strong> CAP, meningitis, gonorrhea, pyelonephritis, Lyme disease, SBP prophylaxis</li>
                            <li><strong>Gaps:</strong> Pseudomonas, ESBL producers, Enterococcus, Listeria, anaerobes</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>CAP</td><td>1-2g IV daily + azithromycin</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q12h</td></tr>
                            <tr><td>Gonorrhea</td><td>500mg IM √ó 1 (if &lt;150kg) or 1g IM √ó 1 (if ‚â•150kg)</td></tr>
                            <tr><td>Pyelonephritis</td><td>1g IV daily</td></tr>
                            <tr><td>Lyme disease (neuro/cardiac)</td><td>2g IV daily √ó 14-28 days</td></tr>
                            <tr><td>SBP prophylaxis</td><td>1g IV daily or 400mg PO norfloxacin daily</td></tr>
                        </table>
                        <p><strong>No renal adjustment needed</strong> (hepatic/biliary excretion)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Biliary sludging/pseudolithiasis (especially prolonged high doses)</li>
                            <li><strong>Do NOT mix with calcium-containing solutions</strong> (precipitates)</li>
                            <li>Ceftriaxone-induced hemolytic anemia (rare but serious)</li>
                            <li>Vitamin K antagonism (prolonged PT/INR)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Do NOT use with calcium-containing IV solutions (precipitation). In neonates, avoid coadministration with calcium products.</div>
                <div class="pearl-box">Ceftriaxone does NOT cover MSSA well - don't use alone for staph infections. Add vancomycin for empiric MRSA coverage.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cap" class="guide-link">IMCRG: CAP</a>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="im_guidev3B20.html#sbp" class="guide-link">IMCRG: SBP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- CEFEPIME -->
        <div class="drug-card" data-search="cefepime maxipime fourth generation pseudomonas neutropenic fever hap nosocomial">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cefepime</span>
                <span class="drug-brand">(Maxipime)</span>
                <span class="drug-class-badge">4th Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">4th generation with enhanced stability against AmpC Œ≤-lactamases and anti-pseudomonal activity. Zwitterionic structure ‚Üí rapid penetration.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Good strep coverage, MSSA (better than CTX)</li>
                            <li><strong>Gram-negative:</strong> Excellent including <em>Pseudomonas aeruginosa</em></li>
                            <li><strong>AmpC stability:</strong> Active against Enterobacter, Citrobacter, Serratia</li>
                            <li><strong>Key uses:</strong> Neutropenic fever, HAP/VAP, complicated UTI, meningitis</li>
                            <li><strong>Gaps:</strong> MRSA, anaerobes, ESBL producers, Acinetobacter</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Neutropenic fever</td><td>2g IV q8h</td></tr>
                            <tr><td>HAP/VAP</td><td>2g IV q8h</td></tr>
                            <tr><td>Complicated UTI</td><td>1-2g IV q12h</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q8h</td></tr>
                            <tr><td>CrCl 30-60</td><td>2g IV q12h</td></tr>
                            <tr><td>CrCl 11-29</td><td>2g IV q24h</td></tr>
                            <tr><td>CrCl ‚â§10 or HD</td><td>1g IV q24h</td></tr>
                        </table>
                        <p><strong>Extended infusion:</strong> 2g over 3-4 hours improves PK/PD</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Neurotoxicity:</strong> Encephalopathy, seizures, myoclonus (especially with renal impairment - MUST dose adjust)</li>
                            <li>Rash, diarrhea</li>
                            <li>Positive Coombs test</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Cefepime neurotoxicity: Patients with renal impairment at high risk for encephalopathy, myoclonus, seizures. ALWAYS adjust dose for renal function.</div>
                <div class="pearl-box">Cefepime is stable against AmpC Œ≤-lactamases (SPACE organisms: Serratia, Pseudomonas, Acinetobacter, Citrobacter, Enterobacter) - use for Enterobacter infections instead of 3rd gen cephalosporins.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#neutropenic-fever" class="guide-link">IMCRG: Neutropenic Fever</a>
                    <a href="im_guidev3B20.html#hap" class="guide-link">IMCRG: HAP/VAP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- CEFTAZIDIME -->
        <div class="drug-card" data-search="ceftazidime fortaz tazicef third generation pseudomonas meningitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ceftazidime</span>
                <span class="drug-brand">(Fortaz, Tazicef)</span>
                <span class="drug-class-badge">3rd Gen (Anti-Pseudomonal)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds PBPs, inhibits cell wall synthesis. Anti-pseudomonal 3rd gen with enhanced gram-negative activity.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Key feature:</strong> Anti-pseudomonal 3rd generation cephalosporin</li>
                            <li>Excellent gram-negative coverage including Pseudomonas</li>
                            <li><strong>Weak gram-positive coverage</strong> (weaker than ceftriaxone)</li>
                            <li><strong>Uses:</strong> Pseudomonal infections, meningitis, CF exacerbations</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Pseudomonas infections</td><td>2g IV q8h</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q8h</td></tr>
                            <tr><td>CrCl 31-50</td><td>1g IV q12h</td></tr>
                            <tr><td>CrCl 16-30</td><td>1g IV q24h</td></tr>
                            <tr><td>CrCl ‚â§15</td><td>500mg IV q24h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Diarrhea, C. diff</li>
                            <li>Hypersensitivity, rash</li>
                            <li>Neurotoxicity (seizures, encephalopathy in renal failure)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Ceftazidime has WEAK gram-positive activity - do not use as monotherapy when gram-positives are suspected</div>
            </div>
        </div>

        <!-- CEFOTAXIME -->
        <div class="drug-card" data-search="cefotaxime claforan third generation meningitis neonates">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cefotaxime</span>
                <span class="drug-brand">(Claforan)</span>
                <span class="drug-class-badge">3rd Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds PBPs, inhibits cell wall synthesis. 3rd gen = enhanced gram-negative, good CNS penetration.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Similar to ceftriaxone but shorter half-life (q6-8h dosing)</li>
                            <li><strong>Preferred in neonates</strong> (no biliary sludging like ceftriaxone)</li>
                            <li>Meningitis, serious gram-negative infections</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>1-2g IV q6-8h (standard infections)</p>
                        <p>Meningitis: 2g IV q4-6h</p>
                        <p><strong>Renal adjustment:</strong> CrCl <20: reduce frequency</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypersensitivity, rash</li>
                            <li>Diarrhea, C. diff</li>
                            <li>Leukopenia (prolonged use)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Use instead of ceftriaxone in neonates - ceftriaxone causes biliary sludging and displaces bilirubin from albumin (kernicterus risk).</div>
            </div>
        </div>

        <!-- CEFTAROLINE -->
        <div class="drug-card" data-search="ceftaroline teflaro fifth generation mrsa cap ssti">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ceftaroline</span>
                <span class="drug-brand">(Teflaro)</span>
                <span class="drug-class-badge">5th Gen Cephalosporin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds PBP2a (mecA-encoded) ‚Üí activity against MRSA. Only Œ≤-lactam with MRSA activity.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Unique feature:</strong> MRSA coverage (only cephalosporin)</li>
                            <li>Also covers MSSA, Strep (including PRSP), common gram-negatives</li>
                            <li><strong>FDA indications:</strong> CAP, acute bacterial skin/soft tissue infections</li>
                            <li><strong>NOT anti-pseudomonal</strong></li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>CAP</td><td>600mg IV q12h √ó 5-7 days</td></tr>
                            <tr><td>ABSSSI</td><td>600mg IV q12h √ó 5-14 days</td></tr>
                            <tr><td>CrCl 31-50</td><td>400mg IV q12h</td></tr>
                            <tr><td>CrCl 15-30</td><td>300mg IV q12h</td></tr>
                            <tr><td>HD</td><td>200mg IV q12h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Diarrhea, nausea</li>
                            <li>Rash, hypersensitivity</li>
                            <li>Positive direct Coombs test (rare hemolytic anemia)</li>
                            <li>C. diff colitis</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Ceftaroline is the only Œ≤-lactam with MRSA activity. Consider for MRSA pneumonia as alternative to vancomycin/linezolid.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTIBIOTICS - CARBAPENEMS ======================= -->
<div class="drug-category" id="antibiotics-carbapenems">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Carbapenems</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- MEROPENEM -->
        <div class="drug-card" data-search="meropenem merrem carbapenem broad spectrum esbl meningitis seizure">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Meropenem</span>
                <span class="drug-brand">(Merrem)</span>
                <span class="drug-class-badge">Carbapenem</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤-lactam with broadest spectrum; stable against most Œ≤-lactamases including ESBLs and AmpC. Binds PBP2.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Broadest Œ≤-lactam spectrum:</strong> Gram-positive (not MRSA, not Enterococcus faecium), Gram-negative (including Pseudomonas, ESBL producers), Anaerobes</li>
                            <li><strong>Key uses:</strong> ESBL infections, severe nosocomial infections, meningitis (best CNS penetration), neutropenic fever</li>
                            <li><strong>Gaps:</strong> MRSA, VRE, <em>Stenotrophomonas</em>, atypicals, carbapenem-resistant organisms (CRE)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>1g IV q8h</td></tr>
                            <tr><td>Meningitis</td><td>2g IV q8h</td></tr>
                            <tr><td>Pseudomonas/severe</td><td>2g IV q8h</td></tr>
                            <tr><td>CrCl 26-50</td><td>1g IV q12h</td></tr>
                            <tr><td>CrCl 10-25</td><td>500mg IV q12h</td></tr>
                            <tr><td>CrCl &lt;10</td><td>500mg IV q24h</td></tr>
                        </table>
                        <p><strong>Extended infusion:</strong> 3-hour infusion improves PK/PD for serious infections</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Seizures (lower risk than imipenem)</li>
                            <li>Diarrhea, <em>C. difficile</em></li>
                            <li>Rash</li>
                            <li>Drug interactions: lowers valproic acid levels significantly</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Carbapenems dramatically lower valproic acid levels (up to 80% reduction) ‚Üí seizure risk. Avoid combination or use alternative antibiotic.</div>
                <div class="pearl-box">Meropenem preferred over imipenem for CNS infections - better CSF penetration and lower seizure threshold.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: ESBL</a>
                </div>
            </div>
        </div>

        <!-- IMIPENEM-CILASTATIN -->
        <div class="drug-card" data-search="imipenem cilastatin primaxin carbapenem broad spectrum seizure">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Imipenem-Cilastatin</span>
                <span class="drug-brand">(Primaxin)</span>
                <span class="drug-class-badge">Carbapenem</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Imipenem = carbapenem antibiotic. Cilastatin = inhibits renal dehydropeptidase (prevents imipenem degradation in kidneys)</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Similar broad spectrum to meropenem</li>
                            <li><strong>Slightly better Enterococcus faecalis coverage</strong></li>
                            <li>Nosocomial infections, polymicrobial infections</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>500mg IV q6h</td></tr>
                            <tr><td>Severe/Pseudomonas</td><td>1g IV q6-8h</td></tr>
                            <tr><td>CrCl 41-70</td><td>500mg IV q8h</td></tr>
                            <tr><td>CrCl 21-40</td><td>250-500mg IV q6-12h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Highest seizure risk of carbapenems</strong> (avoid in CNS infections)</li>
                            <li>Nausea/vomiting (more than meropenem)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Imipenem has the HIGHEST seizure risk among carbapenems. Avoid in CNS infections and patients with seizure history. Use meropenem instead.</div>
            </div>
        </div>

        <!-- ERTAPENEM -->
        <div class="drug-card" data-search="ertapenem invanz carbapenem once daily outpatient esbl no pseudomonas">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ertapenem</span>
                <span class="drug-brand">(Invanz)</span>
                <span class="drug-class-badge">Carbapenem</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Once-daily carbapenem. Long half-life allows outpatient parenteral therapy (OPAT).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Similar to meropenem EXCEPT:</strong> NO Pseudomonas activity, NO Acinetobacter activity</li>
                            <li>Excellent for ESBL producers</li>
                            <li><strong>Key uses:</strong> ESBL UTI/intra-abdominal, community infections, OPAT</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard</td><td>1g IV/IM daily</td></tr>
                            <tr><td>CrCl &lt;30</td><td>500mg IV daily</td></tr>
                        </table>
                        <p>Can give IM for OPAT (mix with lidocaine)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Diarrhea, nausea</li>
                            <li>Seizures (rare, caution in renal impairment/CNS disorders)</li>
                            <li>C. diff colitis</li>
                            <li>Injection site pain (IM)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Ertapenem has NO Pseudomonas coverage - do not use for suspected Pseudomonas infections. Great for OPAT due to once-daily dosing.</div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTIBIOTICS - GLYCOPEPTIDES ======================= -->
<div class="drug-category" id="antibiotics-glycopeptides">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Glycopeptides & Lipoglycopeptides</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- VANCOMYCIN -->
        <div class="drug-card" data-search="vancomycin mrsa clostridium difficile cdiff gram positive trough nephrotoxicity red man">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Vancomycin</span>
                <span class="drug-brand">(Vancocin)</span>
                <span class="drug-class-badge">Glycopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds D-Ala-D-Ala terminus of peptidoglycan precursors ‚Üí inhibits cell wall synthesis. Time-dependent killing with AUC/MIC target.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive only:</strong> MRSA, MSSA (if PCN allergic), coagulase-negative staph, Strep (including PCN-resistant), Enterococcus (not VRE)</li>
                            <li><strong>IV uses:</strong> MRSA bacteremia, endocarditis, osteomyelitis, meningitis, pneumonia, skin/soft tissue</li>
                            <li><strong>Oral vancomycin:</strong> <em>C. difficile</em> infection (NOT absorbed - local effect only)</li>
                            <li><strong>Gaps:</strong> Gram-negatives, VRE, atypicals</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Indication</th><th>Dose</th></tr>
                            <tr><td rowspan="3">IV</td><td>Loading dose</td><td>25-30 mg/kg (actual body weight) √ó 1</td></tr>
                            <tr><td>Maintenance</td><td>15-20 mg/kg q8-12h (adjust to AUC 400-600)</td></tr>
                            <tr><td>CrCl &lt;50</td><td>Extend interval or use AUC-guided dosing</td></tr>
                            <tr><td rowspan="2">PO</td><td>C. diff (non-severe)</td><td>125mg PO QID √ó 10 days</td></tr>
                            <tr><td>C. diff (severe)</td><td>500mg PO QID + metronidazole 500mg IV q8h</td></tr>
                        </table>
                        <p><strong>AUC-guided dosing:</strong> Target AUC/MIC 400-600 (replaces trough-based dosing per 2020 guidelines)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>AUC-guided dosing preferred</strong> over trough-only monitoring</li>
                            <li>If using troughs: target 15-20 mcg/mL for serious MRSA infections</li>
                            <li>Renal function (SCr) - monitor closely with concomitant nephrotoxins</li>
                            <li>Trough before 4th dose (steady state)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Red Man Syndrome:</strong> Histamine release from rapid infusion ‚Üí flushing, pruritus, hypotension. NOT an allergy. Prevent with slower infusion (‚â•1hr for 1g)</li>
                            <li><strong>Nephrotoxicity:</strong> Risk increases with high troughs, prolonged therapy, concomitant nephrotoxins (pip-tazo, aminoglycosides)</li>
                            <li>Ototoxicity (rare, usually with high doses)</li>
                            <li>Neutropenia (prolonged use >2 weeks - check CBC weekly)</li>
                            <li>DRESS syndrome (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Infuse over ‚â•60 minutes (‚â•1g) or ‚â•90 minutes (>1g) to prevent Red Man Syndrome. This is a histamine reaction, NOT an allergy.</div>
                <div class="pearl-box">Oral vancomycin is NOT absorbed systemically - use ONLY for C. difficile colitis. IV vancomycin does NOT reach therapeutic levels in the colon.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cdiff" class="guide-link">IMCRG: C. diff</a>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="id_guide5_5_integrated.html#mrsa" class="guide-link">ID Guide: MRSA</a>
                    <a href="nephrology_study_guide1.html#drugs" class="guide-link">Nephro: Drug Dosing</a>
                </div>
            </div>
        </div>

        <!-- DALBAVANCIN -->
        <div class="drug-card" data-search="dalbavancin dalvance lipoglycopeptide mrsa long-acting opat single dose">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dalbavancin</span>
                <span class="drug-brand">(Dalvance)</span>
                <span class="drug-class-badge">Lipoglycopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Lipoglycopeptide with ultra-long half-life (~14 days). Same mechanism as vancomycin but lipophilic tail enhances potency and duration.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Coverage:</strong> MRSA, MSSA, Streptococci (similar to vancomycin)</li>
                            <li><strong>FDA indication:</strong> Acute bacterial skin/soft tissue infections</li>
                            <li><strong>Off-label:</strong> Osteomyelitis, endocarditis (emerging data)</li>
                            <li><strong>Advantage:</strong> Single or two-dose treatment (outpatient friendly)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Regimen</th><th>Dose</th></tr>
                            <tr><td>Single-dose</td><td>1500mg IV √ó 1</td></tr>
                            <tr><td>Two-dose</td><td>1000mg IV day 1, then 500mg IV day 8</td></tr>
                            <tr><td>CrCl &lt;30 (not on HD)</td><td>1125mg IV √ó 1 or 750mg then 375mg</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Nausea, headache</li>
                            <li>Infusion reactions (slow infusion rate)</li>
                            <li>Diarrhea</li>
                            <li>Generally well-tolerated</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Dalbavancin allows completion of MRSA treatment with 1-2 IV doses - ideal for patients with adherence concerns, IV access issues, or preference to avoid daily antibiotics.</div>
            </div>
        </div>

        <!-- ORITAVANCIN -->
        <div class="drug-card" data-search="oritavancin orbactiv lipoglycopeptide mrsa single dose ssti">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Oritavancin</span>
                <span class="drug-brand">(Orbactiv)</span>
                <span class="drug-class-badge">Lipoglycopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Lipoglycopeptide with ultra-long half-life (~245 hours). Inhibits cell wall synthesis + disrupts membrane integrity (dual mechanism).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Coverage:</strong> MRSA, MSSA, Streptococci (including VRE with vanA - unlike dalbavancin)</li>
                            <li><strong>FDA indication:</strong> Acute bacterial skin/soft tissue infections</li>
                            <li><strong>Advantage:</strong> Single-dose treatment</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>1200mg IV √ó 1 (infuse over 3 hours)</p>
                        <p>No dose adjustment for renal impairment</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Nausea, headache, vomiting</li>
                            <li>Infusion reactions</li>
                            <li>Limb/subcutaneous abscess</li>
                            <li><strong>Interferes with coagulation tests</strong></li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Oritavancin interferes with coagulation tests (PT/INR, aPTT) for up to 5 days after administration - use alternative anticoagulation monitoring if needed. Avoid in patients on IV unfractionated heparin.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTIBIOTICS - FLUOROQUINOLONES ======================= -->
<div class="drug-category" id="antibiotics-fluoroquinolones">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Fluoroquinolones</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- CIPROFLOXACIN -->
        <div class="drug-card" data-search="ciprofloxacin cipro fluoroquinolone uti pseudomonas traveler diarrhea anthrax tendon">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ciprofloxacin</span>
                <span class="drug-brand">(Cipro)</span>
                <span class="drug-class-badge">Fluoroquinolone</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV ‚Üí bactericidal. Concentration-dependent killing.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-negative:</strong> Excellent - E. coli, Klebsiella, Proteus, <em>Pseudomonas aeruginosa</em></li>
                            <li><strong>Atypicals:</strong> Legionella</li>
                            <li><strong>Gram-positive:</strong> POOR (except some activity vs Bacillus anthracis)</li>
                            <li><strong>Key uses:</strong> UTI/pyelonephritis, Pseudomonal infections, traveler's diarrhea, anthrax</li>
                            <li><strong>Gaps:</strong> S. pneumoniae (weak), MRSA, anaerobes</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Uncomplicated UTI</td><td>250mg PO BID √ó 3 days</td></tr>
                            <tr><td>Complicated UTI/pyelonephritis</td><td>500mg PO BID or 400mg IV q12h √ó 7-14 days</td></tr>
                            <tr><td>Pseudomonal infections</td><td>750mg PO BID or 400mg IV q8h</td></tr>
                            <tr><td>Traveler's diarrhea</td><td>500mg PO BID √ó 1-3 days</td></tr>
                            <tr><td>CrCl &lt;30</td><td>Reduce dose by 50%</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Tendinopathy/rupture</strong> (especially Achilles, especially with steroids, elderly, renal impairment)</li>
                            <li><strong>QTc prolongation</strong></li>
                            <li>Peripheral neuropathy (may be irreversible)</li>
                            <li>CNS effects: headache, insomnia, seizures</li>
                            <li>Hypoglycemia (especially in diabetics on sulfonylureas)</li>
                            <li>Aortic aneurysm/dissection (rare)</li>
                            <li>Photosensitivity</li>
                            <li><em>C. difficile</em></li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">FDA Black Box Warning: Tendinitis/rupture, peripheral neuropathy, CNS effects, exacerbation of myasthenia gravis, aortic aneurysm. Reserve for when no alternatives available.</div>
                <div class="warning-box">Do NOT give with cations (calcium, magnesium, aluminum, iron) - chelation significantly reduces absorption. Separate by 2-6 hours.</div>
                <div class="pearl-box">Cipro has POOR S. pneumoniae coverage - do NOT use as monotherapy for respiratory infections. Use respiratory FQ (levofloxacin, moxifloxacin) instead.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#uti" class="guide-link">IMCRG: UTI</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Pseudomonas</a>
                </div>
            </div>
        </div>

        <!-- LEVOFLOXACIN -->
        <div class="drug-card" data-search="levofloxacin levaquin respiratory fluoroquinolone cap pneumonia streptococcus">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Levofloxacin</span>
                <span class="drug-brand">(Levaquin)</span>
                <span class="drug-class-badge">Respiratory FQ</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">L-isomer of ofloxacin; "respiratory fluoroquinolone" with enhanced gram-positive activity including S. pneumoniae.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> S. pneumoniae (including PRSP), MSSA</li>
                            <li><strong>Gram-negative:</strong> Similar to cipro, <em>Pseudomonas</em> (but cipro preferred)</li>
                            <li><strong>Atypicals:</strong> Legionella, Mycoplasma, Chlamydia</li>
                            <li><strong>Key uses:</strong> CAP monotherapy, HAP, UTI, sinusitis, chronic bronchitis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>CAP</td><td>750mg PO/IV daily √ó 5 days</td></tr>
                            <tr><td>HAP</td><td>750mg PO/IV daily √ó 7-14 days</td></tr>
                            <tr><td>UTI (complicated)</td><td>750mg PO/IV daily √ó 5-14 days</td></tr>
                            <tr><td>CrCl 20-49</td><td>750mg q48h or 500mg daily</td></tr>
                            <tr><td>CrCl 10-19</td><td>750mg then 500mg q48h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <p>Same as ciprofloxacin - all FQ class warnings apply</p>
                    </div>
                </div>
                <div class="pearl-box">Levofloxacin is the respiratory FQ of choice when a single agent covering typical and atypical pathogens is needed (CAP monotherapy in PCN-allergic patients).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cap" class="guide-link">IMCRG: CAP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- MOXIFLOXACIN -->
        <div class="drug-card" data-search="moxifloxacin avelox respiratory fluoroquinolone cap anaerobes qtc">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Moxifloxacin</span>
                <span class="drug-brand">(Avelox)</span>
                <span class="drug-class-badge">Respiratory FQ</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits DNA gyrase (gram-negative) and topoisomerase IV (gram-positive). Enhanced gram-positive activity compared to ciprofloxacin.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Best gram-positive coverage of FQs (S. pneumoniae, MSSA)</li>
                            <li><strong>Anaerobic activity</strong> (unique among FQs - covers Bacteroides)</li>
                            <li><strong>NO Pseudomonas activity</strong></li>
                            <li><strong>Uses:</strong> CAP, intra-abdominal infections (with anaerobic coverage), TB (MDR)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>400mg PO/IV daily (no renal adjustment needed)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Highest QTc prolongation risk</strong> among FQs</li>
                            <li>All FQ class warnings</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Moxifloxacin has the highest risk of QTc prolongation among FQs. Avoid in patients with baseline QTc prolongation or on other QT-prolonging drugs.</div>
                <div class="pearl-box">Moxifloxacin is the only FQ with clinically useful anaerobic coverage. No Pseudomonas activity - don't use for suspected Pseudomonal infections.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTIBIOTICS - OTHER ======================= -->
<div class="drug-category" id="antibiotics-other">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Antibiotics - Other Classes</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- METRONIDAZOLE -->
        <div class="drug-card" data-search="metronidazole flagyl anaerobes cdiff clostridium giardia trichomonas">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Metronidazole</span>
                <span class="drug-brand">(Flagyl)</span>
                <span class="drug-class-badge">Nitroimidazole</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Prodrug activated in anaerobic/microaerophilic organisms ‚Üí forms toxic intermediates that damage DNA. Selective for anaerobes.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Anaerobes:</strong> Bacteroides fragilis, Clostridium spp., Fusobacterium, Prevotella</li>
                            <li><strong>Protozoa:</strong> <em>Giardia lamblia</em>, <em>Trichomonas vaginalis</em>, <em>Entamoeba histolytica</em></li>
                            <li><strong>Key uses:</strong> Anaerobic infections, C. diff (second-line), BV, trichomoniasis, giardiasis, H. pylori</li>
                            <li><strong>Gaps:</strong> Aerobes, Actinomyces, Propionibacterium</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Anaerobic infections</td><td>500mg IV/PO q8h</td></tr>
                            <tr><td>C. diff (non-severe, first episode)</td><td>500mg PO TID √ó 10-14 days (vancomycin preferred)</td></tr>
                            <tr><td>Giardiasis</td><td>250mg PO TID √ó 5-7 days</td></tr>
                            <tr><td>Trichomoniasis</td><td>2g PO √ó 1 or 500mg BID √ó 7 days</td></tr>
                            <tr><td>H. pylori (triple therapy)</td><td>500mg PO BID √ó 14 days</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Disulfiram-like reaction with alcohol</strong> (avoid alcohol during and 3 days after)</li>
                            <li>Metallic taste</li>
                            <li>Peripheral neuropathy (prolonged use)</li>
                            <li>Nausea, dark urine</li>
                            <li>CNS effects (seizures with high doses)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Disulfiram-like reaction: Severe nausea, vomiting, flushing, headache with alcohol. Avoid alcohol during therapy and 3 days after completion.</div>
                <div class="pearl-box">For C. diff: Oral vancomycin is now preferred over metronidazole per IDSA guidelines. Metronidazole reserved for when vancomycin unavailable or as adjunct in severe/fulminant disease.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cdiff" class="guide-link">IMCRG: C. diff</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: Anaerobes</a>
                </div>
            </div>
        </div>

        <!-- DOXYCYCLINE -->
        <div class="drug-card" data-search="doxycycline tetracycline atypical cap mrsa community lyme tick rickettsial">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Doxycycline</span>
                <span class="drug-brand">(Vibramycin)</span>
                <span class="drug-class-badge">Tetracycline</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds 30S ribosomal subunit ‚Üí inhibits protein synthesis. Bacteriostatic.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Atypicals:</strong> Mycoplasma, Chlamydia, Legionella</li>
                            <li><strong>Tick-borne:</strong> Rickettsia (RMSF), Ehrlichia, Anaplasma, Borrelia (Lyme)</li>
                            <li><strong>CA-MRSA:</strong> Variable but often active</li>
                            <li><strong>Other:</strong> Vibrio, Brucella, some Nocardia, malaria prophylaxis</li>
                            <li><strong>Key uses:</strong> CAP (with Œ≤-lactam), MRSA skin infections, Lyme disease, STIs (Chlamydia), tick-borne infections, acne</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Most infections</td><td>100mg PO/IV BID</td></tr>
                            <tr><td>Chlamydia</td><td>100mg PO BID √ó 7 days</td></tr>
                            <tr><td>Lyme (early)</td><td>100mg PO BID √ó 10-21 days</td></tr>
                            <tr><td>RMSF/Ehrlichia</td><td>100mg PO/IV BID √ó 7-14 days</td></tr>
                            <tr><td>CA-MRSA skin</td><td>100mg PO BID √ó 5-10 days</td></tr>
                        </table>
                        <p><strong>No renal adjustment needed</strong> (fecal excretion)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Photosensitivity (use sunscreen)</li>
                            <li>GI upset, esophagitis (take with water, stay upright 30 min)</li>
                            <li>Tooth discoloration in children &lt;8 years (avoid in pregnancy)</li>
                            <li>Pill esophagitis (take with full glass of water)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Doxycycline is the drug of choice for ALL tick-borne rickettsial infections (RMSF, Ehrlichia, Anaplasma). Do NOT delay treatment while awaiting diagnostic confirmation - early doxycycline is life-saving.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cap" class="guide-link">IMCRG: CAP</a>
                    <a href="im_guidev3B20.html#ssti" class="guide-link">IMCRG: SSTI</a>
                    <a href="id_guide5_5_integrated.html#tickborne-infections" class="guide-link">ID Guide: Tick-borne</a>
                </div>
            </div>
        </div>

        <!-- LINEZOLID -->
        <div class="drug-card" data-search="linezolid zyvox oxazolidinone mrsa vre vap pneumonia serotonin mao">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Linezolid</span>
                <span class="drug-brand">(Zyvox)</span>
                <span class="drug-class-badge">Oxazolidinone</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds 50S ribosomal subunit at unique site ‚Üí inhibits initiation complex formation. Bacteriostatic (bactericidal vs some strep). Also weak MAO inhibitor.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive only:</strong> MRSA, VRE (including E. faecium), PRSP, VISA/VRSA</li>
                            <li><strong>Key uses:</strong> MRSA pneumonia (may be superior to vanc), VRE infections, serious MRSA when vancomycin not tolerated</li>
                            <li><strong>Excellent oral bioavailability</strong> (~100% - IV and PO equivalent)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p>600mg PO/IV q12h (no renal adjustment)</p>
                        <p>Duration depends on infection - typically 10-28 days</p>
                        <p><strong>Limit therapy to ‚â§2 weeks if possible</strong> due to toxicity</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Myelosuppression:</strong> Thrombocytopenia (reversible), anemia - monitor CBC weekly</li>
                            <li><strong>Peripheral/optic neuropathy</strong> (prolonged use >28 days)</li>
                            <li><strong>Serotonin syndrome</strong> with SSRIs, SNRIs, MAOIs, meperidine, tramadol</li>
                            <li>Lactic acidosis (rare, prolonged therapy)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Serotonin syndrome risk: Avoid concurrent use with SSRIs, SNRIs, MAOIs, tramadol, meperidine. If unavoidable, monitor closely for serotonin syndrome.</div>
                <div class="pearl-box">Linezolid has 100% oral bioavailability - PO and IV doses are equivalent. Preferred for MRSA pneumonia per some data showing better lung penetration than vancomycin.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#hap" class="guide-link">IMCRG: HAP/VAP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: VRE</a>
                </div>
            </div>
        </div>

        <!-- TMP-SMX -->
        <div class="drug-card" data-search="tmp-smx trimethoprim sulfamethoxazole bactrim septra mrsa pcp pneumocystis uti">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Trimethoprim-Sulfamethoxazole</span>
                <span class="drug-brand">(Bactrim, Septra)</span>
                <span class="drug-class-badge">Sulfonamide/DHFR Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Sequential blockade of folate synthesis: SMX inhibits dihydropteroate synthase, TMP inhibits dihydrofolate reductase. Synergistic bactericidal effect.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>CA-MRSA:</strong> Excellent oral option</li>
                            <li><strong>PCP:</strong> Drug of choice for <em>Pneumocystis jirovecii</em> pneumonia (treatment and prophylaxis)</li>
                            <li><strong>Gram-negative:</strong> E. coli (UTI), Stenotrophomonas</li>
                            <li><strong>Other:</strong> Nocardia, Listeria, Toxoplasma, Isospora</li>
                            <li><strong>Key uses:</strong> UTI, CA-MRSA skin infections, PCP, Stenotrophomonas</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose (TMP component)</th></tr>
                            <tr><td>UTI (uncomplicated)</td><td>DS (160/800) PO BID √ó 3 days</td></tr>
                            <tr><td>MRSA skin infection</td><td>DS PO BID √ó 5-10 days</td></tr>
                            <tr><td>PCP treatment</td><td>15-20 mg/kg/day TMP IV/PO divided q6-8h √ó 21 days</td></tr>
                            <tr><td>PCP prophylaxis</td><td>DS PO daily or SS PO daily</td></tr>
                            <tr><td>Stenotrophomonas</td><td>5 mg/kg TMP IV q8h</td></tr>
                        </table>
                        <p>DS = double strength (160mg TMP/800mg SMX)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hyperkalemia</strong> (TMP blocks ENaC in collecting duct - similar to amiloride)</li>
                            <li>Elevated creatinine (TMP inhibits creatinine secretion - not true AKI)</li>
                            <li>Rash (common), Stevens-Johnson syndrome (rare but serious)</li>
                            <li>Myelosuppression (megaloblastic anemia, leukopenia)</li>
                            <li>Crystalluria (maintain hydration)</li>
                            <li>Photosensitivity</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">TMP-SMX causes hyperkalemia - monitor K+ especially in patients on ACEi/ARB, renal impairment, or elderly. Creatinine rise is often artifactual (TMP inhibits secretion).</div>
                <div class="pearl-box">TMP-SMX is drug of choice for Stenotrophomonas maltophilia - a pan-resistant gram-negative that is intrinsically resistant to carbapenems.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#pcp" class="guide-link">IMCRG: PCP</a>
                    <a href="im_guidev3B20.html#uti" class="guide-link">IMCRG: UTI</a>
                    <a href="nephrology_study_guide1.html#hyperkalemia" class="guide-link">Nephro: Hyperkalemia</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- CLINDAMYCIN -->
        <div class="drug-card" data-search="clindamycin cleocin anaerobes mssa mrsa community aspiration toxin inhibition">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Clindamycin</span>
                <span class="drug-brand">(Cleocin)</span>
                <span class="drug-class-badge">Lincosamide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds 50S ribosome ‚Üí inhibits protein synthesis. Bacteriostatic. Also inhibits toxin production (useful in toxin-mediated diseases).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> Strep (GAS, GBS), MSSA, CA-MRSA (check D-test)</li>
                            <li><strong>Anaerobes above diaphragm:</strong> (not reliable for B. fragilis)</li>
                            <li><strong>Key uses:</strong> Aspiration PNA, necrotizing fasciitis (toxin suppression), skin infections, dental infections</li>
                            <li><strong>Toxin suppression:</strong> Added to Œ≤-lactam for strep/staph toxic shock</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>300-450mg PO TID-QID or 600-900mg IV q8h</td></tr>
                            <tr><td>Severe/toxin-mediated</td><td>900mg IV q8h</td></tr>
                            <tr><td>Necrotizing fasciitis</td><td>900mg IV q8h (added to Œ≤-lactam)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>C. difficile:</strong> Highest risk among antibiotics (historically)</li>
                            <li>Diarrhea (common even without C. diff)</li>
                            <li>Rash</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">High risk of C. difficile colitis - reserve for appropriate indications. Monitor for diarrhea.</div>
                <div class="pearl-box">Add clindamycin for toxin suppression in severe group A strep infections (necrotizing fasciitis, toxic shock) - inhibits bacterial protein/toxin synthesis.</div>
            </div>
        </div>

        <!-- DAPTOMYCIN -->
        <div class="drug-card" data-search="daptomycin cubicin lipopeptide mrsa vre bacteremia endocarditis ck muscle">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Daptomycin</span>
                <span class="drug-brand">(Cubicin)</span>
                <span class="drug-class-badge">Lipopeptide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds bacterial membrane ‚Üí rapid depolarization ‚Üí cell death. Concentration-dependent bactericidal. Unique mechanism - no cross-resistance.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-positive:</strong> MRSA, VRE, VISA/VRSA, streptococci</li>
                            <li><strong>Key uses:</strong> MRSA bacteremia, right-sided endocarditis, complicated skin infections, VRE</li>
                            <li><strong>CANNOT use for pneumonia</strong> - inactivated by pulmonary surfactant</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Skin/soft tissue</td><td>4 mg/kg IV daily</td></tr>
                            <tr><td>Bacteremia/endocarditis</td><td>6-10 mg/kg IV daily (higher doses for severe)</td></tr>
                            <tr><td>VRE bacteremia</td><td>8-10 mg/kg IV daily</td></tr>
                            <tr><td>CrCl &lt;30</td><td>Same dose q48h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Myopathy/rhabdomyolysis:</strong> Monitor CPK weekly - hold if CPK >10√ó ULN or symptoms</li>
                            <li>Eosinophilic pneumonia (rare)</li>
                            <li>Peripheral neuropathy</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">DO NOT use daptomycin for pneumonia - inactivated by pulmonary surfactant. No activity in the lung.</div>
                <div class="warning-box">Monitor CPK weekly. Hold statins during therapy to reduce myopathy risk. Discontinue if CPK >10√ó ULN or symptomatic myopathy.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#endocarditis" class="guide-link">IMCRG: Endocarditis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide: MRSA/VRE</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTICOAGULANTS ======================= -->
<div class="drug-category" id="anticoagulants">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü©∏ Anticoagulants</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- HEPARIN -->
        <div class="drug-card" data-search="heparin unfractionated ufh dvt pe vte acs hit ptt anti-xa">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Unfractionated Heparin (UFH)</span>
                <span class="drug-brand">(Heparin)</span>
                <span class="drug-class-badge">Indirect Thrombin Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds antithrombin III ‚Üí potentiates inhibition of thrombin (IIa), Xa, IXa, XIa, XIIa. Requires ATIII for activity.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>VTE treatment (when rapid reversibility needed)</li>
                            <li>ACS (with PCI)</li>
                            <li>Bridging for procedures</li>
                            <li>Cardiopulmonary bypass</li>
                            <li>Preferred in severe renal impairment (no renal clearance)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>VTE treatment</td><td>80 units/kg bolus, then 18 units/kg/hr infusion</td></tr>
                            <tr><td>ACS/PCI</td><td>60 units/kg bolus (max 4000), 12 units/kg/hr (max 1000)</td></tr>
                            <tr><td>DVT prophylaxis</td><td>5000 units SubQ q8-12h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>aPTT:</strong> Target 1.5-2.5√ó control (typically 60-80 sec) - check q6h until stable</li>
                            <li><strong>Anti-Xa:</strong> Target 0.3-0.7 units/mL (more reliable in some patients)</li>
                            <li><strong>Platelets:</strong> Check baseline and day 4 for HIT screening</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Bleeding</strong> - most common</li>
                            <li><strong>HIT (Heparin-Induced Thrombocytopenia):</strong> Type II - immune-mediated, occurs days 5-14, paradoxical thrombosis</li>
                            <li>Osteoporosis (prolonged use)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <p><strong>Protamine sulfate:</strong> 1 mg per 100 units heparin (max 50 mg). Reduce dose if heparin given >30 min ago.</p>
                    </div>
                </div>
                <div class="warning-box">HIT: If platelets drop >50% or to <150K on days 5-14, calculate 4Ts score. Stop ALL heparin (including flushes) and start alternative anticoagulant (argatroban, bivalirudin).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                    <a href="im_guidev3B20.html#acs" class="guide-link">IMCRG: ACS</a>
                </div>
            </div>
        </div>

        <!-- ENOXAPARIN -->
        <div class="drug-card" data-search="enoxaparin lovenox lmwh low molecular weight heparin dvt pe prophylaxis treatment">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Enoxaparin</span>
                <span class="drug-brand">(Lovenox)</span>
                <span class="drug-class-badge">LMWH</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Low molecular weight heparin; primarily anti-Xa activity (3:1 ratio anti-Xa:anti-IIa). More predictable pharmacokinetics than UFH.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>VTE prophylaxis (medical/surgical patients)</li>
                            <li>VTE treatment</li>
                            <li>ACS/NSTEMI</li>
                            <li>Bridge therapy</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>DVT prophylaxis</td><td>40 mg SubQ daily OR 30 mg SubQ q12h (high-risk)</td></tr>
                            <tr><td>VTE treatment</td><td>1 mg/kg SubQ q12h OR 1.5 mg/kg SubQ daily</td></tr>
                            <tr><td>ACS/NSTEMI</td><td>1 mg/kg SubQ q12h</td></tr>
                            <tr><td>CrCl <30</td><td>Prophylaxis: 30 mg daily; Treatment: 1 mg/kg daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Routine monitoring NOT required (predictable PK)</li>
                            <li><strong>Check anti-Xa levels if:</strong> Obesity, renal impairment, pregnancy, extremes of weight</li>
                            <li>Target anti-Xa (peak, 4h post-dose): 0.6-1.0 units/mL (q12h dosing); 1.0-2.0 (daily dosing)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Reversal</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Bleeding, injection site reactions, HIT (lower risk than UFH)</li>
                            <li><strong>Partial reversal:</strong> Protamine 1 mg per 1 mg enoxaparin (within 8h) - only ~60% reversal</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Avoid enoxaparin in severe renal impairment (CrCl <30) if possible - accumulates. If must use, reduce dose and consider anti-Xa monitoring.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                    <a href="nephrology_study_guide1.html#drugs" class="guide-link">Nephro: Drug Dosing</a>
                </div>
            </div>
        </div>

        <!-- WARFARIN -->
        <div class="drug-card" data-search="warfarin coumadin vitamin k antagonist inr afib mechanical valve dvt pe">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Warfarin</span>
                <span class="drug-brand">(Coumadin)</span>
                <span class="drug-class-badge">Vitamin K Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits vitamin K epoxide reductase ‚Üí blocks synthesis of factors II, VII, IX, X, protein C, protein S. Delayed onset (3-5 days for full effect).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Mechanical heart valves</strong> (DOACs contraindicated)</li>
                            <li>Antiphospholipid syndrome with thrombosis</li>
                            <li>AF, VTE (when DOACs not appropriate)</li>
                            <li>LV thrombus</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing & Targets</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>INR Target</th></tr>
                            <tr><td>AF, VTE, bioprosthetic valve</td><td>2.0-3.0</td></tr>
                            <tr><td>Mechanical mitral valve</td><td>2.5-3.5</td></tr>
                            <tr><td>Mechanical aortic valve (newer)</td><td>2.0-3.0</td></tr>
                        </table>
                        <p>Start 5 mg daily; adjust based on INR (check day 3-4, then q2-3 days until stable)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Interactions & Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>MANY drug interactions</strong> - check every new medication</li>
                            <li>Increase INR: Amiodarone, TMP-SMX, metronidazole, fluconazole, statins</li>
                            <li>Decrease INR: Rifampin, carbamazepine, phenytoin, vitamin K</li>
                            <li>Bleeding, skin necrosis (protein C deficiency), teratogenic</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Reversal</th></tr>
                            <tr><td>Supratherapeutic, no bleeding</td><td>Hold warfarin, ¬± vitamin K 1-2.5mg PO</td></tr>
                            <tr><td>INR >10, no bleeding</td><td>Hold + vitamin K 2.5-5mg PO</td></tr>
                            <tr><td>Serious bleeding</td><td>Hold + 4-factor PCC + vitamin K 10mg IV</td></tr>
                            <tr><td>Life-threatening</td><td>4-factor PCC (25-50 units/kg) + vitamin K 10mg IV</td></tr>
                        </table>
                    </div>
                </div>
                <div class="pearl-box">Warfarin initially causes transient hypercoagulable state (protein C/S deplete faster than clotting factors) - always bridge with heparin for 5 days AND until INR therapeutic √ó2.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                    <a href="rheumatology_study_guide4.html#aps" class="guide-link">Rheum: APS</a>
                </div>
            </div>
        </div>

        <!-- APIXABAN -->
        <div class="drug-card" data-search="apixaban eliquis doac noac factor xa afib dvt pe stroke">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Apixaban</span>
                <span class="drug-brand">(Eliquis)</span>
                <span class="drug-class-badge">Direct Xa Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Direct factor Xa inhibitor. Does not require antithrombin. Predictable PK - no routine monitoring needed.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Nonvalvular AF stroke prevention</li>
                            <li>VTE treatment and prevention</li>
                            <li>VTE prophylaxis (hip/knee replacement)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>AF (standard)</td><td>5 mg PO BID</td></tr>
                            <tr><td>AF (dose reduction*)</td><td>2.5 mg PO BID</td></tr>
                            <tr><td>VTE treatment</td><td>10 mg BID √ó 7 days, then 5 mg BID</td></tr>
                            <tr><td>VTE extended prevention</td><td>2.5 mg PO BID</td></tr>
                            <tr><td>DVT prophylaxis (joint)</td><td>2.5 mg PO BID</td></tr>
                        </table>
                        <p>*Reduce to 2.5 mg BID if ‚â•2 of: age ‚â•80, weight ‚â§60 kg, Cr ‚â•1.5</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Best safety profile</strong> among DOACs (lowest bleeding in ARISTOTLE)</li>
                            <li>Can use in moderate renal impairment (with dose adjustment)</li>
                            <li>Avoid with strong dual CYP3A4/P-gp inhibitors (ketoconazole, ritonavir)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <p><strong>Andexanet alfa (Andexxa):</strong> Specific reversal agent for factor Xa inhibitors</p>
                        <p><strong>4-factor PCC:</strong> If andexanet unavailable</p>
                    </div>
                </div>
                <div class="pearl-box">Apixaban has the best safety data among DOACs - lowest rates of major bleeding in trials. Preferred in elderly and patients with renal impairment (can use down to CrCl 15-25).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                </div>
            </div>
        </div>

        <!-- RIVAROXABAN -->
        <div class="drug-card" data-search="rivaroxaban xarelto doac noac factor xa afib dvt pe once daily">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Rivaroxaban</span>
                <span class="drug-brand">(Xarelto)</span>
                <span class="drug-class-badge">Direct Xa Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Direct, selective factor Xa inhibitor. Oral, once-daily dosing. Partially renally cleared (~36%).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications & Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>AF (CrCl >50)</td><td>20 mg PO daily with food</td></tr>
                            <tr><td>AF (CrCl 15-50)</td><td>15 mg PO daily with food</td></tr>
                            <tr><td>VTE treatment</td><td>15 mg BID √ó 21 days, then 20 mg daily</td></tr>
                            <tr><td>VTE extended</td><td>10 mg PO daily</td></tr>
                            <tr><td>CAD/PAD</td><td>2.5 mg PO BID (with aspirin)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>MUST take with food</strong> for adequate absorption (15 mg and 20 mg doses)</li>
                            <li>Once-daily dosing (advantage for adherence)</li>
                            <li>Higher GI bleeding risk vs apixaban</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Rivaroxaban 15 mg and 20 mg doses MUST be taken with food - absorption reduced by 30-40% if taken fasting.</div>
            </div>
        </div>

        <!-- DABIGATRAN -->
        <div class="drug-card" data-search="dabigatran pradaxa doac noac thrombin inhibitor afib idarucizumab">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dabigatran</span>
                <span class="drug-brand">(Pradaxa)</span>
                <span class="drug-class-badge">Direct Thrombin Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Direct thrombin (factor IIa) inhibitor. Only oral DTI available.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>AF (CrCl >30)</td><td>150 mg PO BID</td></tr>
                            <tr><td>AF (CrCl 15-30)</td><td>75 mg PO BID</td></tr>
                            <tr><td>VTE treatment</td><td>150 mg BID after 5-10 days parenteral</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Higher dyspepsia/GI upset rate</li>
                            <li>Store in original container (moisture-sensitive)</li>
                            <li>Most renally dependent DOAC - avoid if CrCl <15</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <p><strong>Idarucizumab (Praxbind):</strong> Specific reversal agent - 5g IV (given as 2 √ó 2.5g)</p>
                    </div>
                </div>
                <div class="pearl-box">Dabigatran is the only DOAC with a specific, fully effective reversal agent (idarucizumab). Consider for patients at high bleeding risk who may need emergent reversal.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= CARDIAC - VASOPRESSORS ======================= -->
<div class="drug-category" id="cardiac-vasopressors">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚ù§Ô∏è Vasopressors & Inotropes</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- NOREPINEPHRINE -->
        <div class="drug-card" data-search="norepinephrine levophed vasopressor septic shock alpha adrenergic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Norepinephrine</span>
                <span class="drug-brand">(Levophed)</span>
                <span class="drug-class-badge">Œ±1 > Œ≤1 Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Potent Œ±1-adrenergic agonist (vasoconstriction) with mild Œ≤1 activity (inotropy). First-line vasopressor for most shock states.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Septic shock:</strong> First-line vasopressor</li>
                            <li>Distributive shock</li>
                            <li>Cardiogenic shock (with inotrope)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Start:</strong> 0.1-0.5 mcg/kg/min</p>
                        <p><strong>Titrate:</strong> 0.1-0.3 mcg/kg/min increments q5-15 min</p>
                        <p><strong>Typical range:</strong> 0.1-2 mcg/kg/min (can go higher in refractory shock)</p>
                        <p><strong>Target:</strong> MAP ‚â•65 mmHg</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Peripheral ischemia (digits, limbs)</li>
                            <li>Arrhythmias</li>
                            <li>Tissue necrosis with extravasation</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Extravasation causes severe tissue necrosis. Use central line when possible. If peripheral, use large vein, monitor closely, and treat extravasation with phentolamine.</div>
                <div class="pearl-box">Norepinephrine is first-line for septic shock per Surviving Sepsis Campaign. Superior to dopamine (less arrhythmia, lower mortality in some analyses).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                    <a href="nephrology_study_guide1.html#hrs" class="guide-link">Nephro: HRS</a>
                </div>
            </div>
        </div>

        <!-- VASOPRESSIN -->
        <div class="drug-card" data-search="vasopressin pitressin v1 receptor septic shock catecholamine sparing">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Vasopressin</span>
                <span class="drug-brand">(Pitressin)</span>
                <span class="drug-class-badge">V1 Receptor Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">V1 receptor agonist ‚Üí vascular smooth muscle contraction. Non-adrenergic mechanism (works when catecholamine receptors downregulated).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Septic shock (add to norepinephrine if MAP not at goal)</li>
                            <li>Catecholamine-sparing strategy</li>
                            <li>Variceal bleeding (alternative to octreotide)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Septic shock:</strong> 0.03-0.04 units/min (fixed dose, no titration)</p>
                        <p><strong>Variceal bleeding:</strong> 0.2-0.4 units/min</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Digital/mesenteric ischemia (vasoconstriction)</li>
                            <li>Hyponatremia (V2 effect at high doses)</li>
                            <li>Arrhythmias</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Vasopressin is used at FIXED dose (0.03-0.04 units/min) in septic shock - not titrated. Add when norepinephrine dose is escalating to reduce catecholamine requirements.</div>
            </div>
        </div>

        <!-- DOBUTAMINE -->
        <div class="drug-card" data-search="dobutamine inotrope beta1 cardiogenic shock heart failure low output">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dobutamine</span>
                <span class="drug-brand">(Dobutrex)</span>
                <span class="drug-class-badge">Œ≤1 Agonist (Inotrope)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤1 agonist ‚Üí increased contractility and cardiac output. Mild Œ≤2 effect ‚Üí may cause vasodilation and hypotension.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Cardiogenic shock:</strong> Low cardiac output with adequate BP</li>
                            <li>Severe heart failure with hypoperfusion</li>
                            <li>Inotropic support post-cardiac surgery</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Start:</strong> 2.5-5 mcg/kg/min</p>
                        <p><strong>Titrate:</strong> Up to 20 mcg/kg/min</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>May cause hypotension (Œ≤2 vasodilation) - often combined with vasopressor</li>
                            <li>Arrhythmogenic</li>
                            <li>Avoid in severe aortic stenosis</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Dobutamine is an INOTROPE (increases contractility) not a vasopressor. It may DROP blood pressure due to Œ≤2 vasodilation. Often used with norepinephrine in cardiogenic shock.</div>
            </div>
        </div>
<!-- ======================= ANTIFUNGALS ======================= -->
<div class="drug-category" id="antifungals">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üçÑ Antifungals</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- FLUCONAZOLE -->
        <div class="drug-card" data-search="fluconazole diflucan azole candida cryptococcus cyp450 qt">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Fluconazole</span>
                <span class="drug-brand">(Diflucan)</span>
                <span class="drug-class-badge">Triazole</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits lanosterol 14-Œ±-demethylase (CYP51) ‚Üí blocks ergosterol synthesis ‚Üí fungal membrane disruption. Fungistatic.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Candida:</strong> C. albicans, C. parapsilosis, C. tropicalis</li>
                            <li><strong>NOT active:</strong> C. krusei (intrinsic resistance), C. glabrata (often resistant)</li>
                            <li><strong>Cryptococcus:</strong> Maintenance therapy</li>
                            <li><strong>Key uses:</strong> Candidiasis (oropharyngeal, esophageal, vulvovaginal, candidemia), cryptococcal meningitis (consolidation/maintenance)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Oropharyngeal candidiasis</td><td>200 mg day 1, then 100-200 mg daily √ó 7-14 days</td></tr>
                            <tr><td>Esophageal candidiasis</td><td>200-400 mg daily √ó 14-21 days</td></tr>
                            <tr><td>Candidemia</td><td>800 mg load, then 400 mg daily (12 mg/kg load, 6 mg/kg daily)</td></tr>
                            <tr><td>Cryptococcal maintenance</td><td>200 mg daily √ó ‚â•1 year</td></tr>
                            <tr><td>VVC (single dose)</td><td>150 mg PO √ó 1</td></tr>
                        </table>
                        <p><strong>Renal:</strong> Reduce dose 50% if CrCl &lt;50</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Interactions</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>QTc prolongation</li>
                            <li>Hepatotoxicity (monitor LFTs)</li>
                            <li><strong>CYP2C9, 2C19, 3A4 inhibitor:</strong> Many drug interactions (warfarin, phenytoin, cyclosporine, tacrolimus)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Fluconazole has excellent oral bioavailability (~90%) and CSF penetration. First-line for susceptible Candida, but always check species - C. glabrata and C. krusei are often resistant.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#candidemia" class="guide-link">IMCRG: Candidemia</a>
                    <a href="id_guide5_5_integrated.html#fungal-infections" class="guide-link">ID Guide: Fungal</a>
                </div>
            </div>
        </div>

        <!-- MICAFUNGIN -->
        <div class="drug-card" data-search="micafungin mycamine echinocandin candida aspergillus beta glucan">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Micafungin</span>
                <span class="drug-brand">(Mycamine)</span>
                <span class="drug-class-badge">Echinocandin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits Œ≤-(1,3)-D-glucan synthase ‚Üí disrupts fungal cell wall. Fungicidal against Candida, fungistatic against Aspergillus.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Candida:</strong> ALL species including C. glabrata, C. krusei (fluconazole-resistant)</li>
                            <li><strong>Aspergillus:</strong> Salvage therapy</li>
                            <li><strong>NOT active:</strong> Cryptococcus, mucormycosis, endemic fungi</li>
                            <li><strong>Key uses:</strong> Candidemia (first-line for severe/unstable), esophageal candidiasis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Candidemia</td><td>100 mg IV daily</td></tr>
                            <tr><td>Esophageal candidiasis</td><td>150 mg IV daily</td></tr>
                            <tr><td>Prophylaxis (HSCT)</td><td>50 mg IV daily</td></tr>
                        </table>
                        <p>No renal or hepatic adjustment needed</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Excellent safety profile</li>
                            <li>Few drug interactions</li>
                            <li>IV only (no oral formulation)</li>
                            <li>Poor CNS penetration - NOT for CNS infections</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Echinocandins (micafungin, caspofungin, anidulafungin) are first-line for severe/critically ill patients with candidemia - broader spectrum than fluconazole and fungicidal.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="id_guide5_5_integrated.html#fungal-infections" class="guide-link">ID Guide: Fungal</a>
                </div>
            </div>
        </div>

        <!-- VORICONAZOLE -->
        <div class="drug-card" data-search="voriconazole vfend azole aspergillus invasive visual photosensitivity">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Voriconazole</span>
                <span class="drug-brand">(Vfend)</span>
                <span class="drug-class-badge">Triazole</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits fungal CYP450-dependent 14Œ±-demethylase ‚Üí blocks ergosterol synthesis ‚Üí fungistatic (fungicidal vs Aspergillus). Broad spectrum triazole.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>First-line for invasive aspergillosis</strong></li>
                            <li>Broad Candida coverage (including C. krusei)</li>
                            <li>Some activity against endemic fungi, Fusarium, Scedosporium</li>
                            <li>NOT active: Mucormycosis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Loading</th><th>Maintenance</th></tr>
                            <tr><td>IV</td><td>6 mg/kg q12h √ó 2 doses</td><td>4 mg/kg q12h</td></tr>
                            <tr><td>PO (>40 kg)</td><td>400 mg q12h √ó 2 doses</td><td>200 mg q12h</td></tr>
                        </table>
                        <p><strong>Target trough:</strong> 1-5 mcg/mL (monitor weekly)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Visual disturbances</strong> (30%) - transient, reversible</li>
                            <li><strong>Photosensitivity</strong> - sunscreen essential, risk of skin cancer with prolonged use</li>
                            <li>Hepatotoxicity (monitor LFTs)</li>
                            <li>QTc prolongation</li>
                            <li>Many drug interactions (CYP450)</li>
                            <li>Fluorosis (prolonged therapy)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Voriconazole levels are highly variable - therapeutic drug monitoring (TDM) is essential. Target trough 1-5 mcg/mL. Toxicity increases with levels >5.5.</div>
                <div class="pearl-box">Voriconazole is first-line for invasive aspergillosis. Visual side effects ("seeing in technicolor") are common but transient - warn patients.</div>
            </div>
        </div>

        <!-- AMPHOTERICIN B -->
        <div class="drug-card" data-search="amphotericin ambisome liposomal polyene nephrotoxic mucormycosis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amphotericin B Liposomal</span>
                <span class="drug-brand">(AmBisome)</span>
                <span class="drug-class-badge">Polyene</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds ergosterol ‚Üí creates membrane pores ‚Üí fungal cell death. Broadest spectrum antifungal.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Broadest antifungal spectrum:</strong> Candida, Aspergillus, Cryptococcus, endemic fungi, Mucormycosis</li>
                            <li><strong>Key uses:</strong> Mucormycosis (first-line), cryptococcal meningitis (induction), severe/refractory fungal infections</li>
                            <li>NOT active: C. lusitaniae, some Aspergillus terreus</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>3-5 mg/kg IV daily</td></tr>
                            <tr><td>Mucormycosis</td><td>5-10 mg/kg IV daily</td></tr>
                            <tr><td>Cryptococcal meningitis</td><td>3-4 mg/kg IV daily + flucytosine √ó 2 weeks</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Nephrotoxicity:</strong> Less with liposomal than conventional (still monitor Cr, K, Mg daily)</li>
                            <li>Infusion reactions (fever, rigors - premedicate)</li>
                            <li>Hypokalemia, hypomagnesemia</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Amphotericin causes renal tubular toxicity - aggressively replace K+ and Mg2+. Consider NS bolus before infusion to reduce nephrotoxicity.</div>
                <div class="pearl-box">ONLY use liposomal amphotericin (AmBisome) - conventional amphotericin has unacceptable nephrotoxicity. Liposomal is first-line for mucormycosis (only antifungal with reliable activity).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro: Nephrotoxins</a>
                    <a href="id_guide5_5_integrated.html#fungal-infections" class="guide-link">ID Guide: Fungal</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= CORTICOSTEROIDS ======================= -->
<div class="drug-category" id="corticosteroids">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíâ Corticosteroids</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- PREDNISONE -->
        <div class="drug-card" data-search="prednisone glucocorticoid anti-inflammatory immunosuppressive taper">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Prednisone</span>
                <span class="drug-brand">(Deltasone)</span>
                <span class="drug-class-badge">Glucocorticoid</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds glucocorticoid receptor ‚Üí translocates to nucleus ‚Üí modulates gene transcription. Anti-inflammatory and immunosuppressive. Prodrug (converted to prednisolone in liver).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>COPD/asthma exacerbation</li>
                            <li>Autoimmune diseases (RA, SLE, vasculitis, IBD)</li>
                            <li>Allergic reactions</li>
                            <li>Adrenal insufficiency replacement</li>
                            <li>Transplant rejection</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>COPD exacerbation</td><td>40 mg PO daily √ó 5 days</td></tr>
                            <tr><td>Asthma exacerbation</td><td>40-60 mg PO daily √ó 5-7 days</td></tr>
                            <tr><td>Anti-inflammatory</td><td>0.5-1 mg/kg/day</td></tr>
                            <tr><td>High-dose immunosuppression</td><td>1-2 mg/kg/day</td></tr>
                            <tr><td>GCA/PMR</td><td>40-60 mg daily (GCA) or 15-20 mg daily (PMR)</td></tr>
                        </table>
                        <p><strong>Relative potency:</strong> Prednisone 5 mg = Hydrocortisone 20 mg = Dexamethasone 0.75 mg</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Metabolic:</strong> Hyperglycemia, weight gain, cushingoid features</li>
                            <li><strong>Bone:</strong> Osteoporosis, avascular necrosis</li>
                            <li><strong>Infection:</strong> Increased susceptibility, masks fever</li>
                            <li><strong>Psychiatric:</strong> Insomnia, mood changes, psychosis</li>
                            <li><strong>GI:</strong> Peptic ulcer (with NSAIDs), pancreatitis</li>
                            <li><strong>Adrenal:</strong> HPA axis suppression (taper if >3 weeks)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Taper required if used >3 weeks or high doses - HPA axis suppression can cause adrenal crisis if stopped abruptly. PCP prophylaxis if prednisone ‚â•20 mg/day for ‚â•1 month.</div>
                <div class="pearl-box">Short courses (‚â§5 days) can be stopped without taper. For longer courses, typical taper: reduce by 10-20% every 1-2 weeks or 5-10 mg per week.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#copd" class="guide-link">IMCRG: COPD</a>
                    <a href="rheumatology_study_guide4.html" class="guide-link">Rheum Guide</a>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro Guide</a>
                </div>
            </div>
        </div>

        <!-- DEXAMETHASONE -->
        <div class="drug-card" data-search="dexamethasone decadron glucocorticoid long-acting cerebral edema covid meningitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dexamethasone</span>
                <span class="drug-brand">(Decadron)</span>
                <span class="drug-class-badge">Glucocorticoid (Long-Acting)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Properties</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Most potent glucocorticoid (7√ó prednisone)</li>
                            <li>Longest half-life (36-54 hr)</li>
                            <li>Minimal mineralocorticoid activity (no salt/water retention)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Bacterial meningitis</td><td>0.15 mg/kg q6h √ó 4 days (give BEFORE or with first abx dose)</td></tr>
                            <tr><td>Cerebral edema (tumor/mets)</td><td>10 mg IV load, then 4 mg q6h</td></tr>
                            <tr><td>COVID-19 (hypoxic)</td><td>6 mg IV/PO daily √ó 10 days</td></tr>
                            <tr><td>Spinal cord compression</td><td>10-100 mg IV load, then high-dose maintenance</td></tr>
                            <tr><td>Croup</td><td>0.6 mg/kg PO √ó 1</td></tr>
                            <tr><td>Nausea (chemo)</td><td>8-20 mg IV/PO</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hyperglycemia (monitor in diabetics)</li>
                            <li>Immunosuppression, increased infection risk</li>
                            <li>Insomnia, psychiatric effects, delirium</li>
                            <li>Long-term: adrenal suppression, osteoporosis, AVN</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Dexamethasone for bacterial meningitis: Give 15-20 min BEFORE first antibiotic dose - reduces hearing loss and mortality in pneumococcal meningitis.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#meningitis" class="guide-link">IMCRG: Meningitis</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                    <a href="rheumatology_study_guide4.html" class="guide-link">Rheum Guide</a>
                </div>
            </div>
        </div>

        <!-- HYDROCORTISONE -->
        <div class="drug-card" data-search="hydrocortisone solu-cortef adrenal insufficiency septic shock stress dose mineralocorticoid">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Hydrocortisone</span>
                <span class="drug-brand">(Solu-Cortef)</span>
                <span class="drug-class-badge">Glucocorticoid + Mineralocorticoid</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Properties</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Physiologic glucocorticoid (cortisol)</li>
                            <li>Has mineralocorticoid activity (sodium retention)</li>
                            <li>Short half-life (8-12 hr)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Adrenal crisis</td><td>100 mg IV bolus, then 50-100 mg q8h or continuous infusion</td></tr>
                            <tr><td>Septic shock (refractory)</td><td>50 mg IV q6h or 200 mg/day continuous √ó 7 days</td></tr>
                            <tr><td>Stress dosing (major surgery)</td><td>50-100 mg IV q8h √ó 1-3 days</td></tr>
                            <tr><td>Physiologic replacement</td><td>15-25 mg PO daily (in divided doses)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hyperglycemia (monitor closely)</li>
                            <li>Fluid retention, hypokalemia (mineralocorticoid effect)</li>
                            <li>Immunosuppression</li>
                            <li>Avoid abrupt discontinuation (adrenal suppression)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Hydrocortisone is preferred for adrenal insufficiency because it provides both glucocorticoid and mineralocorticoid activity. In septic shock, use for refractory hypotension on escalating vasopressors.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#adrenal" class="guide-link">IMCRG: Adrenal Crisis</a>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= CARDIAC - ANTIHYPERTENSIVES ======================= -->
<div class="drug-category" id="cardiac-antihypertensives">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚ù§Ô∏è Antihypertensives</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- LISINOPRIL -->
        <div class="drug-card" data-search="lisinopril ace inhibitor acei hypertension heart failure diabetic nephropathy cough angioedema">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Lisinopril</span>
                <span class="drug-brand">(Prinivil, Zestril)</span>
                <span class="drug-class-badge">ACE Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits angiotensin-converting enzyme ‚Üí blocks conversion of angiotensin I to II ‚Üí vasodilation, decreased aldosterone, reduced cardiac remodeling.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypertension (first-line)</li>
                            <li>HFrEF (mortality benefit)</li>
                            <li>Post-MI (LV dysfunction)</li>
                            <li>Diabetic nephropathy (proteinuria reduction)</li>
                            <li>CKD with proteinuria</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Starting</th><th>Target</th></tr>
                            <tr><td>HTN</td><td>10 mg daily</td><td>20-40 mg daily</td></tr>
                            <tr><td>HFrEF</td><td>2.5-5 mg daily</td><td>20-40 mg daily</td></tr>
                            <tr><td>Post-MI</td><td>5 mg daily</td><td>10 mg daily</td></tr>
                        </table>
                        <p><strong>CrCl 10-30:</strong> Start 2.5-5 mg daily</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Dry cough</strong> (10-20%) - bradykinin accumulation; switch to ARB if intolerable</li>
                            <li><strong>Angioedema</strong> (0.1-0.5%) - more common in Black patients; STOP permanently</li>
                            <li>Hyperkalemia</li>
                            <li>Acute kidney injury (especially with volume depletion, NSAIDs, bilateral RAS)</li>
                            <li>Hypotension (especially first dose in HF)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Contraindicated in pregnancy - fetal toxicity (renal dysgenesis, oligohydramnios, skull hypoplasia). Discontinue immediately if pregnancy detected.</div>
                <div class="warning-box">Check Cr and K+ 1-2 weeks after initiation or dose increase. Up to 30% rise in Cr acceptable if stable. Stop if >30% rise or hyperkalemia develops.</div>
                <div class="pearl-box">ACEi provide mortality benefit in HFrEF independent of BP lowering. Titrate to target doses used in trials (not just until BP controlled).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="nephrology_study_guide1.html#htn" class="guide-link">Nephro: HTN</a>
                </div>
            </div>
        </div>

        <!-- LOSARTAN -->
        <div class="drug-card" data-search="losartan arb angiotensin receptor blocker hypertension heart failure diabetic nephropathy">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Losartan</span>
                <span class="drug-brand">(Cozaar)</span>
                <span class="drug-class-badge">ARB</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Blocks angiotensin II type 1 (AT1) receptor ‚Üí similar effects to ACEi but does NOT affect bradykinin (no cough).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Same as ACEi - use when ACEi not tolerated (cough)</li>
                            <li>Hypertension, HFrEF, diabetic nephropathy</li>
                            <li>Stroke prevention in HTN with LVH</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>HTN:</strong> 25-50 mg daily, max 100 mg daily</p>
                        <p><strong>HFrEF:</strong> Start 25 mg daily, target 150 mg daily</p>
                        <p>Also has uricosuric effect (lowers uric acid)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Similar to ACEi EXCEPT: No cough (no bradykinin effect)</li>
                            <li>Angioedema - less common but still possible</li>
                            <li>Hyperkalemia, AKI</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">ARBs are NOT cough-free for ACEi angioedema - still ~10% cross-reactivity. For ACEi angioedema, consider ARB only if ACEi essential, with close monitoring.</div>
            </div>
        </div>

        <!-- AMLODIPINE -->
        <div class="drug-card" data-search="amlodipine norvasc calcium channel blocker ccb dihydropyridine hypertension angina edema">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amlodipine</span>
                <span class="drug-brand">(Norvasc)</span>
                <span class="drug-class-badge">DHP CCB</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Blocks L-type calcium channels in vascular smooth muscle ‚Üí vasodilation. Dihydropyridine (DHP) = primarily vascular effects (vs non-DHP which affect heart).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypertension (first-line, especially Black patients, elderly)</li>
                            <li>Stable angina</li>
                            <li>Vasospastic (Prinzmetal) angina</li>
                            <li>Raynaud phenomenon</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>HTN:</strong> 2.5-5 mg daily, max 10 mg daily</p>
                        <p><strong>Angina:</strong> 5-10 mg daily</p>
                        <p>Long half-life (30-50 hr) - once daily dosing, takes 7-8 days to reach steady state</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Peripheral edema</strong> (dose-dependent, up to 10%) - NOT fluid overload; due to arteriolar dilation</li>
                            <li>Flushing, headache</li>
                            <li>Gingival hyperplasia</li>
                            <li>Reflex tachycardia (less than other DHPs)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Amlodipine edema is NOT responsive to diuretics - it's redistribution, not volume overload. Adding ACEi/ARB may help by dilating venous side.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#htn" class="guide-link">Nephro: HTN</a>
                    <a href="rheumatology_study_guide4.html#raynauds" class="guide-link">Rheum: Raynaud's</a>
                </div>
            </div>
        </div>

        <!-- METOPROLOL -->
        <div class="drug-card" data-search="metoprolol lopressor toprol beta blocker hypertension heart failure afib rate control">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Metoprolol</span>
                <span class="drug-brand">(Lopressor, Toprol-XL)</span>
                <span class="drug-class-badge">Œ≤1-Selective Blocker</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Selective Œ≤1-adrenergic antagonist ‚Üí decreases HR, contractility, AV conduction, and renin release. Cardioselective at low doses.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypertension</li>
                            <li>HFrEF (metoprolol succinate - mortality benefit)</li>
                            <li>Rate control (AFib, AFL)</li>
                            <li>Post-MI (secondary prevention)</li>
                            <li>Angina</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Indication</th><th>Dose</th></tr>
                            <tr><td rowspan="2">Tartrate (Lopressor)</td><td>HTN</td><td>25-100 mg PO BID</td></tr>
                            <tr><td>Acute rate control</td><td>5 mg IV q5min √ó 3 PRN</td></tr>
                            <tr><td rowspan="2">Succinate (Toprol-XL)</td><td>HTN</td><td>25-100 mg PO daily</td></tr>
                            <tr><td>HFrEF</td><td>Start 12.5-25 mg daily, target 200 mg daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Contraindications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Bradycardia, heart block</li>
                            <li>Fatigue, depression, sexual dysfunction</li>
                            <li>Bronchospasm (less with Œ≤1-selective, but still caution in asthma)</li>
                            <li>Masks hypoglycemia symptoms</li>
                            <li><strong>Avoid in:</strong> Decompensated HF, severe bradycardia, 2nd/3rd degree AV block, severe asthma</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Do NOT stop beta-blockers abruptly - rebound tachycardia, hypertension, angina. Taper over 1-2 weeks.</div>
                <div class="pearl-box">For HFrEF: Only metoprolol SUCCINATE (Toprol-XL) has mortality data - NOT tartrate. Start low and titrate slowly ("start low, go slow").</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                </div>
            </div>
        </div>

        <!-- CARVEDILOL -->
        <div class="drug-card" data-search="carvedilol coreg beta blocker alpha blocker heart failure hypertension">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Carvedilol</span>
                <span class="drug-brand">(Coreg)</span>
                <span class="drug-class-badge">Œ±/Œ≤ Blocker</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-selective Œ≤-blocker (Œ≤1 and Œ≤2) PLUS Œ±1-blocker ‚Üí vasodilation in addition to Œ≤-blockade. Also has antioxidant properties.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>HFrEF (mortality benefit)</li>
                            <li>Hypertension</li>
                            <li>Post-MI with LV dysfunction</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Starting</th><th>Target</th></tr>
                            <tr><td>HFrEF</td><td>3.125 mg BID</td><td>25 mg BID (50 mg BID if >85 kg)</td></tr>
                            <tr><td>HTN</td><td>6.25 mg BID</td><td>25 mg BID</td></tr>
                        </table>
                        <p>Take with food to slow absorption and reduce orthostatic hypotension</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Orthostatic hypotension, dizziness (Œ±-blockade)</li>
                            <li>Bradycardia, fatigue</li>
                            <li>Bronchospasm (caution in asthma/COPD)</li>
                            <li>May mask hypoglycemia symptoms</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Carvedilol has Œ±-blocking (vasodilating) effect - may cause more orthostatic hypotension than metoprolol. Take with food. Both have equal mortality benefit in HFrEF.</div>
            </div>
        </div>

        <!-- LABETALOL -->
        <div class="drug-card" data-search="labetalol trandate alpha beta blocker hypertensive emergency pregnancy safe">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Labetalol</span>
                <span class="drug-brand">(Trandate)</span>
                <span class="drug-class-badge">Œ±/Œ≤ Blocker</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ±1 and non-selective Œ≤-blocker (Œ≤:Œ± ratio ~7:1 IV, ~3:1 PO). Reduces SVR without reflex tachycardia.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hypertensive emergency</strong> (first-line for most)</li>
                            <li><strong>Pregnancy-related HTN</strong> (preeclampsia, eclampsia)</li>
                            <li>Aortic dissection (with esmolol)</li>
                            <li>Perioperative hypertension</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Dose</th></tr>
                            <tr><td>IV bolus</td><td>20 mg, then 40-80 mg q10min PRN (max 300 mg total)</td></tr>
                            <tr><td>IV infusion</td><td>0.5-2 mg/min</td></tr>
                            <tr><td>PO</td><td>100-400 mg BID</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Orthostatic hypotension</li>
                            <li>Bradycardia</li>
                            <li>Bronchospasm (avoid in severe asthma)</li>
                            <li>Nausea, scalp tingling</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Labetalol is preferred for hypertensive emergencies in pregnancy (preeclampsia/eclampsia). Also first-line for most other HTN emergencies.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#htn-emergency" class="guide-link">IMCRG: HTN Emergency</a>
                    <a href="nephrology_study_guide1.html#htnemergency" class="guide-link">Nephro: HTN Emergency</a>
                </div>
            </div>
        </div>

        <!-- HYDRALAZINE -->
        <div class="drug-card" data-search="hydralazine apresoline vasodilator heart failure pregnancy lupus-like">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Hydralazine</span>
                <span class="drug-brand">(Apresoline)</span>
                <span class="drug-class-badge">Direct Vasodilator</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Direct arteriolar vasodilation (mechanism not fully understood - may involve NO). Does NOT dilate veins.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>HFrEF (with isosorbide dinitrate - mortality benefit in Black patients: A-HeFT trial)</li>
                            <li>Hypertension (adjunctive)</li>
                            <li>Pregnancy HTN (alternative to labetalol)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>HFrEF (with nitrate)</td><td>25-100 mg PO TID (BiDil = 37.5/20 mg combo)</td></tr>
                            <tr><td>HTN (acute)</td><td>10-20 mg IV q4-6h PRN</td></tr>
                            <tr><td>HTN (chronic)</td><td>25-100 mg PO BID-QID</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Reflex tachycardia (use with Œ≤-blocker)</li>
                            <li><strong>Drug-induced lupus</strong> (especially with doses >200 mg/day, slow acetylators)</li>
                            <li>Headache, flushing, palpitations</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Drug-induced lupus: ANA+, anti-histone antibodies+. Presents with arthralgias, serositis, rash. Resolves with discontinuation.</div>
                <div class="pearl-box">Hydralazine + isosorbide dinitrate (BiDil) has mortality benefit in Black patients with HFrEF already on ACEi/ARB + Œ≤-blocker (A-HeFT trial).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="rheumatology_study_guide4.html#dil" class="guide-link">Rheum: Drug-Induced Lupus</a>
                </div>
            </div>
        </div>

        <!-- SPIRONOLACTONE -->
        <div class="drug-card" data-search="spironolactone aldactone mra mineralocorticoid antagonist heart failure ascites hyperkalemia gynecomastia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Spironolactone</span>
                <span class="drug-brand">(Aldactone)</span>
                <span class="drug-class-badge">MRA / K+-Sparing Diuretic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Aldosterone receptor antagonist ‚Üí blocks Na+ reabsorption and K+ excretion in collecting duct. Also has anti-androgenic effects.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>HFrEF (mortality benefit - RALES trial)</li>
                            <li>Cirrhosis with ascites (first-line diuretic)</li>
                            <li>Resistant hypertension</li>
                            <li>Primary hyperaldosteronism</li>
                            <li>Hirsutism, acne (off-label)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>HFrEF</td><td>12.5-25 mg daily (max 50 mg)</td></tr>
                            <tr><td>Ascites</td><td>100 mg daily (max 400 mg); ratio 100:40 with furosemide</td></tr>
                            <tr><td>Resistant HTN</td><td>25-50 mg daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hyperkalemia</strong> (especially with ACEi/ARB, renal impairment)</li>
                            <li><strong>Gynecomastia</strong> (anti-androgen effect) - use eplerenone if intolerable</li>
                            <li>Menstrual irregularities</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Monitor K+ closely, especially with ACEi/ARB. Avoid if K+ >5.0 or CrCl <30 mL/min.</div>
                <div class="pearl-box">For cirrhotic ascites: Use spironolactone:furosemide ratio of 100:40 to maintain normokalemia (100 mg spironolactone + 40 mg furosemide).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="im_guidev3B20.html#cirrhosis" class="guide-link">IMCRG: Cirrhosis</a>
                    <a href="nephrology_study_guide1.html#hyperkalemia" class="guide-link">Nephro: Hyperkalemia</a>
                </div>
            </div>
        </div>

        <!-- FUROSEMIDE -->
        <div class="drug-card" data-search="furosemide lasix loop diuretic edema heart failure acute kidney injury">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Furosemide</span>
                <span class="drug-brand">(Lasix)</span>
                <span class="drug-class-badge">Loop Diuretic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits Na-K-2Cl cotransporter (NKCC2) in thick ascending limb ‚Üí blocks 25% of sodium reabsorption. Most potent diuretics.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Acute decompensated heart failure</li>
                            <li>Edema (nephrotic syndrome, cirrhosis)</li>
                            <li>Acute pulmonary edema</li>
                            <li>Hypercalcemia (with saline)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Dose</th></tr>
                            <tr><td>Acute HF (diuretic naive)</td><td>20-40 mg IV</td></tr>
                            <tr><td>Acute HF (on chronic furosemide)</td><td>IV dose = 1-2.5√ó home PO dose</td></tr>
                            <tr><td>Continuous infusion</td><td>5-20 mg/hr (after bolus)</td></tr>
                            <tr><td>Chronic (PO)</td><td>20-80 mg daily-BID</td></tr>
                        </table>
                        <p><strong>IV:PO ratio ~1:2</strong> (40 mg IV ‚âà 80 mg PO)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Electrolyte depletion:</strong> Hypokalemia, hypomagnesemia, hypocalcemia, hyponatremia</li>
                            <li>Volume depletion, hypotension</li>
                            <li>Ototoxicity (especially with aminoglycosides, rapid IV push)</li>
                            <li>Hyperuricemia, gout</li>
                            <li>Metabolic alkalosis (contraction alkalosis)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">DOSE trial: No difference in outcomes between bolus vs continuous infusion, or low vs high dose strategy. Use what achieves adequate diuresis.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro Guide</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= CARDIAC - ANTIARRHYTHMICS ======================= -->
<div class="drug-category" id="cardiac-antiarrhythmics">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚ù§Ô∏è Antiarrhythmics</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- AMIODARONE -->
        <div class="drug-card" data-search="amiodarone pacerone cordarone antiarrhythmic afib vt vf thyroid pulmonary toxicity qt">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Amiodarone</span>
                <span class="drug-brand">(Cordarone, Pacerone)</span>
                <span class="drug-class-badge">Class III Antiarrhythmic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Blocks K+ channels (Class III), but also has Class I (Na+), II (Œ≤-blocking), and IV (Ca2+) effects. Prolongs action potential and refractory period.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Life-threatening ventricular arrhythmias (VT, VF)</li>
                            <li>AF/AFL rate and rhythm control</li>
                            <li>ACLS: Refractory VF/pulseless VT</li>
                            <li>AF in HFrEF (one of few safe options)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Loading</th><th>Maintenance</th></tr>
                            <tr><td>VF/VT (ACLS)</td><td>300 mg IV push</td><td>150 mg IV if needed</td></tr>
                            <tr><td>Stable VT</td><td>150 mg over 10 min</td><td>1 mg/min √ó 6h, then 0.5 mg/min</td></tr>
                            <tr><td>AF (IV)</td><td>150 mg over 10 min</td><td>1 mg/min √ó 6h, then 0.5 mg/min</td></tr>
                            <tr><td>AF (PO loading)</td><td>400-800 mg/day √ó 2-4 weeks</td><td>100-200 mg daily</td></tr>
                        </table>
                        <p>Extremely long half-life (40-55 days) - takes weeks to reach steady state</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Thyroid:</strong> Hypo- or hyperthyroidism (contains iodine) - check TFTs q6 months</li>
                            <li><strong>Pulmonary:</strong> Pulmonary fibrosis (check CXR, PFTs baseline and annually)</li>
                            <li><strong>Hepatic:</strong> Transaminitis, hepatitis (check LFTs q6 months)</li>
                            <li><strong>Cardiac:</strong> QT prolongation, bradycardia, torsades (rare)</li>
                            <li><strong>Other:</strong> Corneal deposits, photosensitivity, blue-gray skin discoloration</li>
                            <li><strong>Drug interactions:</strong> Increases digoxin, warfarin levels (reduce doses by 50%)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Baseline and periodic monitoring required: TFTs, LFTs, CXR, PFTs, ophthalmologic exam. Many drug interactions - check all medications.</div>
                <div class="pearl-box">Amiodarone is one of the few antiarrhythmics safe in HFrEF - most others are contraindicated or proarrhythmic in structural heart disease.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                    <a href="im_guidev3B20.html#vt" class="guide-link">IMCRG: VT</a>
                </div>
            </div>
        </div>

        <!-- DILTIAZEM -->
        <div class="drug-card" data-search="diltiazem cardizem calcium channel blocker rate control afib angina hypertension">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Diltiazem</span>
                <span class="drug-brand">(Cardizem)</span>
                <span class="drug-class-badge">Non-DHP CCB</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-dihydropyridine CCB ‚Üí blocks L-type Ca2+ channels in heart and vessels. Slows AV nodal conduction, reduces HR, and causes vasodilation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>AF/AFL rate control (acute and chronic)</li>
                            <li>SVT (acute termination)</li>
                            <li>Angina (stable, vasospastic)</li>
                            <li>Hypertension</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Indication</th><th>Dose</th></tr>
                            <tr><td rowspan="2">IV</td><td>Acute rate control</td><td>0.25 mg/kg (avg 15-20 mg) over 2 min, may repeat 0.35 mg/kg</td></tr>
                            <tr><td>Infusion</td><td>5-15 mg/hr</td></tr>
                            <tr><td rowspan="2">PO</td><td>Rate control</td><td>120-360 mg daily (extended-release)</td></tr>
                            <tr><td>HTN</td><td>120-540 mg daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Contraindications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>HFrEF</strong> - negative inotropy</li>
                            <li>Pre-excited AF (WPW) - may accelerate accessory pathway</li>
                            <li>Severe bradycardia, 2nd/3rd degree AV block</li>
                            <li>Hypotension</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Do NOT use diltiazem or verapamil in HFrEF - negative inotropic effect can precipitate acute decompensation.</div>
                <div class="pearl-box">For AF rate control: Diltiazem preferred over verapamil (less negative inotropy). Do NOT use in WPW with AF - can accelerate conduction down bypass tract ‚Üí VF.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#afib" class="guide-link">IMCRG: AFib</a>
                </div>
            </div>
        </div>

        <!-- DIGOXIN -->
        <div class="drug-card" data-search="digoxin lanoxin digitalis afib heart failure inotrope toxicity yellow vision">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Digoxin</span>
                <span class="drug-brand">(Lanoxin)</span>
                <span class="drug-class-badge">Cardiac Glycoside</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits Na+/K+-ATPase ‚Üí increases intracellular Ca2+ ‚Üí positive inotropy. Also increases vagal tone ‚Üí slows AV conduction (rate control).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>AF rate control (add-on when Œ≤-blocker/CCB insufficient)</li>
                            <li>HFrEF (reduces hospitalizations, no mortality benefit - DIG trial)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Loading</th><th>Maintenance</th></tr>
                            <tr><td>AF (urgent)</td><td>0.5 mg IV, then 0.25 mg q6h √ó 2</td><td>0.125-0.25 mg daily</td></tr>
                            <tr><td>HF (chronic)</td><td>Usually no load</td><td>0.125-0.25 mg daily</td></tr>
                        </table>
                        <p><strong>Target level:</strong> 0.5-1.0 ng/mL (lower targets associated with better outcomes)</p>
                        <p>Renally cleared - reduce dose with CKD</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Toxicity</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Nausea, vomiting, anorexia</li>
                            <li><strong>Visual:</strong> Yellow-green halos, blurred vision</li>
                            <li><strong>Cardiac:</strong> ANY arrhythmia possible - classically bidirectional VT, atrial tachycardia with block, accelerated junctional rhythm</li>
                            <li><strong>CNS:</strong> Confusion, delirium</li>
                        </ul>
                        <p><strong>Risk factors for toxicity:</strong> Hypokalemia, hypomagnesemia, renal impairment, elderly, drug interactions (amiodarone, verapamil, quinidine)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <p><strong>Digoxin immune Fab (DigiFab):</strong> For life-threatening toxicity (K+ >5.5, hemodynamically unstable arrhythmias)</p>
                    </div>
                </div>
                <div class="warning-box">Digoxin toxicity is potentiated by hypokalemia - always check and correct K+ and Mg2+. Toxicity can occur even at "therapeutic" levels.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#digoxin-toxicity" class="guide-link">IMCRG: Digoxin Toxicity</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= DIABETES MEDICATIONS ======================= -->
<div class="drug-category" id="diabetes">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üç¨ Diabetes Medications</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- METFORMIN -->
        <div class="drug-card" data-search="metformin glucophage biguanide type 2 diabetes first line lactic acidosis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Metformin</span>
                <span class="drug-brand">(Glucophage)</span>
                <span class="drug-class-badge">Biguanide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Decreases hepatic gluconeogenesis, increases peripheral insulin sensitivity. Does NOT stimulate insulin secretion ‚Üí no hypoglycemia risk as monotherapy.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>First-line for T2DM</strong> (unless contraindicated)</li>
                            <li>Prediabetes prevention</li>
                            <li>PCOS (off-label)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Starting</th><th>Target</th></tr>
                            <tr><td>Immediate-release</td><td>500 mg BID with meals</td><td>1000 mg BID (max 2550 mg/day)</td></tr>
                            <tr><td>Extended-release</td><td>500 mg daily with dinner</td><td>1500-2000 mg daily</td></tr>
                        </table>
                        <p><strong>Renal dosing:</strong> eGFR 30-45: max 1000 mg/day; eGFR <30: contraindicated</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Nausea, diarrhea, metallic taste (start low, titrate slowly; use ER formulation)</li>
                            <li><strong>Vitamin B12 deficiency</strong> (monitor periodically)</li>
                            <li><strong>Lactic acidosis</strong> (rare but serious - associated with renal impairment, tissue hypoxia)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Hold metformin before and 48h after iodinated contrast if eGFR <60 (check renal function before restarting). Not needed if eGFR >60.</div>
                <div class="pearl-box">Metformin is weight-neutral to weight-losing, has possible CV benefit, and reduces A1c by ~1-1.5%. Only diabetes medication proven to reduce all-cause mortality (UKPDS).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#t2dm" class="guide-link">IMCRG: T2DM</a>
                    <a href="nephrology_study_guide1.html#ckd" class="guide-link">Nephro: CKD</a>
                </div>
            </div>
        </div>

        <!-- EMPAGLIFLOZIN -->
        <div class="drug-card" data-search="empagliflozin jardiance sglt2 inhibitor heart failure ckd dka euglycemic fournier">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Empagliflozin</span>
                <span class="drug-brand">(Jardiance)</span>
                <span class="drug-class-badge">SGLT2 Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits SGLT2 in proximal tubule ‚Üí blocks glucose reabsorption ‚Üí glycosuria. Also causes natriuresis, reduces preload, and has renoprotective effects.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>T2DM (especially with ASCVD, HF, or CKD)</li>
                            <li><strong>HFrEF and HFpEF</strong> (with or without diabetes - EMPEROR trials)</li>
                            <li><strong>CKD</strong> (slows progression - EMPA-KIDNEY)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>T2DM</td><td>10-25 mg daily</td></tr>
                            <tr><td>HF</td><td>10 mg daily</td></tr>
                            <tr><td>CKD</td><td>10 mg daily (can initiate down to eGFR 20)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Genital mycotic infections</strong> (candidiasis - counsel on hygiene)</li>
                            <li><strong>UTIs</strong></li>
                            <li><strong>Euglycemic DKA</strong> (can occur with normal glucose - hold during illness/surgery)</li>
                            <li>Volume depletion, hypotension</li>
                            <li>Fournier's gangrene (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Euglycemic DKA: Can occur with near-normal glucose. Hold SGLT2i during acute illness, surgery, prolonged fasting, or if DKA suspected.</div>
                <div class="pearl-box">SGLT2 inhibitors reduce HF hospitalizations and slow CKD progression INDEPENDENT of glucose lowering - now guideline-recommended for HF and CKD even without diabetes.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                    <a href="nephrology_study_guide1.html#ckd" class="guide-link">Nephro: CKD</a>
                </div>
            </div>
        </div>

        <!-- SEMAGLUTIDE -->
        <div class="drug-card" data-search="semaglutide ozempic wegovy rybelsus glp1 agonist weight loss cardiovascular">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Semaglutide</span>
                <span class="drug-brand">(Ozempic, Wegovy, Rybelsus)</span>
                <span class="drug-class-badge">GLP-1 Receptor Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">GLP-1 receptor agonist ‚Üí enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, increases satiety. Does NOT cause hypoglycemia as monotherapy.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>T2DM (especially with ASCVD or high CV risk)</li>
                            <li><strong>Weight management</strong> (Wegovy - higher doses)</li>
                            <li>CV risk reduction in T2DM (SUSTAIN-6, SELECT)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Starting</th><th>Target</th></tr>
                            <tr><td>Ozempic (SubQ weekly)</td><td>0.25 mg √ó 4 weeks</td><td>0.5-1 mg weekly (max 2 mg)</td></tr>
                            <tr><td>Wegovy (SubQ weekly)</td><td>0.25 mg √ó 4 weeks</td><td>2.4 mg weekly</td></tr>
                            <tr><td>Rybelsus (oral daily)</td><td>3 mg √ó 30 days</td><td>7-14 mg daily</td></tr>
                        </table>
                        <p><strong>Rybelsus:</strong> Take on empty stomach with ‚â§4 oz water, 30 min before food</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Nausea, vomiting, diarrhea (dose-dependent, improves with time)</li>
                            <li>Pancreatitis (rare)</li>
                            <li>Gallbladder disease</li>
                            <li>Injection site reactions</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Contraindicated in personal/family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome (thyroid C-cell tumors in rodents).</div>
                <div class="pearl-box">GLP-1 agonists provide significant weight loss (10-15% with semaglutide) and CV benefit. Now preferred over sulfonylureas and often used early in T2DM.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#t2dm" class="guide-link">IMCRG: T2DM</a>
                    <a href="im_guidev3B20.html#obesity" class="guide-link">IMCRG: Obesity</a>
                </div>
            </div>
        </div>

        <!-- INSULIN GLARGINE -->
        <div class="drug-card" data-search="insulin glargine lantus basaglar basal long-acting hypoglycemia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Insulin Glargine</span>
                <span class="drug-brand">(Lantus, Basaglar, Toujeo)</span>
                <span class="drug-class-badge">Long-Acting Insulin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Long-acting basal insulin analog. Forms microprecipitates after SubQ injection ‚Üí slow, steady release over ~24 hours. Relatively peakless.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>T1DM (basal component of basal-bolus regimen)</li>
                            <li>T2DM (when oral agents insufficient)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Dose</th></tr>
                            <tr><td>T2DM initiation</td><td>10 units daily OR 0.1-0.2 units/kg daily</td></tr>
                            <tr><td>Titration</td><td>Increase by 2-4 units every 3-7 days to fasting glucose goal</td></tr>
                            <tr><td>T1DM</td><td>~50% of total daily dose as basal</td></tr>
                        </table>
                        <p>Inject at same time daily (bedtime or morning)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hypoglycemia</strong> - less nocturnal hypoglycemia than NPH</li>
                            <li>Weight gain</li>
                            <li>Injection site reactions, lipohypertrophy</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Glargine is "peakless" basal insulin - less nocturnal hypoglycemia than NPH. Cannot be mixed with other insulins. Toujeo (U-300) has even flatter profile.</div>
            </div>
        </div>

        <!-- INSULIN LISPRO -->
        <div class="drug-card" data-search="insulin lispro humalog rapid-acting bolus mealtime hypoglycemia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Insulin Lispro</span>
                <span class="drug-brand">(Humalog)</span>
                <span class="drug-class-badge">Rapid-Acting Insulin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Rapid-acting insulin analog. Faster onset and shorter duration than regular insulin - better matches postprandial glucose rise.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Pharmacokinetics</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Parameter</th><th>Lispro</th><th>Regular</th></tr>
                            <tr><td>Onset</td><td>15-30 min</td><td>30-60 min</td></tr>
                            <tr><td>Peak</td><td>0.5-2.5 hr</td><td>2-4 hr</td></tr>
                            <tr><td>Duration</td><td>3-5 hr</td><td>5-8 hr</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Give within 15 min of starting meal</li>
                            <li>Dose based on carbohydrate counting OR fixed doses</li>
                            <li>Correction factor: 1 unit typically lowers glucose 25-50 mg/dL</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hypoglycemia</strong> (main risk - especially if meal delayed/missed)</li>
                            <li>Injection site reactions</li>
                            <li>Weight gain</li>
                            <li>Hypokalemia (shifts K+ intracellularly)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Rapid-acting insulins (lispro, aspart, glulisine) are preferred over regular insulin for mealtime dosing - better match to postprandial glucose and less late hypoglycemia.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= GI MEDICATIONS ======================= -->
<div class="drug-category" id="gi-meds">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü´Å GI / Hepatic Medications</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- PANTOPRAZOLE -->
        <div class="drug-card" data-search="pantoprazole protonix ppi proton pump inhibitor gerd ulcer gi bleed">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Pantoprazole</span>
                <span class="drug-brand">(Protonix)</span>
                <span class="drug-class-badge">Proton Pump Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Irreversibly inhibits H+/K+-ATPase (proton pump) in gastric parietal cells ‚Üí blocks final step of acid secretion. Most potent acid suppressants.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GERD</li>
                            <li>Peptic ulcer disease (treatment and prophylaxis)</li>
                            <li>H. pylori eradication (part of triple/quadruple therapy)</li>
                            <li>GI bleed prophylaxis (stress ulcer prophylaxis in ICU)</li>
                            <li>Zollinger-Ellison syndrome</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>GERD</td><td>40 mg PO daily √ó 4-8 weeks</td></tr>
                            <tr><td>GI bleed (acute)</td><td>80 mg IV bolus, then 8 mg/hr infusion √ó 72h</td></tr>
                            <tr><td>Stress ulcer prophylaxis</td><td>40 mg IV/PO daily</td></tr>
                        </table>
                        <p>Take 30-60 min before meals for best efficacy</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects (Long-term)</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>C. difficile infection</strong> (reduced gastric acid barrier)</li>
                            <li><strong>Hypomagnesemia</strong> (check Mg if prolonged use)</li>
                            <li>Vitamin B12 deficiency</li>
                            <li>Increased fracture risk</li>
                            <li>Possible increased pneumonia risk</li>
                            <li>AIN (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Avoid long-term PPI use without clear indication - reassess periodically. Associated with C. diff, hypomagnesemia, B12 deficiency, fractures.</div>
                <div class="pearl-box">For GI bleed: High-dose PPI (80 mg bolus + 8 mg/hr drip) is used post-endoscopy for high-risk ulcers. Intermittent dosing may be equivalent to continuous.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#gi-bleed" class="guide-link">IMCRG: GI Bleed</a>
                    <a href="id_guide5_5_integrated.html#cdiff" class="guide-link">ID Guide: C. diff</a>
                </div>
            </div>
        </div>

        <!-- LACTULOSE -->
        <div class="drug-card" data-search="lactulose hepatic encephalopathy ammonia cirrhosis laxative constipation">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Lactulose</span>
                <span class="drug-brand">(Enulose, Kristalose)</span>
                <span class="drug-class-badge">Osmotic Laxative</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-absorbable disaccharide ‚Üí metabolized by colonic bacteria to organic acids ‚Üí lowers colonic pH ‚Üí traps ammonia as NH4+ (non-absorbable) ‚Üí excretion. Also osmotic laxative effect.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hepatic encephalopathy</strong> (first-line treatment and prophylaxis)</li>
                            <li>Chronic constipation</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>HE (acute)</td><td>30-45 mL (20-30 g) PO q1h until bowel movement, then TID-QID</td></tr>
                            <tr><td>HE (maintenance)</td><td>30-45 mL BID-TID; titrate to 2-3 soft stools/day</td></tr>
                            <tr><td>HE (severe/comatose)</td><td>300 mL in 700 mL water/NS as retention enema q4-6h</td></tr>
                            <tr><td>Constipation</td><td>15-30 mL daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Bloating, flatulence, abdominal cramps</li>
                            <li>Diarrhea (dose-related)</li>
                            <li>Electrolyte disturbances with excessive diarrhea</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Titrate lactulose to 2-3 soft bowel movements per day. Rifaximin can be added for refractory/recurrent HE (reduces ammonia-producing bacteria).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#hepatic-encephalopathy" class="guide-link">IMCRG: Hepatic Encephalopathy</a>
                    <a href="im_guidev3B20.html#cirrhosis" class="guide-link">IMCRG: Cirrhosis</a>
                </div>
            </div>
        </div>

        <!-- RIFAXIMIN -->
        <div class="drug-card" data-search="rifaximin xifaxan hepatic encephalopathy ibs-d travelers diarrhea sibo">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Rifaximin</span>
                <span class="drug-brand">(Xifaxan)</span>
                <span class="drug-class-badge">Non-Absorbable Antibiotic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Rifamycin derivative - inhibits bacterial RNA synthesis. Minimal systemic absorption (<0.4%) ‚Üí acts locally in GI tract.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hepatic encephalopathy (add to lactulose for recurrent episodes)</li>
                            <li>IBS-D (diarrhea-predominant)</li>
                            <li>Traveler's diarrhea (E. coli)</li>
                            <li>SIBO (off-label)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>HE prevention</td><td>550 mg PO BID (long-term)</td></tr>
                            <tr><td>IBS-D</td><td>550 mg TID √ó 14 days (can repeat)</td></tr>
                            <tr><td>Traveler's diarrhea</td><td>200 mg TID √ó 3 days</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Generally very well-tolerated (minimal absorption)</li>
                            <li>Nausea, flatulence</li>
                            <li>Peripheral edema</li>
                            <li>C. diff (rare, but possible)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Rifaximin reduces recurrent HE by ~50% when added to lactulose. Very expensive but effective - reserve for recurrent HE after lactulose optimization.</div>
            </div>
        </div>

        <!-- OCTREOTIDE -->
        <div class="drug-card" data-search="octreotide sandostatin somatostatin variceal bleeding carcinoid acromegaly">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Octreotide</span>
                <span class="drug-brand">(Sandostatin)</span>
                <span class="drug-class-badge">Somatostatin Analog</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Synthetic somatostatin analog ‚Üí inhibits splanchnic vasodilation, reduces portal pressure, decreases GI hormone secretion (glucagon, insulin, GH, VIP).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Variceal bleeding</strong> (acute management)</li>
                            <li>Carcinoid syndrome (flushing, diarrhea)</li>
                            <li>Acromegaly</li>
                            <li>Secretory diarrhea (VIPoma, short bowel)</li>
                            <li>Sulfonylurea overdose (refractory hypoglycemia)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Variceal bleed</td><td>50 mcg IV bolus, then 50 mcg/hr infusion √ó 3-5 days</td></tr>
                            <tr><td>Carcinoid crisis prevention</td><td>250-500 mcg IV before procedures</td></tr>
                            <tr><td>SU overdose</td><td>50-100 mcg SubQ q6-12h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Bradycardia (especially IV bolus)</li>
                            <li>Hyperglycemia or hypoglycemia (alters insulin/glucagon)</li>
                            <li>Nausea, abdominal pain</li>
                            <li>Gallstones/biliary sludge (long-term use)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">For variceal bleeding: Start octreotide immediately (don't wait for endoscopy) + antibiotics + PPI. Continue for 3-5 days.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#gi-bleed" class="guide-link">IMCRG: GI Bleed</a>
                    <a href="im_guidev3B20.html#cirrhosis" class="guide-link">IMCRG: Cirrhosis</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= IMMUNOSUPPRESSANTS ======================= -->
<div class="drug-category" id="immunosuppressants">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üõ°Ô∏è Immunosuppressants</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- TACROLIMUS -->
        <div class="drug-card" data-search="tacrolimus prograf calcineurin inhibitor transplant nephrotoxic tremor hyperglycemia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Tacrolimus</span>
                <span class="drug-brand">(Prograf)</span>
                <span class="drug-class-badge">Calcineurin Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds FKBP12 ‚Üí inhibits calcineurin ‚Üí blocks IL-2 transcription ‚Üí suppresses T-cell activation. 10-100√ó more potent than cyclosporine.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Solid organ transplant</strong> (kidney, liver, heart - mainstay)</li>
                            <li>Refractory autoimmune diseases</li>
                            <li>Atopic dermatitis (topical)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing & Monitoring</div>
                    <div class="drug-section-content">
                        <p><strong>Initial:</strong> 0.1-0.2 mg/kg/day PO divided BID</p>
                        <p><strong>Trough target:</strong> Varies by transplant type and time post-transplant</p>
                        <ul>
                            <li>Early post-transplant: 10-15 ng/mL</li>
                            <li>Maintenance: 5-10 ng/mL</li>
                        </ul>
                        <p>Check trough level prior to AM dose</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Nephrotoxicity</strong> (dose-dependent, monitor Cr)</li>
                            <li><strong>Neurotoxicity:</strong> Tremor, headache, seizures, PRES</li>
                            <li><strong>Metabolic:</strong> Hyperglycemia/new-onset diabetes, hyperkalemia</li>
                            <li>Hypertension</li>
                            <li>Increased infection risk</li>
                            <li>Hypomagnesemia</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Many drug interactions via CYP3A4. Increase tacrolimus levels: azoles, diltiazem, grapefruit. Decrease: rifampin, phenytoin, St. John's wort.</div>
                <div class="pearl-box">Tacrolimus causes more diabetes/neurotoxicity than cyclosporine but less hirsutism/gingival hyperplasia. Now preferred over cyclosporine in most transplants.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#transplant" class="guide-link">Nephro: Transplant</a>
                </div>
            </div>
        </div>

        <!-- MYCOPHENOLATE -->
        <div class="drug-card" data-search="mycophenolate cellcept myfortic mofetil transplant gi side effects teratogenic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Mycophenolate</span>
                <span class="drug-brand">(CellCept, Myfortic)</span>
                <span class="drug-class-badge">Antimetabolite</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits inosine monophosphate dehydrogenase (IMPDH) ‚Üí blocks de novo purine synthesis ‚Üí selectively inhibits lymphocyte proliferation (lymphocytes lack salvage pathway).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Solid organ transplant (with calcineurin inhibitor + steroids)</li>
                            <li>Lupus nephritis</li>
                            <li>Vasculitis (maintenance)</li>
                            <li>Myasthenia gravis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Dose</th></tr>
                            <tr><td>CellCept (MMF)</td><td>1000-1500 mg PO BID</td></tr>
                            <tr><td>Myfortic (EC-MPA)</td><td>720 mg PO BID (equivalent to CellCept 1000 mg BID)</td></tr>
                        </table>
                        <p>Myfortic is enteric-coated (theoretically less GI side effects)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Diarrhea, nausea, vomiting (most common, dose-limiting)</li>
                            <li><strong>Myelosuppression:</strong> Leukopenia, anemia, thrombocytopenia</li>
                            <li>Increased infection risk (CMV, BK virus)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Teratogenic - pregnancy category D. Effective contraception required. Associated with first-trimester pregnancy loss and congenital malformations.</div>
                <div class="pearl-box">Mycophenolate replaced azathioprine in most transplant protocols - more effective and better tolerated (no hepatotoxicity like azathioprine).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro Guide</a>
                    <a href="rheumatology_study_guide4.html#sle" class="guide-link">Rheum: SLE</a>
                </div>
            </div>
        </div>

        <!-- AZATHIOPRINE -->
        <div class="drug-card" data-search="azathioprine imuran purine antimetabolite ibd autoimmune tpmt myelosuppression">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Azathioprine</span>
                <span class="drug-brand">(Imuran)</span>
                <span class="drug-class-badge">Purine Antimetabolite</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Prodrug ‚Üí converted to 6-mercaptopurine ‚Üí inhibits purine synthesis ‚Üí suppresses lymphocyte proliferation. Metabolized by TPMT and xanthine oxidase.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>IBD (maintenance)</li>
                            <li>Autoimmune hepatitis</li>
                            <li>Myasthenia gravis</li>
                            <li>SLE, vasculitis (steroid-sparing)</li>
                            <li>Transplant (less common now)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Standard:</strong> 1-3 mg/kg/day PO (typically 50-150 mg daily)</p>
                        <p><strong>Check TPMT genotype/phenotype before starting</strong></p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Interactions</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Myelosuppression</strong> (especially with TPMT deficiency)</li>
                            <li>Hepatotoxicity</li>
                            <li>Pancreatitis</li>
                            <li>GI upset</li>
                            <li>Increased malignancy risk (lymphoma, skin cancer)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">ALLOPURINOL INTERACTION: Allopurinol inhibits xanthine oxidase ‚Üí dramatically increases azathioprine levels ‚Üí severe myelosuppression. Reduce azathioprine dose by 75% or avoid.</div>
                <div class="warning-box">Check TPMT before starting. TPMT deficiency ‚Üí severe myelosuppression. Heterozygotes may need dose reduction.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html" class="guide-link">Rheum Guide</a>
                    <a href="im_guidev3B20.html#ibd" class="guide-link">IMCRG: IBD</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= DMARDs & BIOLOGICS ======================= -->
<div class="drug-category" id="dmards-biologics">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä DMARDs & Biologics</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- METHOTREXATE -->
        <div class="drug-card" data-search="methotrexate mtx rheumatrex folate antagonist rheumatoid arthritis psoriasis hepatotoxicity pneumonitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Methotrexate</span>
                <span class="drug-brand">(Rheumatrex, Trexall)</span>
                <span class="drug-class-badge">DMARD / Folate Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits dihydrofolate reductase ‚Üí blocks folate metabolism. At low doses: anti-inflammatory via adenosine release. At high doses: cytotoxic (oncology).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Rheumatoid arthritis</strong> (first-line DMARD)</li>
                            <li>Psoriasis, psoriatic arthritis</li>
                            <li>Ectopic pregnancy</li>
                            <li>Various malignancies (high-dose)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>RA</td><td>7.5-25 mg PO/SubQ ONCE WEEKLY</td></tr>
                            <tr><td>Psoriasis</td><td>10-25 mg PO ONCE WEEKLY</td></tr>
                        </table>
                        <p><strong>ALWAYS give with folic acid 1 mg daily</strong> to reduce toxicity</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>CBC (myelosuppression)</li>
                            <li>LFTs (hepatotoxicity)</li>
                            <li>Creatinine (renally cleared)</li>
                            <li>Baseline CXR (pneumonitis)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Nausea, stomatitis (reduced by folic acid)</li>
                            <li><strong>Hepatotoxicity:</strong> Transaminitis, fibrosis (monitor LFTs)</li>
                            <li><strong>Pulmonary:</strong> Methotrexate pneumonitis (hypersensitivity, any time)</li>
                            <li><strong>Myelosuppression</strong></li>
                            <li>Infection risk</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Teratogenic - avoid in pregnancy (category X). Requires reliable contraception. Wait 3 months after stopping before conception.</div>
                <div class="warning-box">WEEKLY dosing - daily dosing is a fatal medication error. Always verify "weekly" when prescribing.</div>
                <div class="pearl-box">Methotrexate is anchor drug for RA - start early. Combines well with biologics. Low-dose MTX has excellent long-term safety record.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html#ra" class="guide-link">Rheum: RA</a>
                </div>
            </div>
        </div>

        <!-- RITUXIMAB -->
        <div class="drug-card" data-search="rituximab rituxan anti-cd20 b cell depletion lymphoma ra vasculitis infusion reaction">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Rituximab</span>
                <span class="drug-brand">(Rituxan)</span>
                <span class="drug-class-badge">Anti-CD20 Monoclonal Ab</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Chimeric anti-CD20 monoclonal antibody ‚Üí B-cell depletion via ADCC, CDC, and apoptosis. CD20 on pre-B cells to mature B cells (not plasma cells).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Non-Hodgkin lymphoma, CLL</li>
                            <li>Rheumatoid arthritis (with MTX, after TNF failure)</li>
                            <li>ANCA-associated vasculitis (GPA, MPA)</li>
                            <li>Membranous nephropathy</li>
                            <li>TTP, ITP</li>
                            <li>Pemphigus</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>RA</td><td>1000 mg IV √ó 2 doses (days 1 and 15), repeat q6 months</td></tr>
                            <tr><td>Vasculitis (induction)</td><td>375 mg/m¬≤ weekly √ó 4</td></tr>
                            <tr><td>Lymphoma</td><td>375 mg/m¬≤ weekly √ó 4-8 (varies by protocol)</td></tr>
                        </table>
                        <p>Premedicate: acetaminophen, diphenhydramine, ¬± methylprednisolone</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Infusion reactions</strong> (fever, chills, rigors) - most common with first infusion</li>
                            <li><strong>Infections</strong> (including reactivation of HBV, JC virus ‚Üí PML)</li>
                            <li>Hypogammaglobulinemia (with repeated courses)</li>
                            <li>Late-onset neutropenia</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Screen for Hepatitis B before starting - risk of fatal HBV reactivation. Monitor and consider prophylaxis if HBcAb+.</div>
                <div class="warning-box">PML (progressive multifocal leukoencephalopathy) - rare but serious. Consider in patients with new neurologic symptoms.</div>
                <div class="pearl-box">B-cell depletion lasts 6-12 months. Check CD19/CD20 counts to guide retreatment. May cause prolonged hypogammaglobulinemia with repeated dosing.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html#ra" class="guide-link">Rheum: RA</a>
                    <a href="rheumatology_study_guide4.html#vasculitis" class="guide-link">Rheum: Vasculitis</a>
                    <a href="nephrology_study_guide1.html" class="guide-link">Nephro Guide</a>
                </div>
            </div>
        </div>

        <!-- ADALIMUMAB -->
        <div class="drug-card" data-search="adalimumab humira tnf inhibitor anti-tnf ra psoriasis ibd infection tb">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Adalimumab</span>
                <span class="drug-brand">(Humira)</span>
                <span class="drug-class-badge">TNF-Œ± Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Fully human monoclonal antibody against TNF-Œ± ‚Üí neutralizes TNF-mediated inflammation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Rheumatoid arthritis</li>
                            <li>Psoriatic arthritis, plaque psoriasis</li>
                            <li>Ankylosing spondylitis</li>
                            <li>Crohn's disease, ulcerative colitis</li>
                            <li>Hidradenitis suppurativa</li>
                            <li>Uveitis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>RA/PsA/AS:</strong> 40 mg SubQ every 2 weeks</p>
                        <p><strong>Crohn's:</strong> 160 mg week 0, 80 mg week 2, then 40 mg q2 weeks</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Serious infections</strong> (including TB, fungal infections)</li>
                            <li>Injection site reactions</li>
                            <li>Demyelinating disease (MS-like)</li>
                            <li>Drug-induced lupus</li>
                            <li>Worsening heart failure</li>
                            <li>Malignancy (lymphoma - rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Screen for latent TB before starting - reactivation risk. Also screen for Hepatitis B. Avoid in active infections and moderate-severe heart failure.</div>
                <div class="pearl-box">All TNF inhibitors require TB screening before initiation. Live vaccines contraindicated during therapy.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html#ra" class="guide-link">Rheum: RA</a>
                    <a href="im_guidev3B20.html#ibd" class="guide-link">IMCRG: IBD</a>
                </div>
            </div>
        </div>

        <!-- HYDROXYCHLOROQUINE -->
        <div class="drug-card" data-search="hydroxychloroquine plaquenil antimalarial sle ra retinal toxicity qt">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Hydroxychloroquine</span>
                <span class="drug-brand">(Plaquenil)</span>
                <span class="drug-class-badge">DMARD / Antimalarial</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Accumulates in lysosomes ‚Üí raises pH ‚Üí interferes with antigen processing and TLR signaling. Anti-inflammatory without significant immunosuppression.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>SLE</strong> (virtually all patients - reduces flares, improves survival)</li>
                            <li>Rheumatoid arthritis (mild disease or combination)</li>
                            <li>Sj√∂gren syndrome</li>
                            <li>Malaria prophylaxis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>SLE/RA:</strong> 200-400 mg PO daily (max 5 mg/kg/day to reduce retinal toxicity)</p>
                        <p>Takes 3-6 months for full effect</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Retinal toxicity</strong> ("bull's eye maculopathy") - irreversible; screen annually after 5 years</li>
                            <li>QTc prolongation</li>
                            <li>GI upset, skin hyperpigmentation</li>
                            <li>Neuromyopathy (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Ophthalmologic exam (OCT, visual fields) at baseline and annually after 5 years of use. Retinal toxicity risk increases with cumulative dose.</div>
                <div class="pearl-box">HCQ is the only DMARD safe in pregnancy - continue in pregnant SLE patients (reduces flares). Also protective against thrombosis in APS.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html#sle" class="guide-link">Rheum: SLE</a>
                    <a href="rheumatology_study_guide4.html#ra" class="guide-link">Rheum: RA</a>
                </div>
            </div>
        </div>

        <!-- COLCHICINE -->
        <div class="drug-card" data-search="colchicine colcrys gout pericarditis fmf diarrhea microtubule">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Colchicine</span>
                <span class="drug-brand">(Colcrys)</span>
                <span class="drug-class-badge">Anti-inflammatory</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds tubulin ‚Üí inhibits microtubule assembly ‚Üí blocks neutrophil migration, phagocytosis, and inflammasome activation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Acute gout</li>
                            <li>Gout prophylaxis (when starting ULT)</li>
                            <li><strong>Pericarditis</strong> (reduces recurrence)</li>
                            <li>FMF (familial Mediterranean fever)</li>
                            <li>Beh√ßet disease</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Acute gout (within 36h)</td><td>1.2 mg, then 0.6 mg 1 hour later (total 1.8 mg)</td></tr>
                            <tr><td>Gout prophylaxis</td><td>0.6 mg daily or BID</td></tr>
                            <tr><td>Pericarditis</td><td>0.5 mg BID √ó 3 months</td></tr>
                        </table>
                        <p>Reduce dose with renal impairment and CYP3A4/P-gp inhibitors</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>GI:</strong> Diarrhea, nausea, vomiting (dose-limiting)</li>
                            <li>Myelosuppression (with overdose or drug interactions)</li>
                            <li>Myopathy, neuropathy (rare, with renal impairment)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">DANGEROUS interactions with strong CYP3A4 inhibitors (clarithromycin, ketoconazole) or P-gp inhibitors (cyclosporine) - can cause fatal toxicity. Reduce dose or avoid.</div>
                <div class="pearl-box">For acute gout: Low-dose colchicine (AGREE trial regimen) is as effective and much better tolerated than old high-dose regimens.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html#gout" class="guide-link">Rheum: Gout</a>
                    <a href="im_guidev3B20.html#pericarditis" class="guide-link">IMCRG: Pericarditis</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= PAIN & SEDATION ======================= -->
<div class="drug-category" id="pain-sedation">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Pain & Sedation</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- MORPHINE -->
        <div class="drug-card" data-search="morphine opioid pain mu receptor respiratory depression naloxone">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Morphine</span>
                <span class="drug-brand">(MS Contin, Roxanol)</span>
                <span class="drug-class-badge">Opioid Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œº-opioid receptor agonist ‚Üí analgesia, euphoria, respiratory depression, miosis, decreased GI motility. Also histamine release.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Opioid-Naive Dose</th></tr>
                            <tr><td>IV</td><td>2-4 mg q2-4h PRN</td></tr>
                            <tr><td>PO (IR)</td><td>15-30 mg q4h PRN</td></tr>
                            <tr><td>PO (ER)</td><td>15 mg q12h (titrate)</td></tr>
                        </table>
                        <p><strong>IV:PO ratio = 1:3</strong> (10 mg IV = 30 mg PO)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Respiratory depression</strong> (dose-limiting)</li>
                            <li>Constipation (does NOT develop tolerance)</li>
                            <li>Nausea/vomiting, sedation, pruritus</li>
                            <li>Hypotension (histamine release)</li>
                            <li>Urinary retention</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Active metabolite (M6G) accumulates in renal failure ‚Üí prolonged effect, toxicity. Avoid or reduce dose significantly with CKD. Consider alternatives (fentanyl, hydromorphone).</div>
                <div class="pearl-box">Morphine causes more histamine release (hypotension, pruritus) than other opioids. For hemodynamically unstable patients, fentanyl preferred.</div>
            </div>
        </div>

        <!-- FENTANYL -->
        <div class="drug-card" data-search="fentanyl sublimaze opioid pain icu sedation patch transdermal">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Fentanyl</span>
                <span class="drug-brand">(Sublimaze, Duragesic)</span>
                <span class="drug-class-badge">Opioid Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Properties</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>50-100√ó more potent than morphine</li>
                            <li>Rapid onset (seconds IV, minutes transdermal)</li>
                            <li>Short duration (IV), prolonged (patch)</li>
                            <li>No active metabolites - safer in renal failure</li>
                            <li>Minimal histamine release - preferred in unstable patients</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Dose</th></tr>
                            <tr><td>IV (analgesia)</td><td>25-100 mcg q1-2h PRN</td></tr>
                            <tr><td>IV infusion (ICU)</td><td>25-100 mcg/hr</td></tr>
                            <tr><td>Transdermal patch</td><td>12-100 mcg/hr (change q72h)</td></tr>
                        </table>
                        <p><strong>Conversion:</strong> 100 mcg IV fentanyl ‚âà 10 mg IV morphine</p>
                    </div>
                </div>
                <div class="warning-box">Transdermal patch: For opioid-TOLERANT patients only. 12-24h to reach steady state; effects persist 12-24h after removal. Never apply heat (increases absorption).</div>
                <div class="pearl-box">Fentanyl is preferred in renal failure (no active metabolites) and hemodynamic instability (no histamine release). Chest wall rigidity with rapid high-dose IV push.</div>
            </div>
        </div>

        <!-- NALOXONE -->
        <div class="drug-card" data-search="naloxone narcan opioid reversal overdose respiratory depression">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Naloxone</span>
                <span class="drug-brand">(Narcan)</span>
                <span class="drug-class-badge">Opioid Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Competitive Œº-opioid receptor antagonist ‚Üí rapidly reverses opioid effects (respiratory depression, sedation, analgesia).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Dose</th></tr>
                            <tr><td>Opioid overdose</td><td>0.4-2 mg IV/IM/SubQ/IN, repeat q2-3min PRN</td></tr>
                            <tr><td>Opioid-induced respiratory depression (known tolerance)</td><td>0.04-0.1 mg IV, titrate to respirations (avoid withdrawal)</td></tr>
                            <tr><td>Intranasal (Narcan)</td><td>4 mg IN, may repeat</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Important Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Short duration:</strong> 30-90 min (shorter than most opioids) - may need repeat doses or infusion</li>
                            <li><strong>Precipitates withdrawal</strong> in opioid-dependent patients (not dangerous, but distressing)</li>
                            <li>Goal: Restore respirations, NOT consciousness</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Naloxone duration (30-90 min) is SHORTER than most opioids. Monitor for resedation and redose PRN. Consider infusion (2/3 of effective bolus per hour).</div>
                <div class="pearl-box">In opioid-tolerant patients, titrate small doses (0.04-0.1 mg) to avoid precipitating severe withdrawal. Goal is adequate ventilation, not full alertness.</div>
            </div>
        </div>

        <!-- PROPOFOL -->
        <div class="drug-card" data-search="propofol diprivan sedation icu anesthesia hypotension propofol infusion syndrome">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Propofol</span>
                <span class="drug-brand">(Diprivan)</span>
                <span class="drug-class-badge">IV Anesthetic/Sedative</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Potentiates GABA-A receptor ‚Üí CNS depression. Rapid onset and offset. Lipid emulsion formulation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>ICU sedation (mechanically ventilated)</li>
                            <li>Procedural sedation</li>
                            <li>General anesthesia induction/maintenance</li>
                            <li>Refractory status epilepticus</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Induction</td><td>1-2.5 mg/kg IV push</td></tr>
                            <tr><td>ICU sedation</td><td>5-50 mcg/kg/min (titrate to goal RASS)</td></tr>
                            <tr><td>Procedural sedation</td><td>0.5-1 mg/kg, then 25-75 mcg/kg/min</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hypotension</strong> (common - bolus fluid, consider vasopressors)</li>
                            <li><strong>Respiratory depression/apnea</strong></li>
                            <li>Injection site pain</li>
                            <li>Hypertriglyceridemia (lipid emulsion - check TG if prolonged use)</li>
                            <li><strong>Propofol infusion syndrome</strong> (PRIS) - rare, fatal</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Propofol Infusion Syndrome (PRIS): High doses (>83 mcg/kg/min) for >48h ‚Üí metabolic acidosis, rhabdomyolysis, hyperkalemia, cardiac failure. Monitor for early signs.</div>
                <div class="pearl-box">Propofol has NO analgesic effect - always combine with opioid for painful procedures/conditions. Lipid emulsion provides 1.1 kcal/mL - count toward nutrition.</div>
            </div>
        </div>

        <!-- KETAMINE -->
        <div class="drug-card" data-search="ketamine ketalar dissociative nmda anesthesia analgesia bronchospasm">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ketamine</span>
                <span class="drug-brand">(Ketalar)</span>
                <span class="drug-class-badge">Dissociative Anesthetic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">NMDA receptor antagonist ‚Üí dissociative anesthesia, analgesia, amnesia. Maintains airway reflexes and respiratory drive. Sympathomimetic (releases catecholamines).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Procedural sedation</li>
                            <li>RSI induction (hemodynamically unstable, bronchospasm)</li>
                            <li>Analgesia (low-dose)</li>
                            <li>Treatment-resistant depression (esketamine)</li>
                            <li>Status asthmaticus (bronchodilation)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Procedural sedation</td><td>1-2 mg/kg IV or 4-5 mg/kg IM</td></tr>
                            <tr><td>RSI induction</td><td>1-2 mg/kg IV</td></tr>
                            <tr><td>Analgesia (low-dose)</td><td>0.1-0.3 mg/kg IV</td></tr>
                            <tr><td>Infusion (analgesia)</td><td>0.1-0.5 mg/kg/hr</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Emergence phenomena (hallucinations, dysphoria) - reduced with benzodiazepines</li>
                            <li>Hypersalivation (consider glycopyrrolate)</li>
                            <li>Hypertension, tachycardia (sympathomimetic)</li>
                            <li>Increased ICP (controversial)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Ketamine is ideal for bronchospasm (bronchodilator) and hypotensive patients (maintains BP). Maintains airway reflexes - but not a substitute for NPO status.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTICONVULSANTS ======================= -->
<div class="drug-category" id="anticonvulsants">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üß† Anticonvulsants</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- LEVETIRACETAM -->
        <div class="drug-card" data-search="levetiracetam keppra seizure epilepsy behavioral irritability">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Levetiracetam</span>
                <span class="drug-brand">(Keppra)</span>
                <span class="drug-class-badge">Anticonvulsant</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds SV2A (synaptic vesicle protein) ‚Üí modulates neurotransmitter release. Exact mechanism not fully understood.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Focal (partial) seizures</li>
                            <li>Generalized tonic-clonic seizures</li>
                            <li>Myoclonic seizures</li>
                            <li>Status epilepticus (second-line)</li>
                            <li>Seizure prophylaxis (TBI, SAH, post-craniotomy)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Maintenance</td><td>500-1500 mg PO/IV BID (max 3000 mg/day)</td></tr>
                            <tr><td>Status epilepticus</td><td>20-60 mg/kg IV (max 4500 mg)</td></tr>
                        </table>
                        <p><strong>Renal dosing:</strong> Reduce dose with CrCl &lt;80</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Behavioral:</strong> Irritability, aggression ("Keppra rage"), depression</li>
                            <li>Sedation, fatigue</li>
                            <li>Minimal drug interactions (not CYP450 metabolized)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Levetiracetam advantages: No drug interactions, IV=PO dosing, no drug level monitoring needed. Disadvantage: Behavioral side effects. Can give vitamin B6 to reduce irritability.</div>
            </div>
        </div>

        <!-- PHENYTOIN -->
        <div class="drug-card" data-search="phenytoin dilantin fosphenytoin seizure status epilepticus purple glove zero order">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Phenytoin/Fosphenytoin</span>
                <span class="drug-brand">(Dilantin / Cerebyx)</span>
                <span class="drug-class-badge">Na+ Channel Blocker</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Blocks voltage-gated sodium channels ‚Üí stabilizes neuronal membranes, reduces seizure spread.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Dose</th></tr>
                            <tr><td>Loading (SE)</td><td>20 mg PE/kg IV (fosphenytoin) at 150 mg PE/min</td></tr>
                            <tr><td>Maintenance</td><td>100 mg PO/IV TID or 300 mg daily (extended)</td></tr>
                        </table>
                        <p><strong>Fosphenytoin:</strong> Dosed in phenytoin equivalents (PE). Faster infusion, less tissue necrosis.</p>
                        <p><strong>Target level:</strong> 10-20 mcg/mL (total) or 1-2 mcg/mL (free)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Pharmacokinetics</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Zero-order kinetics:</strong> Small dose changes ‚Üí large level changes</li>
                            <li>90% protein-bound - check FREE level in renal failure, hypoalbuminemia</li>
                            <li>CYP450 inducer - many drug interactions</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Acute toxicity:</strong> Nystagmus ‚Üí ataxia ‚Üí lethargy ‚Üí coma (dose-related)</li>
                            <li><strong>Chronic:</strong> Gingival hyperplasia, hirsutism, coarsening of features</li>
                            <li>Purple glove syndrome (IV phenytoin extravasation)</li>
                            <li>Hypotension, bradycardia (rapid infusion)</li>
                            <li>SJS/TEN (HLA-B*15:02 in Asian patients)</li>
                            <li>Osteoporosis (vitamin D metabolism)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">IV phenytoin: Max rate 50 mg/min (cardiac toxicity). Use fosphenytoin when possible - faster infusion, less tissue injury. Check free level in renal failure/low albumin.</div>
                <div class="pearl-box">Corrected phenytoin (Sheiner-Tozer): For albumin <3.5, adjusted level = measured/(0.2 √ó albumin + 0.1). Or just check free level directly.</div>
            </div>
        </div>

        <!-- VALPROIC ACID -->
        <div class="drug-card" data-search="valproic acid depakote valproate seizure bipolar migraine hepatotoxicity pancreatitis teratogenic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Valproic Acid</span>
                <span class="drug-brand">(Depakote, Depakene)</span>
                <span class="drug-class-badge">Anticonvulsant / Mood Stabilizer</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Multiple mechanisms: Increases GABA, blocks sodium channels, modulates T-type calcium channels.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Generalized seizures (absence, myoclonic, tonic-clonic)</li>
                            <li>Focal seizures</li>
                            <li>Status epilepticus</li>
                            <li>Bipolar disorder (mania)</li>
                            <li>Migraine prophylaxis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Seizures</td><td>10-15 mg/kg/day, increase to 20-60 mg/kg/day</td></tr>
                            <tr><td>Status epilepticus</td><td>20-40 mg/kg IV load</td></tr>
                            <tr><td>Migraine prophylaxis</td><td>500-1000 mg/day divided</td></tr>
                        </table>
                        <p><strong>Target level:</strong> 50-100 mcg/mL</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GI upset, weight gain, hair loss</li>
                            <li>Tremor</li>
                            <li><strong>Hepatotoxicity</strong> (especially children <2, polypharmacy)</li>
                            <li><strong>Pancreatitis</strong></li>
                            <li>Thrombocytopenia, platelet dysfunction</li>
                            <li>Hyperammonemia (even with normal LFTs)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Highly teratogenic - neural tube defects. Contraindicated in pregnancy for migraine/bipolar. If must use for epilepsy, use lowest effective dose + high-dose folate.</div>
                <div class="warning-box">Valproate + carbapenem (meropenem, ertapenem) ‚Üí dramatically reduces VPA levels. Avoid combination or use alternative antibiotic.</div>
                <div class="pearl-box">Check ammonia if altered mental status on valproate - hyperammonemic encephalopathy can occur even with therapeutic levels and normal LFTs. Treat with lactulose or L-carnitine.</div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= TOXICOLOGY & ANTIDOTES ======================= -->
<div class="drug-category" id="toxicology">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚ò†Ô∏è Toxicology & Antidotes</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- N-ACETYLCYSTEINE -->
        <div class="drug-card" data-search="n-acetylcysteine nac acetaminophen tylenol overdose glutathione rumack matthew">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">N-Acetylcysteine (NAC)</span>
                <span class="drug-brand">(Mucomyst, Acetadote)</span>
                <span class="drug-class-badge">Acetaminophen Antidote</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Replenishes glutathione stores ‚Üí detoxifies NAPQI (toxic acetaminophen metabolite). Also direct hepatoprotective effects.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Acetaminophen overdose</strong> (most effective within 8-10h, beneficial up to 24h+)</li>
                            <li>Acetaminophen level above Rumack-Matthew nomogram line</li>
                            <li>Acute liver failure (any etiology - some benefit)</li>
                            <li>Contrast-induced nephropathy prevention (controversial)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Protocol</th></tr>
                            <tr><td>IV (21-hour)</td><td>150 mg/kg over 1h, then 50 mg/kg over 4h, then 100 mg/kg over 16h</td></tr>
                            <tr><td>PO (72-hour)</td><td>140 mg/kg load, then 70 mg/kg q4h √ó 17 doses</td></tr>
                        </table>
                        <p>IV and PO equally effective. IV preferred if vomiting or altered mental status.</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Anaphylactoid reaction</strong> (flushing, bronchospasm, hypotension) - usually with IV loading; slow infusion, give antihistamines</li>
                            <li>Nausea, vomiting (PO - smells like sulfur)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Start NAC if ANY concern for significant ingestion - don't wait for level if >8 hours post-ingestion. NAC is virtually non-toxic and can be stopped if not indicated.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#acetaminophen" class="guide-link">IMCRG: Acetaminophen OD</a>
                </div>
            </div>
        </div>

        <!-- FLUMAZENIL -->
        <div class="drug-card" data-search="flumazenil romazicon benzodiazepine reversal overdose seizure">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Flumazenil</span>
                <span class="drug-brand">(Romazicon)</span>
                <span class="drug-class-badge">Benzodiazepine Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Competitive antagonist at GABA-A benzodiazepine binding site ‚Üí reverses benzodiazepine effects.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Procedural sedation reversal:</strong> 0.2 mg IV over 15 sec, repeat 0.2 mg q1min PRN (max 1 mg)</p>
                        <p><strong>Overdose:</strong> 0.2 mg IV, then 0.3 mg, then 0.5 mg q1min (max 3-5 mg)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è CRITICAL Contraindications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Chronic benzodiazepine use</strong> - precipitates withdrawal seizures</li>
                            <li><strong>Seizure disorder</strong> controlled by benzodiazepines</li>
                            <li><strong>Mixed overdose</strong> with pro-convulsant (TCA, cocaine)</li>
                            <li>Unknown ingestion history</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Can precipitate seizures in benzodiazepine-dependent patients or mixed overdoses. Rarely indicated in overdose setting - supportive care preferred. Reserved for iatrogenic oversedation.</div>
                <div class="warning-box">Duration shorter than most benzodiazepines - resedation may occur. Monitor for at least 2 hours after last dose.</div>
            </div>
        </div>

        <!-- FOMEPIZOLE -->
        <div class="drug-card" data-search="fomepizole antizol methanol ethylene glycol toxic alcohol alcohol dehydrogenase">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Fomepizole</span>
                <span class="drug-brand">(Antizol)</span>
                <span class="drug-class-badge">Alcohol Dehydrogenase Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits alcohol dehydrogenase ‚Üí blocks conversion of methanol/ethylene glycol to toxic metabolites (formic acid, glycolic acid/oxalate).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Methanol poisoning</strong></li>
                            <li><strong>Ethylene glycol poisoning</strong></li>
                            <li>Suspected toxic alcohol with metabolic acidosis + osmol gap</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Loading:</strong> 15 mg/kg IV over 30 min</p>
                        <p><strong>Maintenance:</strong> 10 mg/kg q12h √ó 4 doses, then 15 mg/kg q12h until level <20</p>
                        <p><strong>During dialysis:</strong> q4h dosing (drug removed by HD)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Headache, nausea</li>
                            <li>Injection site reactions</li>
                            <li>Rash, eosinophilia (rare)</li>
                            <li>Generally well-tolerated</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Fomepizole is preferred over ethanol infusion - easier to dose, no CNS depression. Start empirically if toxic alcohol suspected while awaiting levels. Dialysis indicated for severe acidosis, renal failure, visual symptoms (methanol), or high levels.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#toxic-alcohol" class="guide-link">IMCRG: Toxic Alcohols</a>
                    <a href="nephrology_study_guide1.html#acidosis" class="guide-link">Nephro: Metabolic Acidosis</a>
                </div>
            </div>
        </div>

        <!-- ACTIVATED CHARCOAL -->
        <div class="drug-card" data-search="activated charcoal decontamination ingestion overdose aspiration">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Activated Charcoal</span>
                <span class="drug-brand">(Actidose)</span>
                <span class="drug-class-badge">GI Decontaminant</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Highly porous surface adsorbs toxins in GI tract ‚Üí prevents systemic absorption.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ When to Use</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Within 1-2 hours of ingestion (greatest benefit)</li>
                            <li>Potentially life-threatening ingestion</li>
                            <li>Airway protected (alert or intubated)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Single dose:</strong> 1 g/kg PO/NG (typical adult dose 50-100g)</p>
                        <p><strong>Multi-dose:</strong> 25-50g q4-6h (for carbamazepine, dapsone, phenobarbital, quinine, theophylline)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Contraindications & Limitations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Not adsorbed:</strong> Metals (iron, lithium, lead), alcohols, hydrocarbons, acids/alkalis</li>
                            <li><strong>Contraindicated:</strong> Unprotected airway, GI perforation/obstruction, caustic ingestion</li>
                            <li>Risk of aspiration pneumonitis</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Remember "PHAILS" - charcoal does NOT adsorb: Pesticides/petroleum, Hydrocarbons, Acids/alkalis/alcohols, Iron, Lithium, Solvents.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ELECTROLYTE REPLACEMENT ======================= -->
<div class="drug-category" id="electrolytes">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚öóÔ∏è Electrolyte Replacement</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- POTASSIUM -->
        <div class="drug-card" data-search="potassium kcl hypokalemia replacement iv oral">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Potassium Chloride</span>
                <span class="drug-brand">(KCl, K-Dur)</span>
                <span class="drug-class-badge">Electrolyte</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Replacement Guidelines</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>K+ Level</th><th>Replacement</th></tr>
                            <tr><td>3.0-3.4 mEq/L</td><td>40-80 mEq PO daily</td></tr>
                            <tr><td>2.5-2.9 mEq/L</td><td>40 mEq PO q4-6h OR 10-20 mEq/hr IV</td></tr>
                            <tr><td>&lt;2.5 or symptomatic</td><td>10-20 mEq/hr IV (max 40 mEq/hr via central line)</td></tr>
                        </table>
                        <p><strong>Rule of thumb:</strong> 10 mEq K+ raises serum K+ by ~0.1 mEq/L</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Safety</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Max peripheral IV rate:</strong> 10 mEq/hr (burning, phlebitis)</li>
                            <li><strong>Max central IV rate:</strong> 20-40 mEq/hr with cardiac monitoring</li>
                            <li>Always check Mg (hypomagnesemia ‚Üí refractory hypokalemia)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Can't correct hypokalemia without correcting hypomagnesemia - Mg is required for K+ retention. Always check and replace Mg first.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#hypokalemia" class="guide-link">Nephro: Hypokalemia</a>
                </div>
            </div>
        </div>

        <!-- MAGNESIUM -->
        <div class="drug-card" data-search="magnesium sulfate oxide hypomagnesemia torsades eclampsia asthma">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Magnesium</span>
                <span class="drug-brand">(MgSO4, Mg Oxide)</span>
                <span class="drug-class-badge">Electrolyte</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypomagnesemia</li>
                            <li><strong>Torsades de pointes</strong> (even with normal Mg)</li>
                            <li><strong>Eclampsia/preeclampsia</strong> prophylaxis</li>
                            <li>Severe asthma (bronchodilation)</li>
                            <li>Digoxin toxicity with arrhythmia</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Mild deficiency</td><td>1-2 g IV over 1h or PO</td></tr>
                            <tr><td>Moderate deficiency</td><td>2-4 g IV over 4-6h</td></tr>
                            <tr><td>Torsades (acute)</td><td>2 g IV push over 1-2 min</td></tr>
                            <tr><td>Eclampsia prophylaxis</td><td>4-6 g IV load, then 1-2 g/hr</td></tr>
                            <tr><td>Severe asthma</td><td>2 g IV over 20 min</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Flushing, hypotension (rapid infusion)</li>
                            <li>Muscle weakness, hyporeflexia (toxicity)</li>
                            <li>Respiratory depression (severe toxicity)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Monitor reflexes (first sign of toxicity). Antidote for Mg toxicity: Calcium gluconate 1-2 g IV. Reduce dose in renal failure.</div>
                <div class="pearl-box">1 g MgSO4 = 8 mEq Mg = 98 mg elemental Mg. Serum Mg poorly reflects total body stores - may need empiric replacement.</div>
            </div>
        </div>

        <!-- CALCIUM -->
        <div class="drug-card" data-search="calcium gluconate chloride hypocalcemia hyperkalemia ccb overdose">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Calcium Gluconate/Chloride</span>
                <span class="drug-brand">(CaCl, Ca Gluconate)</span>
                <span class="drug-class-badge">Electrolyte</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Symptomatic hypocalcemia (tetany, seizures, QT prolongation)</li>
                            <li><strong>Hyperkalemia</strong> with EKG changes (cardiac membrane stabilization)</li>
                            <li>Calcium channel blocker overdose</li>
                            <li>Hydrofluoric acid burns</li>
                            <li>Magnesium toxicity</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Elemental Ca</th><th>Dose</th></tr>
                            <tr><td>Ca Gluconate 10%</td><td>93 mg per 10 mL</td><td>1-2 g (10-20 mL) IV over 10 min</td></tr>
                            <tr><td>Ca Chloride 10%</td><td>273 mg per 10 mL</td><td>500 mg-1 g (5-10 mL) IV over 5 min</td></tr>
                        </table>
                        <p><strong>Ca Gluconate:</strong> Preferred for peripheral IV (less tissue necrosis)</p>
                        <p><strong>Ca Chloride:</strong> 3√ó more elemental Ca, central line preferred</p>
                    </div>
                </div>
                <div class="warning-box">Ca Chloride causes severe tissue necrosis with extravasation - use central line or Ca Gluconate peripherally. Do NOT mix with bicarbonate (precipitates).</div>
                <div class="pearl-box">Calcium in hyperkalemia: Stabilizes cardiac membrane but does NOT lower K+. Effect lasts 30-60 min - use as bridge while other treatments take effect.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#hyperkalemia" class="guide-link">Nephro: Hyperkalemia</a>
                    <a href="nephrology_study_guide1.html#hypocalcemia" class="guide-link">Nephro: Hypocalcemia</a>
                </div>
            </div>
        </div>

        <!-- SODIUM BICARBONATE -->
        <div class="drug-card" data-search="sodium bicarbonate nahco3 metabolic acidosis hyperkalemia tca overdose urine alkalinization">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Sodium Bicarbonate</span>
                <span class="drug-brand">(NaHCO3)</span>
                <span class="drug-class-badge">Alkalinizing Agent</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Severe metabolic acidosis (pH <7.1, controversial)</li>
                            <li><strong>Hyperkalemia</strong> (shifts K+ into cells, especially with acidosis)</li>
                            <li><strong>TCA overdose</strong> (treats sodium channel blockade - wide QRS)</li>
                            <li>Salicylate toxicity (urine alkalinization)</li>
                            <li>Rhabdomyolysis prevention (urine pH >6.5)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Severe acidosis</td><td>1-2 mEq/kg IV bolus</td></tr>
                            <tr><td>Hyperkalemia</td><td>50-100 mEq IV over 5 min</td></tr>
                            <tr><td>TCA toxicity</td><td>1-2 mEq/kg IV bolus, repeat PRN for QRS narrowing</td></tr>
                            <tr><td>Urine alkalinization</td><td>150 mEq in 1L D5W at 150-200 mL/hr</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Causes CO2 generation (paradoxical intracellular acidosis)</li>
                            <li>Volume overload, hypernatremia</li>
                            <li>Hypokalemia (K+ shifts into cells)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">TCA overdose: Bicarb boluses to achieve arterial pH 7.50-7.55 and narrow QRS <100 ms. Much more effective than lidocaine for TCA-induced arrhythmias.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#acidosis" class="guide-link">Nephro: Metabolic Acidosis</a>
                    <a href="im_guidev3B20.html#hyperkalemia" class="guide-link">IMCRG: Hyperkalemia</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ANTIVIRALS ======================= -->
<div class="drug-category" id="antivirals">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü¶† Antivirals</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- ACYCLOVIR -->
        <div class="drug-card" data-search="acyclovir zovirax valacyclovir hsv vzv herpes zoster encephalitis nephrotoxicity">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Acyclovir / Valacyclovir</span>
                <span class="drug-brand">(Zovirax / Valtrex)</span>
                <span class="drug-class-badge">Nucleoside Analog</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Requires viral thymidine kinase activation ‚Üí incorporated into viral DNA ‚Üí chain termination. Selective for infected cells. Valacyclovir is oral prodrug with better bioavailability.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>HSV-1, HSV-2:</strong> Genital herpes, oral herpes, encephalitis, keratitis</li>
                            <li><strong>VZV:</strong> Shingles (zoster), chickenpox</li>
                            <li>Limited activity: EBV, CMV (not first-line)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Acyclovir IV</th><th>Valacyclovir PO</th></tr>
                            <tr><td>HSV encephalitis</td><td>10 mg/kg IV q8h √ó 14-21 days</td><td>‚Äî</td></tr>
                            <tr><td>Herpes zoster</td><td>10 mg/kg IV q8h</td><td>1 g PO TID √ó 7 days</td></tr>
                            <tr><td>Genital HSV (primary)</td><td>5 mg/kg IV q8h</td><td>1 g PO BID √ó 7-10 days</td></tr>
                            <tr><td>Genital HSV (recurrent)</td><td>‚Äî</td><td>500 mg PO BID √ó 3 days</td></tr>
                            <tr><td>HSV suppression</td><td>‚Äî</td><td>500-1000 mg PO daily</td></tr>
                        </table>
                        <p><strong>Renal dosing:</strong> Significantly reduce dose with CKD (renally cleared)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Nephrotoxicity:</strong> Crystal precipitation in tubules (hydrate well, avoid rapid infusion)</li>
                            <li><strong>Neurotoxicity:</strong> Tremor, confusion, hallucinations, seizures (especially with renal impairment)</li>
                            <li>Phlebitis (IV)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">IV acyclovir: Infuse slowly over 1 hour with adequate hydration to prevent crystalline nephropathy. Reduce dose in renal impairment.</div>
                <div class="pearl-box">Valacyclovir has 3-5√ó better oral bioavailability than acyclovir - preferred for most outpatient indications. IV acyclovir still required for severe infections (encephalitis, disseminated).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#encephalitis" class="guide-link">IMCRG: Encephalitis</a>
                    <a href="id_guide5_5_integrated.html#hsv" class="guide-link">ID Guide: HSV</a>
                </div>
            </div>
        </div>

        <!-- GANCICLOVIR -->
        <div class="drug-card" data-search="ganciclovir valganciclovir cytovene valcyte cmv cytomegalovirus transplant retinitis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ganciclovir / Valganciclovir</span>
                <span class="drug-brand">(Cytovene / Valcyte)</span>
                <span class="drug-class-badge">Nucleoside Analog</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Similar to acyclovir but activated by CMV UL97 kinase ‚Üí incorporation into viral DNA ‚Üí chain termination. More active against CMV than acyclovir.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>CMV disease</strong> (retinitis, colitis, pneumonitis, encephalitis)</li>
                            <li><strong>CMV prophylaxis</strong> in transplant recipients</li>
                            <li>Also active against HSV, VZV, HHV-6</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Ganciclovir IV</th><th>Valganciclovir PO</th></tr>
                            <tr><td>CMV treatment (induction)</td><td>5 mg/kg IV q12h √ó 14-21 days</td><td>900 mg PO BID √ó 21 days</td></tr>
                            <tr><td>CMV treatment (maintenance)</td><td>5 mg/kg IV daily</td><td>900 mg PO daily</td></tr>
                            <tr><td>CMV prophylaxis</td><td>5 mg/kg IV daily</td><td>900 mg PO daily</td></tr>
                        </table>
                        <p><strong>Significant renal adjustment required</strong></p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Myelosuppression:</strong> Neutropenia (40%), thrombocytopenia, anemia - dose-limiting</li>
                            <li>Nephrotoxicity</li>
                            <li>CNS toxicity (confusion, seizures)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Myelosuppression (especially neutropenia) is common and dose-limiting. Monitor CBC frequently (twice weekly during induction). May require G-CSF support or dose reduction.</div>
                <div class="pearl-box">Valganciclovir has excellent bioavailability (~60%) - can often use oral instead of IV. Foscarnet or cidofovir are alternatives for ganciclovir-resistant CMV.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="id_guide5_5_integrated.html#cmv" class="guide-link">ID Guide: CMV</a>
                    <a href="nephrology_study_guide1.html#transplant" class="guide-link">Nephro: Transplant</a>
                </div>
            </div>
        </div>

        <!-- OSELTAMIVIR -->
        <div class="drug-card" data-search="oseltamivir tamiflu influenza flu neuraminidase inhibitor">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Oseltamivir</span>
                <span class="drug-brand">(Tamiflu)</span>
                <span class="drug-class-badge">Neuraminidase Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits influenza neuraminidase ‚Üí prevents viral release from infected cells ‚Üí limits spread.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Influenza A and B treatment (within 48h of symptoms, but can give later in severe cases)</li>
                            <li>Influenza prophylaxis (post-exposure)</li>
                            <li>Greatest benefit in high-risk patients and hospitalized</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Treatment</td><td>75 mg PO BID √ó 5 days</td></tr>
                            <tr><td>Severe/hospitalized</td><td>75 mg PO BID √ó 10 days (or until clinical improvement)</td></tr>
                            <tr><td>Prophylaxis</td><td>75 mg PO daily √ó 7-10 days</td></tr>
                        </table>
                        <p><strong>CrCl 10-30:</strong> 75 mg daily (treatment); 75 mg every other day (prophylaxis)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Nausea, vomiting (take with food)</li>
                            <li>Neuropsychiatric events (rare, more in children)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Start within 48h for maximum benefit, but still treat hospitalized patients even if presenting later - reduces mortality and complications. Can give via NG tube if needed.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="id_guide5_5_integrated.html#influenza" class="guide-link">ID Guide: Influenza</a>
                </div>
            </div>
        </div>

        <!-- PAXLOVID -->
        <div class="drug-card" data-search="paxlovid nirmatrelvir ritonavir covid-19 sars-cov-2 protease inhibitor drug interactions">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Nirmatrelvir-Ritonavir</span>
                <span class="drug-brand">(Paxlovid)</span>
                <span class="drug-class-badge">COVID-19 Antiviral</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Nirmatrelvir inhibits SARS-CoV-2 main protease (Mpro). Ritonavir is a CYP3A4 inhibitor (boosting agent) - prolongs nirmatrelvir levels.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Mild-moderate COVID-19 in adults at high risk for progression</li>
                            <li>Start within 5 days of symptom onset</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Renal Function</th><th>Dose</th></tr>
                            <tr><td>eGFR ‚â•60</td><td>300 mg nirmatrelvir + 100 mg ritonavir PO BID √ó 5 days</td></tr>
                            <tr><td>eGFR 30-59</td><td>150 mg nirmatrelvir + 100 mg ritonavir PO BID √ó 5 days</td></tr>
                            <tr><td>eGFR <30</td><td>Not recommended</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Drug Interactions</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>MANY significant interactions</strong> due to ritonavir (CYP3A4 inhibitor)</li>
                            <li><strong>Hold/avoid:</strong> Certain statins, sedatives, immunosuppressants (tacrolimus - major), anticoagulants</li>
                            <li><strong>Check all medications</strong> before prescribing</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Ritonavir causes major CYP3A4 interactions. Check EVERY medication. Many need to be held (tacrolimus, some statins, rivaroxaban, etc.). Use Liverpool COVID-19 Drug Interactions checker.</div>
                <div class="pearl-box">Most effective when started within 5 days of symptoms. "Paxlovid rebound" (symptoms returning after treatment) occurs in ~10-15% but is usually mild.</div>
            </div>
        </div>

        <!-- REMDESIVIR -->
        <div class="drug-card" data-search="remdesivir veklury covid-19 sars-cov-2 rna polymerase">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Remdesivir</span>
                <span class="drug-brand">(Veklury)</span>
                <span class="drug-class-badge">COVID-19 Antiviral</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Nucleotide analog prodrug ‚Üí inhibits viral RNA-dependent RNA polymerase ‚Üí premature chain termination.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>COVID-19 requiring hospitalization</li>
                            <li>High-risk outpatients with mild-moderate COVID (3-day course)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Setting</th><th>Dose</th></tr>
                            <tr><td>Hospitalized</td><td>200 mg IV day 1, then 100 mg IV daily √ó 5 days (up to 10 if no improvement)</td></tr>
                            <tr><td>Outpatient (high-risk)</td><td>200 mg IV day 1, then 100 mg IV days 2-3</td></tr>
                        </table>
                        <p>Avoid if eGFR <30 (cyclodextrin vehicle accumulation)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Transaminase elevation (monitor LFTs)</li>
                            <li>Nausea</li>
                            <li>Bradycardia (rare)</li>
                            <li>Hypersensitivity reactions</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Greatest benefit when given early in illness to hospitalized patients not yet requiring high-flow O2 or mechanical ventilation. Less clear benefit in severe/late disease.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= PULMONARY MEDICATIONS ======================= -->
<div class="drug-category" id="pulmonary">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü´Å Pulmonary Medications</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- ALBUTEROL -->
        <div class="drug-card" data-search="albuterol salbutamol proventil ventolin beta agonist bronchodilator asthma copd">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Albuterol</span>
                <span class="drug-brand">(Proventil, Ventolin)</span>
                <span class="drug-class-badge">Short-Acting Œ≤2 Agonist (SABA)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ≤2-adrenergic agonist ‚Üí bronchial smooth muscle relaxation ‚Üí bronchodilation. Onset 5-15 min, duration 4-6 hours.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Acute asthma/COPD exacerbation (first-line rescue)</li>
                            <li>Bronchospasm</li>
                            <li>Hyperkalemia (drives K+ into cells)</li>
                            <li>Exercise-induced bronchospasm prevention</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Dose</th></tr>
                            <tr><td>MDI (acute)</td><td>4-8 puffs q20min √ó 3, then q1-4h</td></tr>
                            <tr><td>Nebulizer (acute)</td><td>2.5-5 mg q20min √ó 3, then q1-4h</td></tr>
                            <tr><td>Continuous neb</td><td>10-15 mg/hr</td></tr>
                            <tr><td>Hyperkalemia</td><td>10-20 mg nebulized</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Tachycardia, palpitations</li>
                            <li>Tremor</li>
                            <li>Hypokalemia (shifts K+ into cells)</li>
                            <li>Hyperglycemia</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">MDI with spacer is as effective as nebulizer in most patients and faster to administer. Continuous nebulization reserved for severe exacerbations not responding to intermittent dosing.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#asthma" class="guide-link">IMCRG: Asthma</a>
                    <a href="im_guidev3B20.html#copd" class="guide-link">IMCRG: COPD</a>
                </div>
            </div>
        </div>

        <!-- IPRATROPIUM -->
        <div class="drug-card" data-search="ipratropium atrovent anticholinergic copd asthma bronchodilator">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ipratropium</span>
                <span class="drug-brand">(Atrovent)</span>
                <span class="drug-class-badge">Short-Acting Anticholinergic (SAMA)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Muscarinic receptor antagonist ‚Üí blocks acetylcholine-mediated bronchoconstriction and mucus secretion. Slower onset (15-30 min) than albuterol but additive effect.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>COPD exacerbation (combined with SABA)</li>
                            <li>Severe asthma exacerbation (add to SABA)</li>
                            <li>Rhinorrhea (nasal spray)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Dose</th></tr>
                            <tr><td>Nebulizer</td><td>0.5 mg q20min √ó 3, then q4-6h</td></tr>
                            <tr><td>MDI</td><td>4-8 puffs q20min √ó 3</td></tr>
                            <tr><td>DuoNeb (with albuterol)</td><td>3 mL (ipratropium 0.5 mg + albuterol 2.5 mg)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Dry mouth (most common)</li>
                            <li>Urinary retention (caution in BPH)</li>
                            <li>Paradoxical bronchospasm (rare)</li>
                            <li>Avoid in narrow-angle glaucoma</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Ipratropium + albuterol more effective than either alone in COPD exacerbations. In asthma, add ipratropium only for moderate-severe exacerbations.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#copd" class="guide-link">IMCRG: COPD</a>
                </div>
            </div>
        </div>

        <!-- TIOTROPIUM -->
        <div class="drug-card" data-search="tiotropium spiriva lama long-acting anticholinergic copd maintenance">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Tiotropium</span>
                <span class="drug-brand">(Spiriva)</span>
                <span class="drug-class-badge">Long-Acting Anticholinergic (LAMA)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Long-acting muscarinic antagonist (M3 receptor) ‚Üí sustained bronchodilation. Once-daily dosing.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>COPD maintenance therapy (reduces exacerbations)</li>
                            <li>Asthma add-on therapy (step 4-5)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Spiriva HandiHaler:</strong> 18 mcg (1 capsule) inhaled once daily</p>
                        <p><strong>Spiriva Respimat:</strong> 2.5 mcg (2 puffs) once daily</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Dry mouth (most common)</li>
                            <li>Urinary retention (caution in BPH)</li>
                            <li>Constipation</li>
                            <li>Closed-angle glaucoma (rare - avoid direct eye contact)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">LAMA reduces COPD exacerbations better than LABA alone. LAMA + LABA combination (e.g., Anoro) is first-line for symptomatic COPD patients.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#copd" class="guide-link">IMCRG: COPD</a>
                </div>
            </div>
        </div>

        <!-- BUDESONIDE/FORMOTEROL -->
        <div class="drug-card" data-search="budesonide formoterol symbicort ics laba inhaled corticosteroid asthma copd">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Budesonide-Formoterol</span>
                <span class="drug-brand">(Symbicort)</span>
                <span class="drug-class-badge">ICS-LABA Combination</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Budesonide (ICS):</strong> Anti-inflammatory - reduces airway inflammation, mucus production</li>
                            <li><strong>Formoterol (LABA):</strong> Long-acting Œ≤2 agonist - sustained bronchodilation (12h)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Asthma maintenance (step 3+) - can also use as rescue (SMART therapy)</li>
                            <li>COPD with frequent exacerbations</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Asthma maintenance</td><td>1-2 puffs BID (80/4.5 or 160/4.5)</td></tr>
                            <tr><td>SMART (maintenance + rescue)</td><td>1-2 puffs BID + PRN (max 12 puffs/day)</td></tr>
                            <tr><td>COPD</td><td>2 puffs BID (160/4.5)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>ICS effects:</strong> Oral candidiasis (rinse mouth), dysphonia, cough</li>
                            <li><strong>LABA effects:</strong> Tachycardia, tremor, hypokalemia</li>
                            <li>Systemic steroid effects at high doses (adrenal suppression, osteoporosis)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">LABAs increase asthma-related death when used WITHOUT ICS. Always use LABA with ICS in asthma - never as monotherapy.</div>
                <div class="pearl-box">SMART therapy (budesonide-formoterol for maintenance AND rescue) reduces exacerbations better than separate controller + SABA rescue. Now preferred approach per GINA guidelines.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#asthma" class="guide-link">IMCRG: Asthma</a>
                    <a href="im_guidev3B20.html#copd" class="guide-link">IMCRG: COPD</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= HEMATOLOGY ======================= -->
<div class="drug-category" id="hematology">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü©∏ Hematology Agents</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- TRANEXAMIC ACID -->
        <div class="drug-card" data-search="tranexamic acid txa lysteda cyklokapron antifibrinolytic bleeding trauma hemorrhage">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Tranexamic Acid (TXA)</span>
                <span class="drug-brand">(Lysteda, Cyklokapron)</span>
                <span class="drug-class-badge">Antifibrinolytic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Competitively inhibits plasminogen activation ‚Üí prevents fibrin degradation ‚Üí stabilizes clots.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Trauma with hemorrhage</strong> (give within 3 hours of injury)</li>
                            <li>Postpartum hemorrhage</li>
                            <li>Heavy menstrual bleeding</li>
                            <li>GI bleeding (some evidence)</li>
                            <li>Perioperative bleeding (cardiac surgery, orthopedic)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Trauma (CRASH-2)</td><td>1 g IV over 10 min, then 1 g over 8 hours</td></tr>
                            <tr><td>Postpartum hemorrhage</td><td>1 g IV over 10 min (repeat √ó 1 if needed)</td></tr>
                            <tr><td>Menorrhagia</td><td>1300 mg PO TID √ó 5 days (during menses)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Theoretical thrombosis risk (not seen in trials)</li>
                            <li>Seizures at very high doses (rare)</li>
                            <li>Use caution in DIC, active intravascular clotting</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">In trauma: Give within 3 hours of injury. After 3 hours, TXA may increase mortality (CRASH-2). Time matters!</div>
                <div class="pearl-box">CRASH-2 showed 10% reduction in death due to bleeding in trauma. WOMAN trial showed benefit in postpartum hemorrhage. Inexpensive and widely available.</div>
            </div>
        </div>

        <!-- FILGRASTIM -->
        <div class="drug-card" data-search="filgrastim neupogen gcsf granulocyte colony stimulating factor neutropenia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Filgrastim</span>
                <span class="drug-brand">(Neupogen, Zarxio)</span>
                <span class="drug-class-badge">G-CSF</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Recombinant G-CSF ‚Üí stimulates neutrophil production, maturation, and release from bone marrow. Also enhances neutrophil function.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Chemotherapy-induced neutropenia (prophylaxis and treatment)</li>
                            <li>Febrile neutropenia (adjunct)</li>
                            <li>Severe chronic neutropenia</li>
                            <li>Stem cell mobilization</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Neutropenia prophylaxis</td><td>5 mcg/kg SubQ daily (start 24-72h post-chemo)</td></tr>
                            <tr><td>Stem cell mobilization</td><td>10 mcg/kg SubQ daily √ó 4-7 days</td></tr>
                        </table>
                        <p><strong>Pegfilgrastim (Neulasta):</strong> 6 mg SubQ √ó 1 (long-acting, once per chemo cycle)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Bone pain</strong> (most common - from marrow expansion)</li>
                            <li>Splenic rupture (rare - avoid contact sports)</li>
                            <li>Capillary leak syndrome (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Bone pain from G-CSF can be significant - treat with antihistamines, NSAIDs, or opioids. Pegfilgrastim (once per cycle) is more convenient than daily filgrastim.</div>
            </div>
        </div>

        <!-- VITAMIN K -->
        <div class="drug-card" data-search="vitamin k phytonadione warfarin reversal coagulopathy inr">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Vitamin K (Phytonadione)</span>
                <span class="drug-brand">(Mephyton)</span>
                <span class="drug-class-badge">Vitamin / Reversal Agent</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Essential cofactor for hepatic synthesis of clotting factors II, VII, IX, X and proteins C and S. Reverses warfarin by providing substrate for gamma-carboxylation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Warfarin reversal (elevated INR)</li>
                            <li>Vitamin K deficiency (malnutrition, malabsorption)</li>
                            <li>Coagulopathy of liver disease</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Route</th><th>Dose</th></tr>
                            <tr><td>INR 4.5-10, no bleeding</td><td>PO</td><td>1-2.5 mg (omit 1-2 doses)</td></tr>
                            <tr><td>INR >10, no bleeding</td><td>PO</td><td>2.5-5 mg</td></tr>
                            <tr><td>Serious bleeding</td><td>IV</td><td>10 mg (with PCC)</td></tr>
                            <tr><td>Life-threatening bleeding</td><td>IV</td><td>10 mg (with 4-factor PCC)</td></tr>
                        </table>
                        <p>PO takes 12-24h; IV takes 6-12h. For emergent reversal, must use PCC (immediate effect).</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>IV vitamin K: Give slowly (over 30 min) - rare anaphylactoid reactions</li>
                            <li>SubQ absorption unpredictable - avoid</li>
                            <li>High doses may cause warfarin resistance for days</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Vitamin K alone is NOT sufficient for serious bleeding on warfarin - use 4-factor PCC for immediate reversal. Vitamin K ensures sustained reversal once PCC wears off (12-24h).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#gi-bleed" class="guide-link">IMCRG: GI Bleed</a>
                </div>
            </div>
        </div>

        <!-- 4-FACTOR PCC -->
        <div class="drug-card" data-search="prothrombin complex concentrate pcc kcentra warfarin reversal factor xa inhibitor bleeding">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">4-Factor PCC</span>
                <span class="drug-brand">(Kcentra)</span>
                <span class="drug-class-badge">Clotting Factor Concentrate</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Contains factors II, VII, IX, X plus proteins C and S. Immediately replaces vitamin K-dependent clotting factors.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Warfarin reversal</strong> with serious/life-threatening bleeding or urgent surgery</li>
                            <li><strong>Factor Xa inhibitor reversal</strong> (when andexanet not available)</li>
                            <li>Coagulopathy with bleeding (liver disease, trauma)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Baseline INR</th><th>Dose (units/kg)</th></tr>
                            <tr><td>2-4</td><td>25 units/kg (max 2500)</td></tr>
                            <tr><td>4-6</td><td>35 units/kg (max 3500)</td></tr>
                            <tr><td>>6</td><td>50 units/kg (max 5000)</td></tr>
                        </table>
                        <p>Give with vitamin K 10 mg IV (for sustained effect)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Thrombosis risk (contains procoagulant factors)</li>
                            <li>Duration of effect ~12-24h (needs vitamin K for sustained reversal)</li>
                            <li>Preferred over FFP (faster, less volume, more predictable)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">4-factor PCC is preferred over FFP for warfarin reversal: Works in minutes (vs hours for FFP), no volume overload, no ABO matching needed.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= NEUROLOGY / PSYCHIATRY ======================= -->
<div class="drug-category" id="neuro-psych">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üß† Neurology / Psychiatry</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- ALTEPLASE -->
        <div class="drug-card" data-search="alteplase tpa tissue plasminogen activator thrombolytic stroke mi pe">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Alteplase (tPA)</span>
                <span class="drug-brand">(Activase)</span>
                <span class="drug-class-badge">Thrombolytic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Recombinant tissue plasminogen activator ‚Üí converts plasminogen to plasmin ‚Üí fibrin clot lysis. Relatively fibrin-selective.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Acute ischemic stroke</strong> (within 4.5 hours of symptom onset)</li>
                            <li><strong>Massive/submassive PE</strong> (with hemodynamic instability or RV dysfunction)</li>
                            <li><strong>STEMI</strong> (when PCI not available within 120 min)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Acute ischemic stroke</td><td>0.9 mg/kg (max 90 mg): 10% bolus, 90% over 60 min</td></tr>
                            <tr><td>PE</td><td>100 mg IV over 2 hours</td></tr>
                            <tr><td>STEMI</td><td>15 mg bolus, then 0.75 mg/kg over 30 min, then 0.5 mg/kg over 60 min</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Contraindications (Stroke)</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Absolute:</strong> Active bleeding, recent intracranial surgery/trauma, previous ICH, known AVM/aneurysm, BP >185/110 despite treatment</li>
                            <li><strong>Relative:</strong> Recent major surgery, GI bleed, platelets <100K, INR >1.7, glucose <50 or >400</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Major bleeding risk including intracranial hemorrhage (~6% symptomatic ICH in stroke). Strict BP control required post-tPA (<180/105).</div>
                <div class="pearl-box">Door-to-needle time goal: <60 min. Tenecteplase (single bolus) increasingly used as alternative. Do NOT give anticoagulation for 24h post-tPA.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#stroke" class="guide-link">IMCRG: Stroke</a>
                    <a href="im_guidev3B20.html#pe" class="guide-link">IMCRG: PE</a>
                </div>
            </div>
        </div>

        <!-- HALOPERIDOL -->
        <div class="drug-card" data-search="haloperidol haldol antipsychotic delirium agitation dopamine qt eps">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Haloperidol</span>
                <span class="drug-brand">(Haldol)</span>
                <span class="drug-class-badge">Typical Antipsychotic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">D2 dopamine receptor antagonist ‚Üí antipsychotic, antiemetic effects. High potency, low anticholinergic activity.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Acute agitation/psychosis</li>
                            <li>Delirium (when pharmacotherapy indicated)</li>
                            <li>Nausea/vomiting (refractory)</li>
                            <li>Schizophrenia (maintenance)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Acute agitation</td><td>2-5 mg IM/IV, repeat q30-60min PRN</td></tr>
                            <tr><td>Delirium</td><td>0.5-1 mg PO/IV q4-6h PRN (start low in elderly)</td></tr>
                            <tr><td>Nausea</td><td>0.5-2 mg PO/IV q4-6h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>QTc prolongation</strong> (check EKG if IV route)</li>
                            <li><strong>Extrapyramidal symptoms:</strong> Dystonia, akathisia, parkinsonism</li>
                            <li><strong>Neuroleptic malignant syndrome</strong> (rare - rigidity, fever, AMS)</li>
                            <li>Lowered seizure threshold</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Increased mortality in elderly patients with dementia-related psychosis. QTc prolongation and torsades risk with IV administration - monitor EKG.</div>
                <div class="pearl-box">For acute agitation: IM haloperidol + lorazepam + diphenhydramine ("B52" cocktail) is commonly used. IV haloperidol has lower EPS risk but more QTc risk.</div>
            </div>
        </div>

        <!-- QUETIAPINE -->
        <div class="drug-card" data-search="quetiapine seroquel atypical antipsychotic bipolar insomnia delirium">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Quetiapine</span>
                <span class="drug-brand">(Seroquel)</span>
                <span class="drug-class-badge">Atypical Antipsychotic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Antagonist at multiple receptors: D2 dopamine, 5-HT2A serotonin, H1 histamine, Œ±1 adrenergic. Lower D2 affinity ‚Üí less EPS than typical antipsychotics.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Schizophrenia</li>
                            <li>Bipolar disorder (mania, depression)</li>
                            <li>Delirium (often preferred in Parkinson's, Lewy body)</li>
                            <li>Insomnia (off-label, low dose)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Delirium</td><td>12.5-50 mg PO qHS (start low)</td></tr>
                            <tr><td>Bipolar/schizophrenia</td><td>25-100 mg BID, titrate to 400-800 mg/day</td></tr>
                            <tr><td>Insomnia (off-label)</td><td>25-100 mg qHS</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Sedation</strong> (prominent - H1 blockade)</li>
                            <li><strong>Orthostatic hypotension</strong> (Œ±1 blockade)</li>
                            <li>Metabolic effects: Weight gain, hyperglycemia, dyslipidemia</li>
                            <li>QTc prolongation (less than haloperidol)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Quetiapine has the lowest D2 affinity of antipsychotics - preferred for delirium in Parkinson's disease and Lewy body dementia where D2 blockade worsens parkinsonism.</div>
            </div>
        </div>

        <!-- LORAZEPAM -->
        <div class="drug-card" data-search="lorazepam ativan benzodiazepine anxiety seizure sedation alcohol withdrawal">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Lorazepam</span>
                <span class="drug-brand">(Ativan)</span>
                <span class="drug-class-badge">Benzodiazepine</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Enhances GABA-A receptor activity ‚Üí anxiolytic, sedative, anticonvulsant, amnestic, muscle relaxant effects. Intermediate-acting.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Acute anxiety/agitation</li>
                            <li><strong>Status epilepticus</strong> (first-line)</li>
                            <li><strong>Alcohol withdrawal</strong></li>
                            <li>Procedural sedation</li>
                            <li>Chemotherapy-induced nausea</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Anxiety/agitation</td><td>0.5-2 mg PO/IV/IM q4-6h PRN</td></tr>
                            <tr><td>Status epilepticus</td><td>4 mg IV (0.1 mg/kg), may repeat √ó 1</td></tr>
                            <tr><td>Alcohol withdrawal (CIWA)</td><td>1-4 mg IV/PO q1h PRN based on CIWA score</td></tr>
                            <tr><td>Procedural sedation</td><td>1-2 mg IV</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Respiratory depression (especially with opioids)</li>
                            <li>Sedation, cognitive impairment</li>
                            <li>Paradoxical agitation (elderly)</li>
                            <li>Dependence with chronic use</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Lorazepam preferred in liver disease - metabolized by glucuronidation (not CYP450). "LOT" benzos (Lorazepam, Oxazepam, Temazepam) are safer in hepatic impairment.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#status-epilepticus" class="guide-link">IMCRG: Status Epilepticus</a>
                    <a href="im_guidev3B20.html#alcohol-withdrawal" class="guide-link">IMCRG: Alcohol Withdrawal</a>
                </div>
            </div>
        </div>

        <!-- SERTRALINE -->
        <div class="drug-card" data-search="sertraline zoloft ssri depression anxiety serotonin">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Sertraline</span>
                <span class="drug-brand">(Zoloft)</span>
                <span class="drug-class-badge">SSRI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Selective serotonin reuptake inhibitor ‚Üí increases synaptic serotonin. Effects take 2-4 weeks to manifest.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Major depressive disorder</li>
                            <li>Generalized anxiety disorder, panic disorder</li>
                            <li>PTSD</li>
                            <li>OCD</li>
                            <li>Social anxiety disorder</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Depression/anxiety:</strong> Start 25-50 mg daily, increase by 25-50 mg q1-2 weeks to 100-200 mg daily</p>
                        <p><strong>OCD:</strong> May require higher doses (up to 200 mg)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GI upset, diarrhea (more than other SSRIs)</li>
                            <li>Sexual dysfunction</li>
                            <li>Insomnia or sedation</li>
                            <li>Weight changes</li>
                            <li>Serotonin syndrome (with other serotonergic drugs)</li>
                            <li>Hyponatremia (SIADH, especially elderly)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Increased risk of suicidal thinking in children, adolescents, and young adults (18-24). Monitor closely during initiation and dose changes.</div>
                <div class="warning-box">Do not combine with MAOIs - serotonin syndrome risk. Taper gradually (do not stop abruptly) - discontinuation syndrome.</div>
                <div class="pearl-box">Sertraline has the most GI side effects of SSRIs but fewest drug interactions. Generally well-tolerated and first-line for most anxiety/depression.</div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= GOUT MEDICATIONS ======================= -->
<div class="drug-category" id="gout">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíé Gout Medications</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- ALLOPURINOL -->
        <div class="drug-card" data-search="allopurinol zyloprim uric acid xanthine oxidase gout urate lowering ult hypersensitivity">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Allopurinol</span>
                <span class="drug-brand">(Zyloprim)</span>
                <span class="drug-class-badge">Xanthine Oxidase Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits xanthine oxidase ‚Üí blocks conversion of hypoxanthine to xanthine to uric acid ‚Üí reduces uric acid production.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Chronic gout (urate-lowering therapy)</li>
                            <li>Recurrent gout flares (‚â•2/year)</li>
                            <li>Tophi</li>
                            <li>Tumor lysis syndrome prevention</li>
                            <li>Uric acid nephropathy/stones</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Step</th><th>Dose</th></tr>
                            <tr><td>Start</td><td>100 mg daily (50 mg if CKD stage 4+)</td></tr>
                            <tr><td>Titrate</td><td>Increase by 100 mg q2-4 weeks</td></tr>
                            <tr><td>Target</td><td>Uric acid <6 mg/dL (or <5 if tophi)</td></tr>
                            <tr><td>Max</td><td>800 mg/day</td></tr>
                        </table>
                        <p>Start with colchicine or NSAID prophylaxis √ó 3-6 months to prevent flares during initiation.</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Gout flare (during initiation - use prophylaxis)</li>
                            <li><strong>Allopurinol hypersensitivity syndrome (AHS):</strong> Rash, eosinophilia, hepatitis, renal failure - can be fatal</li>
                            <li>Rash (may precede AHS)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Screen for HLA-B*58:01 in high-risk populations (Korean, Han Chinese, Thai) before starting - strong association with severe hypersensitivity (SJS/TEN, DRESS).</div>
                <div class="warning-box">Allopurinol + azathioprine/6-MP: Major interaction ‚Üí severe myelosuppression. Reduce azathioprine dose by 75% or avoid combination.</div>
                <div class="pearl-box">"Start low, go slow" - starting at high doses increases flare and hypersensitivity risk. Most patients need 300-400 mg to reach target uric acid.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="rheumatology_study_guide4.html#gout" class="guide-link">Rheum: Gout</a>
                </div>
            </div>
        </div>

        <!-- FEBUXOSTAT -->
        <div class="drug-card" data-search="febuxostat uloric xanthine oxidase gout allopurinol alternative cardiovascular">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Febuxostat</span>
                <span class="drug-brand">(Uloric)</span>
                <span class="drug-class-badge">Xanthine Oxidase Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-purine xanthine oxidase inhibitor. More potent urate-lowering than allopurinol. Hepatic metabolism (not affected by renal function).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Gout in patients intolerant to allopurinol</li>
                            <li>Inadequate response to allopurinol</li>
                            <li>Allopurinol contraindicated</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Start:</strong> 40 mg PO daily</p>
                        <p><strong>Increase to:</strong> 80 mg daily if uric acid not at goal after 2 weeks</p>
                        <p>No dose adjustment for mild-moderate renal impairment</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Gout flares (during initiation - use prophylaxis)</li>
                            <li>LFT elevations</li>
                            <li>Nausea, arthralgias</li>
                            <li><strong>Cardiovascular death risk (black box warning)</strong></li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">FDA black box for cardiovascular death: CARES trial showed higher CV death with febuxostat vs allopurinol. Reserve for allopurinol failure/intolerance.</div>
                <div class="pearl-box">Febuxostat is second-line due to CV concerns. Advantage: Can use in CKD without dose adjustment (hepatic metabolism).</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANESTHESIA / PARALYTICS ======================= -->
<div class="drug-category" id="anesthesia">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üí® Anesthesia / Paralytics</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- SUCCINYLCHOLINE -->
        <div class="drug-card" data-search="succinylcholine anectine depolarizing paralytic rsi hyperkalemia malignant hyperthermia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Succinylcholine</span>
                <span class="drug-brand">(Anectine)</span>
                <span class="drug-class-badge">Depolarizing Paralytic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Depolarizing neuromuscular blocker ‚Üí binds ACh receptors ‚Üí sustained depolarization ‚Üí paralysis. Fastest onset of any paralytic.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Rapid sequence intubation (RSI) - when fast onset/offset needed</li>
                            <li>ECT</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing & Pharmacokinetics</div>
                    <div class="drug-section-content">
                        <p><strong>RSI dose:</strong> 1-1.5 mg/kg IV push</p>
                        <p><strong>Onset:</strong> 45-60 seconds (fastest)</p>
                        <p><strong>Duration:</strong> 6-10 minutes (metabolized by pseudocholinesterase)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Contraindications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hyperkalemia</strong> or conditions with upregulated ACh receptors:
                                <ul>
                                    <li>Burns >24h old</li>
                                    <li>Crush injuries, denervation >72h</li>
                                    <li>Prolonged immobility</li>
                                    <li>Neuromuscular disease (muscular dystrophy)</li>
                                </ul>
                            </li>
                            <li><strong>Personal/family history of malignant hyperthermia</strong></li>
                            <li>Pseudocholinesterase deficiency (prolonged paralysis)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Can cause fatal hyperkalemia in susceptible patients. Avoid in burns, crush injuries, denervation, prolonged immobility, neuromuscular disease.</div>
                <div class="warning-box">Malignant hyperthermia: Presents with hyperthermia, rigidity, hypercarbia, rhabdomyolysis. Treat with dantrolene. Have dantrolene available when using succinylcholine.</div>
                <div class="pearl-box">Succinylcholine is the fastest-onset paralytic but has many contraindications. Rocuronium 1.2 mg/kg with sugammadex available is often preferred alternative.</div>
            </div>
        </div>

        <!-- ROCURONIUM -->
        <div class="drug-card" data-search="rocuronium zemuron nondepolarizing paralytic rsi sugammadex intubation">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Rocuronium</span>
                <span class="drug-brand">(Zemuron)</span>
                <span class="drug-class-badge">Non-Depolarizing Paralytic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Competitive antagonist at nicotinic ACh receptors ‚Üí non-depolarizing neuromuscular blockade. Aminosteroid structure.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>RSI (especially when succinylcholine contraindicated)</li>
                            <li>Surgical paralysis</li>
                            <li>ICU paralysis (ARDS, shivering)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard intubation</td><td>0.6 mg/kg (onset 1-2 min)</td></tr>
                            <tr><td>RSI (rapid sequence)</td><td>1-1.2 mg/kg (onset 45-60 sec)</td></tr>
                            <tr><td>Maintenance</td><td>0.1-0.2 mg/kg PRN or 0.1-0.2 mg/kg/hr infusion</td></tr>
                        </table>
                        <p><strong>Duration:</strong> 30-45 min (standard dose); 60+ min (RSI dose)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚Ü©Ô∏è Reversal</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Sugammadex (Bridion):</strong> 2-4 mg/kg (standard), 16 mg/kg (immediate) - rapid, complete reversal</li>
                            <li><strong>Neostigmine + glycopyrrolate:</strong> Traditional reversal (slower, requires some spontaneous recovery)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Prolonged paralysis (hepatic/renal impairment, hypothermia)</li>
                            <li>Tachycardia (mild vagolytic effect)</li>
                            <li>Awareness if inadequate sedation (patient cannot move but is awake)</li>
                            <li>Anaphylaxis (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">ALWAYS ensure adequate sedation before paralysis. Monitor with train-of-four. Prolonged use associated with ICU-acquired weakness.</div>
                <div class="pearl-box">High-dose rocuronium (1.2 mg/kg) + sugammadex available is now preferred over succinylcholine for RSI in many centers - similar onset, safer profile, complete reversal possible.</div>
            </div>
        </div>

        <!-- ETOMIDATE -->
        <div class="drug-card" data-search="etomidate amidate induction rsi hemodynamically stable adrenal suppression">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Etomidate</span>
                <span class="drug-brand">(Amidate)</span>
                <span class="drug-class-badge">Induction Agent</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">GABA-A agonist ‚Üí rapid sedation/anesthesia. Minimal cardiovascular effects (does not release histamine, minimal sympathetic effects).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>RSI induction - especially in hemodynamically unstable patients</li>
                            <li>Procedural sedation</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Induction:</strong> 0.3 mg/kg IV push</p>
                        <p><strong>Onset:</strong> 15-30 seconds</p>
                        <p><strong>Duration:</strong> 5-10 minutes</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Adrenal suppression</strong> (inhibits 11Œ≤-hydroxylase) - single dose likely not clinically significant</li>
                            <li>Myoclonus (not seizures)</li>
                            <li>Pain on injection</li>
                            <li>Nausea/vomiting</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Adrenal suppression: Single-dose etomidate blocks cortisol synthesis for 24-48h. Controversial in septic shock - some avoid, others use with stress-dose steroids.</div>
                <div class="pearl-box">Etomidate is "hemodynamically neutral" - best choice for hypotensive patients needing intubation. Ketamine is alternative if etomidate unavailable.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ANTIPARASITICS ======================= -->
<div class="drug-category" id="antiparasitics">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü¶ü Antiparasitics</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- IVERMECTIN -->
        <div class="drug-card" data-search="ivermectin stromectol strongyloides scabies onchocerciasis loa loa">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ivermectin</span>
                <span class="drug-brand">(Stromectol)</span>
                <span class="drug-class-badge">Antiparasitic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds glutamate-gated chloride channels in parasites ‚Üí hyperpolarization ‚Üí paralysis and death. Does not cross human BBB (normally).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Strongyloidiasis</strong> (must treat before immunosuppression)</li>
                            <li><strong>Scabies</strong></li>
                            <li>Onchocerciasis (river blindness)</li>
                            <li>Ascariasis, enterobiasis (pinworm)</li>
                            <li>Head lice</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Strongyloidiasis</td><td>200 mcg/kg PO √ó 1-2 days (repeat day 14)</td></tr>
                            <tr><td>Hyperinfection syndrome</td><td>200 mcg/kg daily until negative √ó 2 weeks</td></tr>
                            <tr><td>Scabies</td><td>200 mcg/kg PO √ó 1 (repeat day 8-14)</td></tr>
                        </table>
                        <p>Take on empty stomach with water</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Screen for Loa loa coinfection in endemic areas (West/Central Africa) - can cause fatal encephalopathy</li>
                            <li>Generally well-tolerated</li>
                            <li>Mazzotti reaction possible with onchocerciasis (inflammatory response to dying parasites)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">MUST screen for Strongyloides before starting immunosuppression (steroids, chemotherapy, transplant) - can cause fatal hyperinfection syndrome.</div>
                <div class="pearl-box">Strongyloides can persist for decades (autoinfection cycle). Screen with serology in anyone from endemic areas before immunosuppression.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="id_guide5_5_integrated.html#parasites" class="guide-link">ID Guide: Parasites</a>
                </div>
            </div>
        </div>

        <!-- MEBENDAZOLE/ALBENDAZOLE -->
        <div class="drug-card" data-search="albendazole mebendazole benzimidazole helminth pinworm hookworm roundworm tapeworm">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Albendazole / Mebendazole</span>
                <span class="drug-brand">(Albenza / Emverm)</span>
                <span class="drug-class-badge">Benzimidazole</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds Œ≤-tubulin ‚Üí inhibits microtubule formation ‚Üí disrupts glucose uptake ‚Üí parasite death. Broad-spectrum antihelminthic.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Intestinal nematodes:</strong> Ascaris, hookworm, whipworm, pinworm</li>
                            <li><strong>Tissue parasites:</strong> Neurocysticercosis, hydatid cyst (albendazole)</li>
                            <li><strong>Giardia</strong> (alternative)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Drug</th><th>Dose</th></tr>
                            <tr><td>Pinworm</td><td>Mebendazole</td><td>100 mg √ó 1 (repeat in 2 weeks)</td></tr>
                            <tr><td>Roundworm/hookworm</td><td>Albendazole</td><td>400 mg √ó 1-3 days</td></tr>
                            <tr><td>Neurocysticercosis</td><td>Albendazole</td><td>7.5 mg/kg BID √ó 8-30 days + steroids</td></tr>
                            <tr><td>Hydatid cyst</td><td>Albendazole</td><td>400 mg BID √ó 1-6 months</td></tr>
                        </table>
                        <p>Albendazole: Take with fatty meal (increases absorption 5√ó)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GI upset</li>
                            <li>Elevated LFTs (monitor with prolonged use)</li>
                            <li>Bone marrow suppression (rare, prolonged therapy)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Neurocysticercosis: Give steroids BEFORE albendazole to prevent inflammatory response from dying cysts. Can worsen symptoms acutely without steroids.</div>
                <div class="pearl-box">Albendazole has better systemic absorption than mebendazole - preferred for tissue parasites. Mebendazole stays in gut - fine for intestinal worms only.</div>
            </div>
        </div>

    </div>
</div>

<!-- FOOTER AND JAVASCRIPT -->

<!-- ======================= ANTIEMETICS ======================= -->
<div class="drug-category" id="antiemetics">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü§¢ Antiemetics</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- ONDANSETRON -->
        <div class="drug-card" data-search="ondansetron zofran serotonin 5ht3 nausea vomiting ponv chemotherapy qt">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ondansetron</span>
                <span class="drug-brand">(Zofran)</span>
                <span class="drug-class-badge">5-HT3 Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Selective serotonin 5-HT3 receptor antagonist in CTZ and vagal afferents ‚Üí blocks nausea/vomiting signals. No dopamine blockade (no EPS).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Chemotherapy-induced nausea/vomiting (CINV)</li>
                            <li>Post-operative nausea/vomiting (PONV)</li>
                            <li>General nausea/vomiting</li>
                            <li>Radiation-induced nausea</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>PONV prevention</td><td>4 mg IV/PO at induction or end of surgery</td></tr>
                            <tr><td>General nausea</td><td>4-8 mg IV/PO q6-8h PRN</td></tr>
                            <tr><td>CINV (moderate)</td><td>8 mg PO BID or 8 mg IV √ó 1</td></tr>
                            <tr><td>CINV (high risk)</td><td>24 mg PO √ó 1 (pre-chemo)</td></tr>
                        </table>
                        <p><strong>Max single IV dose:</strong> 16 mg (QTc concern)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>QTc prolongation</strong> (dose-dependent, especially IV >16 mg)</li>
                            <li>Headache (most common)</li>
                            <li>Constipation</li>
                            <li>Serotonin syndrome (rare, with other serotonergic drugs)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">QTc prolongation risk: Avoid in congenital long QT. Use caution with other QT-prolonging drugs. Max single IV dose 16 mg per FDA.</div>
                <div class="pearl-box">Ondansetron causes constipation - use cautiously in bowel obstruction. No EPS risk unlike dopamine antagonists. ODT (oral dissolving tablet) useful for active vomiting.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#nausea" class="guide-link">IMCRG: Nausea/Vomiting</a>
                </div>
            </div>
        </div>

        <!-- PROCHLORPERAZINE -->
        <div class="drug-card" data-search="prochlorperazine compazine dopamine antagonist nausea vomiting migraine eps">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Prochlorperazine</span>
                <span class="drug-brand">(Compazine)</span>
                <span class="drug-class-badge">Dopamine Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">D2 dopamine receptor antagonist in CTZ ‚Üí antiemetic. Also phenothiazine with antipsychotic properties.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Nausea/vomiting</li>
                            <li><strong>Migraine</strong> (with or without metoclopramide)</li>
                            <li>Vertigo</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Dose</th></tr>
                            <tr><td>PO</td><td>5-10 mg q6-8h PRN</td></tr>
                            <tr><td>IV/IM</td><td>5-10 mg q6h PRN (max 40 mg/day)</td></tr>
                            <tr><td>PR</td><td>25 mg q12h PRN</td></tr>
                            <tr><td>Migraine</td><td>10 mg IV (often with diphenhydramine)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Extrapyramidal symptoms</strong> (dystonia, akathisia) - give with diphenhydramine</li>
                            <li>Sedation</li>
                            <li>QTc prolongation</li>
                            <li>Hypotension</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">For migraine: Prochlorperazine 10 mg IV + diphenhydramine 25 mg IV is highly effective. The diphenhydramine prevents dystonic reactions.</div>
            </div>
        </div>

        <!-- METOCLOPRAMIDE -->
        <div class="drug-card" data-search="metoclopramide reglan prokinetic gastroparesis nausea dopamine tardive dyskinesia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Metoclopramide</span>
                <span class="drug-brand">(Reglan)</span>
                <span class="drug-class-badge">Prokinetic / D2 Antagonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">D2 antagonist (antiemetic) + 5-HT4 agonist + acetylcholine release ‚Üí prokinetic effects. Increases gastric emptying and LES tone.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Diabetic gastroparesis</li>
                            <li>GERD (second-line)</li>
                            <li>Nausea/vomiting</li>
                            <li>Post-operative ileus</li>
                            <li>Facilitate feeding tube placement</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Gastroparesis</td><td>5-10 mg PO/IV 30 min before meals and at bedtime</td></tr>
                            <tr><td>Nausea</td><td>10 mg IV q6h PRN</td></tr>
                            <tr><td>Tube placement</td><td>10-20 mg IV √ó 1</td></tr>
                        </table>
                        <p><strong>Limit use to &lt;12 weeks</strong> (tardive dyskinesia risk)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Tardive dyskinesia</strong> (irreversible, cumulative dose-related)</li>
                            <li>Acute dystonia, akathisia, parkinsonism</li>
                            <li>Drowsiness</li>
                            <li>Prolactin elevation (galactorrhea)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Tardive dyskinesia: Risk increases with duration >12 weeks and cumulative dose. Often irreversible. Limit treatment duration.</div>
                <div class="pearl-box">The only FDA-approved prokinetic for gastroparesis. Limit to 12 weeks when possible. IV given over 15 min to reduce dystonia risk.</div>
            </div>
        </div>

        <!-- PROMETHAZINE -->
        <div class="drug-card" data-search="promethazine phenergan antihistamine nausea sedation tissue necrosis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Promethazine</span>
                <span class="drug-brand">(Phenergan)</span>
                <span class="drug-class-badge">H1 Antihistamine / Phenothiazine</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">H1 antihistamine with anticholinergic and antidopaminergic properties ‚Üí antiemetic, sedative, antipruritic effects.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Nausea/vomiting</li>
                            <li>Motion sickness</li>
                            <li>Allergic reactions</li>
                            <li>Sedation</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Dose</th></tr>
                            <tr><td>PO/PR</td><td>12.5-25 mg q4-6h PRN</td></tr>
                            <tr><td>IM (preferred parenteral)</td><td>12.5-25 mg q4-6h PRN</td></tr>
                            <tr><td>IV (if must use)</td><td>6.25-12.5 mg slow push through running IV</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Severe tissue injury</strong> with IV extravasation or intra-arterial injection (gangrene, amputation)</li>
                            <li>Heavy sedation</li>
                            <li>Respiratory depression (especially in children)</li>
                            <li>Anticholinergic effects</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">IV administration carries risk of severe tissue necrosis. NEVER give SubQ or intra-arterial. IM or deep IV through large vein preferred. Contraindicated in children &lt;2 years (fatal respiratory depression).</div>
                <div class="warning-box">Many institutions have restricted or removed IV promethazine due to tissue injury risk. Consider ondansetron or prochlorperazine instead.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ADDITIONAL PAIN MEDICATIONS ======================= -->
<div class="drug-category" id="pain-additional">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Additional Pain Medications</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- HYDROMORPHONE -->
        <div class="drug-card" data-search="hydromorphone dilaudid opioid pain mu receptor potent">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Hydromorphone</span>
                <span class="drug-brand">(Dilaudid)</span>
                <span class="drug-class-badge">Opioid Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œº-opioid receptor agonist, ~5-7√ó more potent than morphine. Semi-synthetic opioid with no active metabolites (safer in renal failure than morphine).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Opioid-Naive Dose</th><th>Conversion</th></tr>
                            <tr><td>IV</td><td>0.2-0.6 mg q2-3h PRN</td><td>1.5 mg IV = 10 mg morphine IV</td></tr>
                            <tr><td>PO</td><td>2-4 mg q4-6h PRN</td><td>4 mg PO = 20-30 mg morphine PO</td></tr>
                            <tr><td>PCA</td><td>0.2 mg demand, 6-10 min lockout</td><td>‚Äî</td></tr>
                        </table>
                        <p><strong>IV:PO ratio = 1:4</strong> (0.5 mg IV ‚âà 2 mg PO)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Preferred over morphine in renal failure</strong> (no active metabolites)</li>
                            <li>Less histamine release than morphine</li>
                            <li>Higher potency ‚Üí higher abuse potential (may request by name)</li>
                            <li>Same side effects as morphine (respiratory depression, constipation, etc.)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Hydromorphone is preferred over morphine in CKD/ESRD patients - morphine's metabolite (M6G) accumulates and causes prolonged sedation. Also causes less histamine release.</div>
            </div>
        </div>

        <!-- KETOROLAC -->
        <div class="drug-card" data-search="ketorolac toradol nsaid iv pain renal gi bleeding">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Ketorolac</span>
                <span class="drug-brand">(Toradol)</span>
                <span class="drug-class-badge">IV NSAID</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-selective COX inhibitor ‚Üí inhibits prostaglandin synthesis ‚Üí analgesic, anti-inflammatory, antipyretic. Potent analgesic (30 mg ‚âà 10 mg morphine).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Moderate-severe acute pain (post-operative)</li>
                            <li>Renal colic</li>
                            <li>Opioid-sparing analgesia</li>
                            <li>Migraine (adjunct)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Patient</th><th>Dose</th></tr>
                            <tr><td>Adults <65 years</td><td>30 mg IV/IM q6h (max 120 mg/day)</td></tr>
                            <tr><td>Adults ‚â•65 years or <50 kg</td><td>15 mg IV/IM q6h (max 60 mg/day)</td></tr>
                            <tr><td>Oral (continuation only)</td><td>10 mg q4-6h (max 40 mg/day)</td></tr>
                        </table>
                        <p><strong>Maximum duration: 5 days total (all routes combined)</strong></p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Contraindications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Active or history of GI bleeding/peptic ulcer</strong></li>
                            <li><strong>Renal impairment</strong> (including risk factors: hypovolemia, elderly, ACEi/ARB, diuretics)</li>
                            <li>Perioperative CABG</li>
                            <li>Active bleeding or coagulopathy</li>
                            <li>Third trimester pregnancy</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Increased risk of GI bleeding, cardiovascular events, and renal failure. Maximum 5 days. Not for chronic pain.</div>
                <div class="warning-box">Avoid in elderly, CKD, hypovolemia, or with other nephrotoxins. Even short courses can cause AKI in at-risk patients.</div>
                <div class="pearl-box">Excellent for renal colic and post-op pain. Limited to 5 days to reduce GI/renal risk. Very effective opioid-sparing agent when not contraindicated.</div>
            </div>
        </div>

        <!-- ACETAMINOPHEN IV -->
        <div class="drug-card" data-search="acetaminophen ofirmev tylenol iv pain fever hepatotoxicity">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Acetaminophen IV</span>
                <span class="drug-brand">(Ofirmev)</span>
                <span class="drug-class-badge">Analgesic / Antipyretic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Central COX inhibition and possible serotonergic/cannabinoid pathway effects. Analgesic and antipyretic without significant anti-inflammatory effect.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Mild-moderate pain (when PO not possible)</li>
                            <li>Fever</li>
                            <li>Multimodal analgesia (opioid-sparing)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Weight</th><th>Dose</th></tr>
                            <tr><td>‚â•50 kg</td><td>1000 mg IV q6h PRN (max 4 g/day)</td></tr>
                            <tr><td><50 kg</td><td>15 mg/kg IV q6h (max 75 mg/kg/day)</td></tr>
                            <tr><td>Hepatic impairment</td><td>Reduce to 2 g/day max</td></tr>
                        </table>
                        <p>Infuse over 15 minutes</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hepatotoxicity</strong> with overdose (>4 g/day) - account for ALL acetaminophen sources</li>
                            <li>Reduce max dose in liver disease, chronic alcohol use, malnutrition</li>
                            <li>IV is expensive - use PO/PR when feasible</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">IV acetaminophen is much more expensive than PO ($20-40 vs cents). Reserve for NPO patients or when rapid onset needed. Efficacy similar to oral.</div>
            </div>
        </div>

        <!-- TRAMADOL -->
        <div class="drug-card" data-search="tramadol ultram opioid snri pain seizure serotonin syndrome">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Tramadol</span>
                <span class="drug-brand">(Ultram)</span>
                <span class="drug-class-badge">Opioid + SNRI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Weak Œº-opioid agonist + norepinephrine and serotonin reuptake inhibitor. Dual mechanism for pain relief.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Dose</th></tr>
                            <tr><td>Immediate-release</td><td>50-100 mg PO q4-6h PRN (max 400 mg/day)</td></tr>
                            <tr><td>Extended-release</td><td>100 mg daily, titrate to 200-300 mg daily</td></tr>
                            <tr><td>CrCl <30</td><td>50-100 mg q12h (max 200 mg/day)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Interactions</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Seizures</strong> (lowers seizure threshold, especially with SSRIs/SNRIs)</li>
                            <li><strong>Serotonin syndrome</strong> (with SSRIs, SNRIs, MAOIs, TCAs)</li>
                            <li>Nausea, dizziness, constipation</li>
                            <li>Dependence (schedule IV)</li>
                            <li>Variable metabolism (CYP2D6) - poor metabolizers get less effect</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Avoid with seizure history and serotonergic medications. Serotonin syndrome and seizures more common than with traditional opioids.</div>
                <div class="pearl-box">Tramadol is NOT a "safe" opioid alternative - has abuse potential and unique risks (seizures, serotonin syndrome). ~10% of population are poor CYP2D6 metabolizers with minimal analgesic effect.</div>
            </div>
        </div>

        <!-- GABAPENTIN -->
        <div class="drug-card" data-search="gabapentin neurontin neuropathic pain seizure gaba pregabalin lyrica">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Gabapentin / Pregabalin</span>
                <span class="drug-brand">(Neurontin / Lyrica)</span>
                <span class="drug-class-badge">Gabapentinoid</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds Œ±2Œ¥ subunit of voltage-gated calcium channels ‚Üí reduces excitatory neurotransmitter release. NOT a GABA agonist despite name.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Neuropathic pain (diabetic neuropathy, PHN)</li>
                            <li>Fibromyalgia (pregabalin)</li>
                            <li>Partial seizures (adjunct)</li>
                            <li>Perioperative pain (multimodal)</li>
                            <li>Alcohol withdrawal (adjunct)</li>
                            <li>Restless leg syndrome</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Drug</th><th>Starting</th><th>Target</th></tr>
                            <tr><td>Gabapentin</td><td>100-300 mg TID</td><td>300-1200 mg TID (max 3600 mg/day)</td></tr>
                            <tr><td>Pregabalin</td><td>50-75 mg BID</td><td>150-300 mg BID (max 600 mg/day)</td></tr>
                        </table>
                        <p><strong>Significant renal adjustment required</strong> (both renally cleared)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Sedation, dizziness</li>
                            <li>Peripheral edema</li>
                            <li>Weight gain</li>
                            <li>Cognitive impairment (especially elderly)</li>
                            <li><strong>Respiratory depression</strong> (especially with opioids, in elderly, COPD)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">FDA warning: Serious breathing problems when combined with opioids or in patients with respiratory risk factors. Start low in elderly.</div>
                <div class="pearl-box">Pregabalin has linear pharmacokinetics and faster onset than gabapentin. Both are schedule V (abuse potential). Taper when discontinuing to avoid withdrawal.</div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ICU SEDATION ======================= -->
<div class="drug-category" id="icu-sedation">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üè• ICU Sedation</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- DEXMEDETOMIDINE -->
        <div class="drug-card" data-search="dexmedetomidine precedex alpha2 agonist sedation icu bradycardia arousable">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dexmedetomidine</span>
                <span class="drug-brand">(Precedex)</span>
                <span class="drug-class-badge">Œ±2-Adrenergic Agonist</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Selective Œ±2-adrenergic agonist in locus coeruleus ‚Üí sedation, anxiolysis, analgesia WITHOUT respiratory depression. Produces "arousable" sedation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>ICU sedation (especially for extubation, light sedation)</li>
                            <li>Procedural sedation</li>
                            <li>Alcohol/benzodiazepine withdrawal (adjunct)</li>
                            <li>Delirium management</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Setting</th><th>Loading</th><th>Infusion</th></tr>
                            <tr><td>ICU sedation</td><td>0.5-1 mcg/kg over 10 min (optional)</td><td>0.2-0.7 mcg/kg/hr</td></tr>
                            <tr><td>Procedural</td><td>1 mcg/kg over 10 min</td><td>0.2-1 mcg/kg/hr</td></tr>
                        </table>
                        <p>Titrate to target RASS (usually 0 to -2)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Bradycardia</strong> (common, dose-dependent)</li>
                            <li><strong>Hypotension</strong> (avoid/reduce loading dose if concerned)</li>
                            <li>Transient hypertension (with loading dose)</li>
                            <li>Does NOT cause respiratory depression (unique advantage)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Dexmedetomidine allows "wake-up" sedation - patients can be aroused for neuro exams then return to sedation. No respiratory depression = ideal for weaning/extubation. More expensive than propofol.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#alcohol-withdrawal" class="guide-link">IMCRG: Alcohol Withdrawal</a>
                </div>
            </div>
        </div>

        <!-- MIDAZOLAM -->
        <div class="drug-card" data-search="midazolam versed benzodiazepine sedation seizure status epilepticus short acting">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Midazolam</span>
                <span class="drug-brand">(Versed)</span>
                <span class="drug-class-badge">Benzodiazepine</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">GABA-A receptor potentiation. Short-acting, water-soluble benzodiazepine. Rapid onset, short duration (ideal for procedures).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Procedural sedation</li>
                            <li>ICU sedation (continuous infusion)</li>
                            <li>Status epilepticus (IM when IV not available)</li>
                            <li>Pre-operative anxiolysis</li>
                            <li>RSI premedication</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Procedural sedation</td><td>0.5-2 mg IV q2-3min (titrate to effect)</td></tr>
                            <tr><td>ICU infusion</td><td>0.02-0.1 mg/kg/hr</td></tr>
                            <tr><td>Status epilepticus (IM)</td><td>10 mg IM √ó 1</td></tr>
                            <tr><td>Anxiolysis</td><td>0.5-1 mg IV</td></tr>
                        </table>
                        <p><strong>Onset:</strong> 1-3 min IV; <strong>Duration:</strong> 30-60 min</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Respiratory depression (especially with opioids)</li>
                            <li>Hypotension</li>
                            <li>Paradoxical agitation (rare)</li>
                            <li>Prolonged sedation with infusion (accumulation in lipid stores)</li>
                            <li>Tachyphylaxis with prolonged use</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Active metabolite (1-hydroxymidazolam) accumulates in renal failure ‚Üí prolonged sedation. Consider lorazepam or alternative in CKD.</div>
                <div class="pearl-box">For status epilepticus when IV access unavailable: IM midazolam 10 mg is as effective as IV lorazepam (RAMPART trial). Intranasal also effective.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#status-epilepticus" class="guide-link">IMCRG: Status Epilepticus</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ADDITIONAL CARDIAC ======================= -->
<div class="drug-category" id="cardiac-additional">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚ù§Ô∏è Additional Cardiac Medications</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- NITROGLYCERIN -->
        <div class="drug-card" data-search="nitroglycerin ntg nitrate angina acs heart failure preload vasodilator headache">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Nitroglycerin</span>
                <span class="drug-brand">(Nitrostat, Nitro-Bid)</span>
                <span class="drug-class-badge">Nitrate / Vasodilator</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Releases NO ‚Üí activates guanylyl cyclase ‚Üí smooth muscle relaxation. Primarily venodilation (reduces preload) at low doses; arterial dilation at higher doses.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Acute coronary syndrome (ACS)</li>
                            <li>Stable angina (prophylaxis and acute relief)</li>
                            <li>Acute decompensated heart failure (preload reduction)</li>
                            <li>Hypertensive emergency (with pulmonary edema)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Dose</th></tr>
                            <tr><td>Sublingual (acute angina)</td><td>0.4 mg q5min √ó 3 doses</td></tr>
                            <tr><td>IV infusion</td><td>Start 5-10 mcg/min, titrate by 5-10 mcg/min q3-5min</td></tr>
                            <tr><td>Topical paste</td><td>0.5-2 inches q6h</td></tr>
                            <tr><td>Patch</td><td>0.2-0.8 mg/hr (remove 10-12h overnight for nitrate-free interval)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Contraindications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Headache</strong> (very common - cerebral vasodilation)</li>
                            <li>Hypotension, reflex tachycardia</li>
                            <li><strong>Contraindicated with PDE5 inhibitors</strong> (sildenafil, tadalafil) ‚Üí severe hypotension</li>
                            <li>Contraindicated in RV infarct (preload-dependent)</li>
                            <li>Tolerance develops with continuous use</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Ask about PDE5 inhibitor use (Viagra, Cialis) - contraindicated within 24-48 hours. Also avoid in RV infarct (causes severe hypotension).</div>
                <div class="pearl-box">Nitrate tolerance develops with continuous use - provide 10-12 hour nitrate-free interval daily. In acute HF, high-dose NTG boluses (400 mcg SL or 200-400 mcg IV) can rapidly reduce preload.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#acs" class="guide-link">IMCRG: ACS</a>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                </div>
            </div>
        </div>

        <!-- NITROPRUSSIDE -->
        <div class="drug-card" data-search="nitroprusside nipride sodium cyanide hypertensive emergency afterload vasodilator">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Sodium Nitroprusside</span>
                <span class="drug-brand">(Nipride)</span>
                <span class="drug-class-badge">Arterial + Venous Vasodilator</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Direct NO donor ‚Üí balanced arterial AND venous dilation (reduces both preload and afterload). Immediate onset/offset.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypertensive emergency</li>
                            <li>Acute aortic dissection (with Œ≤-blocker)</li>
                            <li>Acute heart failure (afterload reduction)</li>
                            <li>Controlled hypotension during surgery</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Start:</strong> 0.3-0.5 mcg/kg/min</p>
                        <p><strong>Titrate:</strong> Increase by 0.5 mcg/kg/min q5min to effect</p>
                        <p><strong>Max:</strong> 10 mcg/kg/min (cyanide toxicity risk above this)</p>
                        <p>Protect from light (wrap tubing)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Cyanide toxicity:</strong> With prolonged use, high doses, renal/hepatic impairment</li>
                            <li><strong>Thiocyanate toxicity:</strong> With prolonged use and renal failure</li>
                            <li>Hypotension (profound, rapid)</li>
                            <li>Reflex tachycardia</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Cyanide toxicity: Releases cyanide during metabolism. Risk with high doses (>2 mcg/kg/min for >48h) or renal impairment. Signs: lactic acidosis, AMS, seizures. Treat with hydroxocobalamin or sodium thiosulfate.</div>
                <div class="warning-box">Limit to short-term use (<48-72h). Monitor thiocyanate levels if >48h use. Co-administer sodium thiosulfate for prolonged infusions.</div>
                <div class="pearl-box">For aortic dissection: Must use with Œ≤-blocker first (to prevent reflex tachycardia and increased dP/dt). Clevidipine or nicardipine are safer alternatives.</div>
            </div>
        </div>

        <!-- ESMOLOL -->
        <div class="drug-card" data-search="esmolol brevibloc beta blocker short acting aortic dissection svt rate control">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Esmolol</span>
                <span class="drug-brand">(Brevibloc)</span>
                <span class="drug-class-badge">Ultra-Short Œ≤1 Blocker</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Cardioselective Œ≤1-blocker with ultra-short half-life (9 min). Metabolized by RBC esterases - not affected by renal/hepatic function.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Aortic dissection</strong> (first-line - reduce HR and dP/dt)</li>
                            <li>SVT rate control</li>
                            <li>Perioperative tachycardia/hypertension</li>
                            <li>Thyroid storm</li>
                            <li>When Œ≤-blocker needed but uncertain about tolerance</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Loading</th><th>Infusion</th></tr>
                            <tr><td>SVT/rate control</td><td>500 mcg/kg over 1 min</td><td>50-200 mcg/kg/min</td></tr>
                            <tr><td>Aortic dissection</td><td>500 mcg/kg over 1 min</td><td>50-200 mcg/kg/min (target HR <60)</td></tr>
                        </table>
                        <p>Can repeat loading dose and uptitrate q4min</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypotension (most common)</li>
                            <li>Bradycardia</li>
                            <li>Effects resolve within 10-20 min of stopping</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Ultra-short half-life (9 min) allows rapid titration and quick offset if problems occur. Ideal "test dose" when unsure if patient will tolerate Œ≤-blocker. For aortic dissection: Target HR <60, SBP 100-120.</div>
            </div>
        </div>

        <!-- ADENOSINE -->
        <div class="drug-card" data-search="adenosine adenocard svt psvt av node transient asystole theophylline">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Adenosine</span>
                <span class="drug-brand">(Adenocard)</span>
                <span class="drug-class-badge">Antiarrhythmic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Activates A1 adenosine receptors ‚Üí transiently blocks AV node conduction. Ultra-short half-life (<10 seconds).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Stable regular narrow-complex SVT</strong> (AVNRT, AVRT)</li>
                            <li>Diagnostic: Unmask atrial activity (flutter waves)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Line</th><th>Dose</th></tr>
                            <tr><td>Peripheral IV</td><td>6 mg rapid push ‚Üí 12 mg ‚Üí 12 mg (q1-2min)</td></tr>
                            <tr><td>Central line</td><td>3 mg rapid push (closer to heart)</td></tr>
                        </table>
                        <p><strong>MUST give as rapid IV push followed by 20 mL NS flush</strong></p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects & Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Transient asystole</strong> (expected - warn patient "you may feel like you're dying")</li>
                            <li>Chest discomfort, flushing, dyspnea</li>
                            <li>May cause bronchospasm (caution in asthma)</li>
                            <li>May precipitate AFib</li>
                            <li><strong>Theophylline/caffeine antagonize effect</strong> (may need higher doses)</li>
                            <li><strong>Dipyridamole/carbamazepine potentiate effect</strong> (use lower doses)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Contraindicated in pre-excited AF (WPW with AF) - can accelerate conduction down bypass tract ‚Üí VF. Only use for regular narrow-complex tachycardia.</div>
                <div class="pearl-box">Must give RAPIDLY through large-bore proximal IV followed by flush - drug is metabolized in seconds. Have patient on monitor, defibrillator ready (rarely needed).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#svt" class="guide-link">IMCRG: SVT</a>
                </div>
            </div>
        </div>

        <!-- ATROPINE -->
        <div class="drug-card" data-search="atropine anticholinergic bradycardia acls organophosphate muscarinic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Atropine</span>
                <span class="drug-brand">(Atropine)</span>
                <span class="drug-class-badge">Anticholinergic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Competitive muscarinic receptor antagonist ‚Üí blocks vagal (parasympathetic) effects on heart ‚Üí increases HR and AV conduction.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Symptomatic bradycardia</strong> (ACLS)</li>
                            <li>Organophosphate/carbamate poisoning</li>
                            <li>Premedication (reduce secretions)</li>
                            <li>Reversal of muscarinic effects (neostigmine)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Symptomatic bradycardia</td><td>0.5-1 mg IV q3-5min (max 3 mg)</td></tr>
                            <tr><td>Organophosphate poisoning</td><td>2-4 mg IV, repeat q5-10min until secretions dry</td></tr>
                            <tr><td>Pre-intubation</td><td>0.01-0.02 mg/kg IV</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Minimum dose 0.5 mg (lower doses may cause paradoxical bradycardia)</li>
                            <li>Less effective for infranodal (Mobitz II, complete) heart block</li>
                            <li>NOT recommended for asystole/PEA (removed from ACLS)</li>
                            <li>Anticholinergic side effects: dry mouth, urinary retention, confusion</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Atropine works on SA and AV node - effective for sinus bradycardia and AV nodal block (Mobitz I). Less effective for infranodal block (Mobitz II, complete) - prepare for pacing.</div>
            </div>
        </div>

        <!-- ATORVASTATIN -->
        <div class="drug-card" data-search="atorvastatin lipitor statin hmg-coa reductase cholesterol ldl ascvd myopathy">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Atorvastatin</span>
                <span class="drug-brand">(Lipitor)</span>
                <span class="drug-class-badge">HMG-CoA Reductase Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits HMG-CoA reductase ‚Üí blocks cholesterol synthesis in liver ‚Üí upregulates LDL receptors ‚Üí reduces LDL cholesterol. Also anti-inflammatory (plaque stabilization).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>ASCVD (secondary prevention)</li>
                            <li>High-risk primary prevention</li>
                            <li>ACS (high-intensity statin regardless of baseline LDL)</li>
                            <li>Diabetes with elevated ASCVD risk</li>
                            <li>Hypercholesterolemia</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Intensity</th><th>Dose</th><th>Expected LDL Reduction</th></tr>
                            <tr><td>High-intensity</td><td>40-80 mg daily</td><td>‚â•50%</td></tr>
                            <tr><td>Moderate-intensity</td><td>10-20 mg daily</td><td>30-49%</td></tr>
                        </table>
                        <p>Can take any time of day (long half-life unlike simvastatin)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Myopathy/myalgia</strong> (muscle pain without CK elevation common; rhabdomyolysis rare)</li>
                            <li>Hepatotoxicity (check LFTs at baseline; routine monitoring not required)</li>
                            <li>New-onset diabetes (modest increase)</li>
                            <li>Drug interactions (CYP3A4 substrate)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">For ACS: Start high-intensity statin (atorvastatin 80 mg or rosuvastatin 20-40 mg) regardless of LDL level - provides early benefit from plaque stabilization beyond LDL lowering.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#acs" class="guide-link">IMCRG: ACS</a>
                    <a href="im_guidev3B20.html#hyperlipidemia" class="guide-link">IMCRG: Hyperlipidemia</a>
                </div>
            </div>
        </div>

        <!-- SACUBITRIL-VALSARTAN -->
        <div class="drug-card" data-search="sacubitril valsartan entresto arni neprilysin heart failure hfref">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Sacubitril-Valsartan</span>
                <span class="drug-brand">(Entresto)</span>
                <span class="drug-class-badge">ARNI</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Combination of ARB (valsartan) + neprilysin inhibitor (sacubitril). Neprilysin breaks down natriuretic peptides ‚Üí inhibition increases NP levels ‚Üí vasodilation, natriuresis, reduced fibrosis.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>HFrEF (EF ‚â§40%)</strong> - replaces ACEi/ARB</li>
                            <li>HFmrEF and HFpEF (some benefit)</li>
                            <li>Use in patients tolerating ACEi/ARB</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Starting Dose</th><th>Target</th></tr>
                            <tr><td>ACEi/ARB-naive or low BP</td><td>24/26 mg BID</td></tr>
                            <tr><td>Converting from ACEi/ARB</td><td>49/51 mg BID</td></tr>
                            <tr><td>Target dose</td><td>97/103 mg BID</td></tr>
                        </table>
                        <p><strong>Must stop ACEi 36 hours before starting</strong> (angioedema risk)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypotension (most common limiting factor)</li>
                            <li>Hyperkalemia</li>
                            <li>Renal impairment</li>
                            <li><strong>Angioedema</strong> (especially if switching from ACEi without washout)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Contraindicated in pregnancy. Do not use with ACEi - allow 36-hour washout. Do not use with aliskiren in diabetes.</div>
                <div class="pearl-box">PARADIGM-HF: 20% reduction in CV death and HF hospitalization vs enalapril. Now guideline-recommended over ACEi/ARB for HFrEF. BNP cannot be used to monitor HF (inhibited by drug) - use NT-proBNP instead.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#heart-failure" class="guide-link">IMCRG: Heart Failure</a>
                </div>
            </div>
        </div>

        <!-- ISOSORBIDE -->
        <div class="drug-card" data-search="isosorbide mononitrate dinitrate imdur nitrate angina preload nitrate-free interval">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Isosorbide Mononitrate/Dinitrate</span>
                <span class="drug-brand">(Imdur / Isordil)</span>
                <span class="drug-class-badge">Oral Nitrate</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Same as nitroglycerin (NO release ‚Üí venodilation ‚Üí preload reduction). Mononitrate is active form; dinitrate requires hepatic conversion.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Chronic stable angina prophylaxis</li>
                            <li>HFrEF (with hydralazine - mortality benefit in Black patients)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Drug</th><th>Dose</th><th>Note</th></tr>
                            <tr><td>Isosorbide mononitrate (Imdur)</td><td>30-60 mg daily, max 240 mg</td><td>Once daily dosing provides nitrate-free interval</td></tr>
                            <tr><td>Isosorbide dinitrate</td><td>10-40 mg TID</td><td>Dose asymmetrically (8 AM, 1 PM, 6 PM) for nitrate-free interval</td></tr>
                            <tr><td>BiDil (dinitrate + hydralazine)</td><td>20/37.5 mg TID, titrate to 40/75 mg TID</td><td>For HFrEF in Black patients</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Must have nitrate-free interval</strong> (10-14 hours) to prevent tolerance</li>
                            <li>Headache common (cerebral vasodilation)</li>
                            <li>Avoid with PDE5 inhibitors</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">A-HeFT trial: Isosorbide dinitrate + hydralazine (BiDil) reduces mortality in Black patients with HFrEF already on standard therapy. Provides additional mortality benefit.</div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ADDITIONAL ANTIBIOTICS ======================= -->
<div class="drug-category" id="antibiotics-additional">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Additional Antibiotics</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- AZITHROMYCIN -->
        <div class="drug-card" data-search="azithromycin zithromax zpak macrolide atypical cap chlamydia qt">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Azithromycin</span>
                <span class="drug-brand">(Zithromax, Z-Pak)</span>
                <span class="drug-class-badge">Macrolide</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Binds 50S ribosomal subunit ‚Üí inhibits bacterial protein synthesis. Bacteriostatic. Excellent tissue penetration and long half-life (68h).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Atypicals:</strong> Mycoplasma, Chlamydia, Legionella</li>
                            <li><strong>Respiratory:</strong> S. pneumoniae, H. influenzae (some resistance)</li>
                            <li><strong>Key uses:</strong> CAP (with Œ≤-lactam), acute bronchitis, STIs (chlamydia, gonorrhea adjunct), MAC prophylaxis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>CAP</td><td>500 mg IV/PO day 1, then 250 mg daily √ó 4 days (or 500 mg √ó 3 days)</td></tr>
                            <tr><td>Chlamydia</td><td>1 g PO √ó 1</td></tr>
                            <tr><td>MAC prophylaxis</td><td>1200 mg PO weekly</td></tr>
                            <tr><td>Traveler's diarrhea</td><td>1 g PO √ó 1 or 500 mg daily √ó 3 days</td></tr>
                        </table>
                        <p>No renal adjustment needed</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GI upset (less than erythromycin)</li>
                            <li><strong>QTc prolongation</strong></li>
                            <li>Hepatotoxicity (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Long half-life allows short courses (5-day or 3-day). For CAP, add to Œ≤-lactam for atypical coverage. Increasing S. pneumoniae resistance limits monotherapy for pneumonia.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#cap" class="guide-link">IMCRG: CAP</a>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- AZTREONAM -->
        <div class="drug-card" data-search="aztreonam azactam monobactam gram negative pcn allergy pseudomonas">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Aztreonam</span>
                <span class="drug-brand">(Azactam)</span>
                <span class="drug-class-badge">Monobactam</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Monobactam (monocyclic Œ≤-lactam) ‚Üí binds PBP3 in gram-negatives only. No cross-reactivity with penicillin allergy (different ring structure).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Gram-negative ONLY:</strong> Including Pseudomonas aeruginosa</li>
                            <li><strong>NO gram-positive or anaerobic activity</strong></li>
                            <li><strong>Key use:</strong> Gram-negative coverage in severe penicillin allergy</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Standard infections</td><td>1-2 g IV q8h</td></tr>
                            <tr><td>Pseudomonas/severe infections</td><td>2 g IV q6-8h</td></tr>
                        </table>
                        <p><strong>Renal adjustment required</strong></p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>SAFE in penicillin allergy</strong> (no cross-reactivity)</li>
                            <li>Cross-reacts with ceftazidime (shared side chain) - avoid if ceftazidime allergy</li>
                            <li>Must combine with agent for gram-positives/anaerobes if broad coverage needed</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Aztreonam is the "go-to" for gram-negative coverage in severe Œ≤-lactam allergy. Combine with vancomycin + metronidazole for broad-spectrum coverage equivalent to pip-tazo.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="id_guide5_5_integrated.html" class="guide-link">ID Guide</a>
                </div>
            </div>
        </div>

        <!-- NITROFURANTOIN -->
        <div class="drug-card" data-search="nitrofurantoin macrobid macrodantin uti uncomplicated cystitis pulmonary">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Nitrofurantoin</span>
                <span class="drug-brand">(Macrobid, Macrodantin)</span>
                <span class="drug-class-badge">Urinary Antiseptic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Multiple mechanisms: inhibits bacterial enzymes, damages DNA. Concentrated in urine (not effective for systemic infections).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Spectrum & Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Uncomplicated cystitis</strong> (first-line)</li>
                            <li><strong>UTI prophylaxis</strong></li>
                            <li>Active against: E. coli, Enterococcus, S. saprophyticus</li>
                            <li>NOT active: Pseudomonas, Proteus, Serratia</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Uncomplicated cystitis</td><td>Macrobid 100 mg PO BID √ó 5 days</td></tr>
                            <tr><td>Prophylaxis</td><td>50-100 mg PO qHS</td></tr>
                        </table>
                        <p><strong>Contraindicated if CrCl <30</strong> (inadequate urine concentration + toxicity risk)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GI upset (take with food)</li>
                            <li><strong>Pulmonary toxicity</strong> (acute hypersensitivity or chronic fibrosis with long-term use)</li>
                            <li>Peripheral neuropathy</li>
                            <li>Hepatotoxicity</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Avoid in CrCl <30 - inadequate urine levels and increased toxicity. Not for pyelonephritis (no tissue penetration). Monitor for pulmonary toxicity with prolonged use.</div>
                <div class="pearl-box">First-line for uncomplicated cystitis per IDSA guidelines. Preserves fluoroquinolones for more serious infections. Must have adequate renal function for urine concentration.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= BOWEL REGIMEN / GI ======================= -->
<div class="drug-category" id="bowel-regimen">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üöΩ Bowel Regimen / GI</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- DOCUSATE/SENNA -->
        <div class="drug-card" data-search="docusate colace senna senokot stool softener stimulant laxative constipation opioid">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Docusate / Senna</span>
                <span class="drug-brand">(Colace / Senokot)</span>
                <span class="drug-class-badge">Stool Softener + Stimulant</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Docusate:</strong> Surfactant stool softener (allows water/fat penetration)</li>
                            <li><strong>Senna:</strong> Stimulant laxative (increases intestinal motility via myenteric plexus)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Opioid-induced constipation prophylaxis (start with opioids)</li>
                            <li>General constipation</li>
                            <li>Hospital bowel regimen</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Drug</th><th>Dose</th></tr>
                            <tr><td>Docusate sodium</td><td>100 mg PO BID</td></tr>
                            <tr><td>Senna</td><td>8.6-17.2 mg (1-2 tabs) PO qHS-BID</td></tr>
                            <tr><td>Senna-S (combo)</td><td>1-2 tabs PO BID</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Docusate alone is minimally effective - combine with stimulant</li>
                            <li>Senna is the more effective component</li>
                            <li>Avoid stimulants in bowel obstruction</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Evidence suggests docusate adds little to senna alone for opioid-induced constipation. Many institutions use senna ¬± osmotic laxative (MiraLAX) instead of docusate.</div>
            </div>
        </div>

        <!-- POLYETHYLENE GLYCOL -->
        <div class="drug-card" data-search="polyethylene glycol peg miralax osmotic laxative constipation bowel prep">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Polyethylene Glycol (PEG)</span>
                <span class="drug-brand">(MiraLAX, GoLYTELY)</span>
                <span class="drug-class-badge">Osmotic Laxative</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-absorbable osmotic agent ‚Üí draws water into bowel lumen ‚Üí softens stool and increases peristalsis.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Chronic constipation</li>
                            <li>Opioid-induced constipation</li>
                            <li>Hepatic encephalopathy (if lactulose not tolerated)</li>
                            <li>Bowel prep (GoLYTELY - large volume)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Constipation</td><td>17 g (1 capful) PO daily in 8 oz liquid</td></tr>
                            <tr><td>Bowel prep (GoLYTELY)</td><td>240 mL q10min until 4L consumed</td></tr>
                        </table>
                        <p>Takes 1-3 days for effect; can titrate up</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Minimal electrolyte disturbance (unlike other osmotics)</li>
                            <li>Safe for long-term use</li>
                            <li>Avoid in bowel obstruction</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">PEG 3350 is tasteless and mixes well - better tolerated than lactulose. First-line osmotic laxative for chronic constipation. Can use for fecal impaction disimpaction.</div>
            </div>
        </div>

        <!-- FAMOTIDINE -->
        <div class="drug-card" data-search="famotidine pepcid h2 blocker histamine gerd ulcer stress prophylaxis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Famotidine</span>
                <span class="drug-brand">(Pepcid)</span>
                <span class="drug-class-badge">H2 Receptor Blocker</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Competitively blocks histamine H2 receptors on parietal cells ‚Üí reduces gastric acid secretion. Less potent than PPIs but faster onset.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GERD (mild-moderate)</li>
                            <li>Peptic ulcer disease</li>
                            <li>Stress ulcer prophylaxis (alternative to PPI)</li>
                            <li>Allergic reaction (adjunct to H1 blocker)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>GERD</td><td>20-40 mg PO BID</td></tr>
                            <tr><td>Stress ulcer prophylaxis</td><td>20 mg IV q12h</td></tr>
                            <tr><td>Allergic reaction</td><td>20 mg IV (with diphenhydramine)</td></tr>
                        </table>
                        <p>Reduce dose with CrCl <50</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Generally well tolerated</li>
                            <li>Headache, dizziness</li>
                            <li>Less long-term concerns than PPIs (C. diff, pneumonia, hypomagnesemia)</li>
                            <li>Tachyphylaxis with continuous use</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">H2 blockers have fewer long-term side effects than PPIs - consider for long-term acid suppression if possible. Adding to antihistamine in allergic reactions may provide additional benefit.</div>
            </div>
        </div>

        <!-- SUCRALFATE -->
        <div class="drug-card" data-search="sucralfate carafate mucosal protectant ulcer stress prophylaxis drug interactions">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Sucralfate</span>
                <span class="drug-brand">(Carafate)</span>
                <span class="drug-class-badge">Mucosal Protectant</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Forms protective paste over ulcer/erosion sites in acidic environment ‚Üí physical barrier against acid and pepsin. Does NOT reduce acid secretion.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Stress ulcer prophylaxis</li>
                            <li>Duodenal ulcer treatment</li>
                            <li>Radiation/chemotherapy-induced mucositis (off-label)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Duodenal ulcer</td><td>1 g PO QID (1h before meals and at bedtime)</td></tr>
                            <tr><td>Stress ulcer prophylaxis</td><td>1 g PO QID or via NG tube</td></tr>
                        </table>
                        <p>Take on empty stomach (needs acidic environment)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Major drug interactions:</strong> Binds many drugs (fluoroquinolones, phenytoin, warfarin, levothyroxine) ‚Üí separate by 2 hours</li>
                            <li>May cause constipation</li>
                            <li>Contains aluminum - avoid in renal failure</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Sucralfate is less commonly used now due to drug interactions and QID dosing. May have lower pneumonia risk than acid-suppressing agents for stress prophylaxis.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= ADDITIONAL ANTICOAGULATION ======================= -->
<div class="drug-category" id="anticoag-additional">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü©∏ Additional Anticoagulants</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- ARGATROBAN -->
        <div class="drug-card" data-search="argatroban direct thrombin inhibitor hit heparin induced thrombocytopenia hepatic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Argatroban</span>
                <span class="drug-brand">(Argatroban)</span>
                <span class="drug-class-badge">Direct Thrombin Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Reversible direct thrombin (factor IIa) inhibitor. Does NOT require antithrombin. Hepatically metabolized - NOT affected by renal function.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Heparin-induced thrombocytopenia (HIT)</strong> - first-line</li>
                            <li>HIT with thrombosis (HITT)</li>
                            <li>PCI in patients with HIT</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Setting</th><th>Dose</th></tr>
                            <tr><td>HIT (normal hepatic function)</td><td>2 mcg/kg/min IV continuous</td></tr>
                            <tr><td>HIT (hepatic impairment)</td><td>0.5 mcg/kg/min (adjust by hepatic function)</td></tr>
                            <tr><td>Critically ill</td><td>Start 0.5-1 mcg/kg/min</td></tr>
                        </table>
                        <p><strong>Monitor aPTT:</strong> Target 1.5-3√ó baseline (typically 60-100 sec)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hepatically metabolized - reduce dose significantly in liver disease</li>
                            <li>Half-life ~50 min - allows quick titration</li>
                            <li><strong>Prolongs INR</strong> - complicates warfarin transition (use overlap formula or use factor Xa assay)</li>
                            <li>No reversal agent</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Argatroban artificially elevates INR. When transitioning to warfarin, target INR >4 on argatroban, then recheck 4-6h after stopping argatroban.</div>
                <div class="pearl-box">First-line for HIT. Alternative is bivalirudin. Fondaparinux is off-label option. Continue anticoagulation until platelets recover to >150K and for minimum 4 weeks (longer if thrombosis).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#hit" class="guide-link">IMCRG: HIT</a>
                </div>
            </div>
        </div>

        <!-- FONDAPARINUX -->
        <div class="drug-card" data-search="fondaparinux arixtra factor xa indirect vte dvt pe hit alternative">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Fondaparinux</span>
                <span class="drug-brand">(Arixtra)</span>
                <span class="drug-class-badge">Indirect Factor Xa Inhibitor</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Synthetic pentasaccharide that selectively binds antithrombin ‚Üí potentiates factor Xa inhibition. Does NOT bind PF4 ‚Üí does NOT cause HIT.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>VTE prophylaxis (hip/knee surgery)</li>
                            <li>VTE treatment (alternative to LMWH)</li>
                            <li>HIT (off-label but safe - no cross-reactivity with HIT antibodies)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>VTE prophylaxis</td><td>2.5 mg SubQ daily</td></tr>
                            <tr><td>VTE treatment (<50 kg)</td><td>5 mg SubQ daily</td></tr>
                            <tr><td>VTE treatment (50-100 kg)</td><td>7.5 mg SubQ daily</td></tr>
                            <tr><td>VTE treatment (>100 kg)</td><td>10 mg SubQ daily</td></tr>
                        </table>
                        <p><strong>Contraindicated if CrCl <30</strong> (renally cleared, long half-life)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Long half-life (17-21 hours) - once daily dosing</li>
                            <li>NO reversal agent (andexanet alfa may work, not approved)</li>
                            <li>Avoid in severe renal impairment (CrCl <30)</li>
                            <li>Avoid if weight <50 kg for treatment</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Fondaparinux is the only anticoagulant that NEVER causes HIT (no PF4 binding). Can be used for prophylaxis or treatment when HIT history/concern exists. Very long half-life limits its use when reversibility needed.</div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ENDOCRINE ======================= -->
<div class="drug-category" id="endocrine">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü¶ã Endocrine Medications</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- LEVOTHYROXINE -->
        <div class="drug-card" data-search="levothyroxine synthroid t4 hypothyroid thyroid myxedema drug interactions">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Levothyroxine</span>
                <span class="drug-brand">(Synthroid, Levoxyl)</span>
                <span class="drug-class-badge">Thyroid Hormone</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Synthetic T4 (thyroxine) ‚Üí converted to T3 (active form) in peripheral tissues. Replaces or supplements endogenous thyroid hormone.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypothyroidism</li>
                            <li>TSH suppression (thyroid cancer)</li>
                            <li>Myxedema coma (with IV formulation)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Population</th><th>Dose</th></tr>
                            <tr><td>Young/healthy</td><td>1.6 mcg/kg/day (full replacement)</td></tr>
                            <tr><td>Elderly/cardiac disease</td><td>Start 25-50 mcg daily, increase q4-6 weeks</td></tr>
                            <tr><td>Myxedema coma</td><td>200-500 mcg IV √ó 1, then 50-100 mcg IV daily</td></tr>
                        </table>
                        <p><strong>Take on empty stomach</strong>, 30-60 min before breakfast or at bedtime</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Drug Interactions</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Absorption decreased by:</strong> Calcium, iron, PPIs, sucralfate, aluminum antacids - separate by 4 hours</li>
                            <li><strong>Increased metabolism:</strong> Phenytoin, carbamazepine, rifampin</li>
                            <li>Warfarin effect increased (monitor INR)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üìä Monitoring</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Check TSH 6-8 weeks after initiation or dose change</li>
                            <li>Once stable, check annually</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">In elderly or cardiac disease, start LOW and titrate SLOWLY - rapid replacement can precipitate arrhythmia, angina, or MI.</div>
                <div class="pearl-box">Many hospitalized patients have "sick euthyroid syndrome" - low T3/T4 with normal or low TSH. Generally don't treat unless clearly hypothyroid pre-admission. Continue home dose in hospital (can give IV at 75% of PO dose if NPO).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#hypothyroid" class="guide-link">IMCRG: Hypothyroidism</a>
                </div>
            </div>
        </div>

        <!-- METHIMAZOLE -->
        <div class="drug-card" data-search="methimazole tapazole ptu propylthiouracil antithyroid hyperthyroidism graves thyroid storm">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Methimazole / PTU</span>
                <span class="drug-brand">(Tapazole / PTU)</span>
                <span class="drug-class-badge">Antithyroid</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inhibits thyroid peroxidase ‚Üí blocks thyroid hormone synthesis. PTU also blocks peripheral T4‚ÜíT3 conversion (useful in thyroid storm).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Graves disease</li>
                            <li>Hyperthyroidism (pre-RAI or surgery)</li>
                            <li>Thyroid storm</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Drug</th><th>Starting Dose</th><th>Thyroid Storm</th></tr>
                            <tr><td>Methimazole</td><td>10-30 mg PO daily</td><td>20-25 mg PO q4h</td></tr>
                            <tr><td>PTU</td><td>100 mg PO TID</td><td>200-250 mg PO q4h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Agranulocytosis</strong> (0.2-0.5%) - check WBC if fever/sore throat</li>
                            <li>Rash, urticaria</li>
                            <li><strong>PTU:</strong> Hepatotoxicity (can be fatal - reserve for thyroid storm or 1st trimester pregnancy)</li>
                            <li>Methimazole: Teratogenic in 1st trimester</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">PTU: Severe hepatotoxicity including liver failure. Reserve PTU for thyroid storm (blocks T4‚ÜíT3 conversion) and 1st trimester pregnancy. Use methimazole in most other situations.</div>
                <div class="pearl-box">For thyroid storm: PTU preferred initially (blocks peripheral conversion), then can switch to methimazole. Add Œ≤-blocker, steroids (block peripheral conversion), and supportive care.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#hyperthyroid" class="guide-link">IMCRG: Hyperthyroidism</a>
                </div>
            </div>
        </div>

        <!-- DEXTROSE -->
        <div class="drug-card" data-search="dextrose d50 glucose hypoglycemia d10 d5">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Dextrose (D50, D10)</span>
                <span class="drug-brand">(Dextrose)</span>
                <span class="drug-class-badge">Glucose</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypoglycemia treatment</li>
                            <li>Hyperkalemia (with insulin)</li>
                            <li>TPN component</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Formulation</th><th>Dose</th></tr>
                            <tr><td>Hypoglycemia (symptomatic)</td><td>D50 (50%)</td><td>25-50 mL (12.5-25 g) IV push</td></tr>
                            <tr><td>Hyperkalemia (with insulin)</td><td>D50 (50%)</td><td>25 g (50 mL) with 10 units regular insulin</td></tr>
                            <tr><td>Hypoglycemia (peripheral IV)</td><td>D10 (10%)</td><td>100-250 mL</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>D50 is hyperosmolar</strong> (2525 mOsm/L) - can cause phlebitis, tissue necrosis with extravasation</li>
                            <li>Prefer D10 or D25 through peripheral IV</li>
                            <li>D50 can cause rebound hypoglycemia</li>
                            <li>Give thiamine BEFORE glucose in suspected Wernicke's</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">In alcoholics or malnourished patients, give THIAMINE before or with glucose to prevent precipitating Wernicke encephalopathy.</div>
                <div class="pearl-box">D10 through peripheral IV is safer than D50. Glucagon 1 mg IM/SubQ is alternative if IV access not available.</div>
            </div>
        </div>

        <!-- REGULAR INSULIN -->
        <div class="drug-card" data-search="regular insulin humulin r novolin r short acting dka hyperkalemia iv insulin">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Regular Insulin</span>
                <span class="drug-brand">(Humulin R, Novolin R)</span>
                <span class="drug-class-badge">Short-Acting Insulin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Properties</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Onset</th><th>Peak</th><th>Duration</th></tr>
                            <tr><td>IV</td><td>Immediate</td><td>15-30 min</td><td>30-60 min</td></tr>
                            <tr><td>SubQ</td><td>30-60 min</td><td>2-4 hr</td><td>5-8 hr</td></tr>
                        </table>
                        <p>Only insulin that can be given IV</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>DKA/HHS:</strong> IV insulin drip</li>
                            <li><strong>Hyperkalemia:</strong> With dextrose to shift K+ intracellularly</li>
                            <li>Sliding scale / correction doses</li>
                            <li>Mealtime coverage (if rapid-acting unavailable)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>DKA</td><td>0.1 units/kg bolus (optional), then 0.1 units/kg/hr infusion</td></tr>
                            <tr><td>Hyperkalemia</td><td>10 units IV with 25g dextrose (D50 50 mL)</td></tr>
                            <tr><td>Correction (SubQ)</td><td>Per sliding scale</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>DKA:</strong> Overlap SubQ insulin 1-2h before stopping drip to prevent rebound</li>
                            <li><strong>Hyperkalemia:</strong> Effect lasts 4-6h; give D50 to prevent hypoglycemia (unless glucose >250)</li>
                            <li>Adsorbs to IV tubing - run ~20 mL through tubing before attaching</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">For DKA: Don't stop insulin drip until anion gap closes. Overlap with SubQ insulin 1-2h before discontinuing drip. K+ should be >3.3 before starting insulin.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#dka" class="guide-link">IMCRG: DKA</a>
                    <a href="nephrology_study_guide1.html#hyperkalemia" class="guide-link">Nephro: Hyperkalemia</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= HEME/NEPHRO AGENTS ======================= -->
<div class="drug-category" id="heme-nephro">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>ü©∏ Heme/Nephrology Agents</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- IV IRON -->
        <div class="drug-card" data-search="iron sucrose venofer ferric carboxymaltose injectafer iv iron anemia ckd">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">IV Iron (Iron Sucrose / Ferric Carboxymaltose)</span>
                <span class="drug-brand">(Venofer / Injectafer)</span>
                <span class="drug-class-badge">Iron Replacement</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Provides elemental iron for hemoglobin synthesis. IV formulations bypass GI absorption issues.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Iron deficiency anemia (oral intolerance or failure)</li>
                            <li>CKD-associated anemia</li>
                            <li>Heart failure with iron deficiency</li>
                            <li>Perioperative anemia</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Formulation</th><th>Dose</th></tr>
                            <tr><td>Iron sucrose (Venofer)</td><td>200 mg IV √ó 5 doses (1000 mg total) or 300 mg √ó 3</td></tr>
                            <tr><td>Ferric carboxymaltose (Injectafer)</td><td>750 mg IV √ó 2 (1 week apart) if <50 kg; 15 mg/kg √ó 2 if ‚â•50 kg</td></tr>
                            <tr><td>Iron dextran (INFeD)</td><td>Test dose required; can give full dose in single infusion</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hypersensitivity reactions</strong> (rare with newer formulations)</li>
                            <li>Hypophosphatemia (especially ferric carboxymaltose)</li>
                            <li>Hypotension (infuse slowly)</li>
                            <li>Injection site reactions</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Ferric carboxymaltose allows larger single doses (750 mg) with less total visits. Iron sucrose has excellent safety record in CKD. Check ferritin and TSAT before and after treatment.</div>
            </div>
        </div>

        <!-- EPOETIN -->
        <div class="drug-card" data-search="epoetin alfa epogen procrit darbepoetin aranesp epo erythropoietin anemia ckd">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Epoetin / Darbepoetin</span>
                <span class="drug-brand">(Epogen, Procrit / Aranesp)</span>
                <span class="drug-class-badge">Erythropoiesis-Stimulating Agent</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Recombinant erythropoietin ‚Üí stimulates RBC production in bone marrow. Darbepoetin has longer half-life (allows less frequent dosing).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>CKD-associated anemia (Hgb <10)</li>
                            <li>Chemotherapy-induced anemia</li>
                            <li>HIV-associated anemia (zidovudine)</li>
                            <li>Perisurgical (reduce transfusions)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Agent</th><th>CKD Dose</th></tr>
                            <tr><td>Epoetin alfa</td><td>50-100 units/kg SubQ 3√ó/week</td></tr>
                            <tr><td>Darbepoetin alfa</td><td>0.45 mcg/kg SubQ weekly or 0.75 mcg/kg q2 weeks</td></tr>
                        </table>
                        <p><strong>Target Hgb: 10-11 g/dL</strong> (not to exceed 11.5)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hypertension</strong> (most common)</li>
                            <li><strong>Thrombotic events</strong> (stroke, MI, DVT) - increased with higher Hgb targets</li>
                            <li>Pure red cell aplasia (rare, with antibodies)</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">ESAs increase risk of death, MI, stroke, and tumor progression when targeting Hgb >11. Use lowest dose to avoid transfusion. Not recommended in cancer unless receiving chemotherapy.</div>
                <div class="pearl-box">Ensure iron stores adequate before starting (TSAT >20%, ferritin >100). Poor response often due to iron deficiency, inflammation, or blood loss.</div>
            </div>
        </div>

        <!-- DESMOPRESSIN -->
        <div class="drug-card" data-search="desmopressin ddavp vasopressin diabetes insipidus bleeding von willebrand uremic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Desmopressin (DDAVP)</span>
                <span class="drug-brand">(DDAVP, Stimate)</span>
                <span class="drug-class-badge">Vasopressin Analog</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Synthetic vasopressin analog with enhanced V2 receptor activity (antidiuretic, releases vWF/factor VIII) and minimal V1 activity (no vasoconstriction).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Central diabetes insipidus</strong></li>
                            <li><strong>Uremic bleeding</strong> (temporary improvement)</li>
                            <li>von Willebrand disease (type 1)</li>
                            <li>Hemophilia A (mild)</li>
                            <li>Nocturnal enuresis</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Central DI</td><td>1-4 mcg IV/SubQ daily or 10-40 mcg intranasal</td></tr>
                            <tr><td>Uremic bleeding</td><td>0.3 mcg/kg IV over 30 min</td></tr>
                            <tr><td>vWD/Hemophilia A</td><td>0.3 mcg/kg IV over 30 min (before procedure)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hyponatremia</strong> (water retention) - limit fluid intake</li>
                            <li>Headache, flushing</li>
                            <li>Tachyphylaxis (repeated dosing less effective)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Monitor sodium closely - DDAVP causes water retention. Restrict free water intake. Avoid in patients with hyponatremia.</div>
                <div class="pearl-box">For uremic bleeding: DDAVP effect lasts 4-8h with tachyphylaxis. Other options include estrogen, dialysis, and cryoprecipitate. Test dose recommended for vWD to confirm response.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#di" class="guide-link">Nephro: DI</a>
                </div>
            </div>
        </div>

        <!-- SEVELAMER -->
        <div class="drug-card" data-search="sevelamer renagel renvela phosphate binder ckd esrd hyperphosphatemia">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Sevelamer</span>
                <span class="drug-brand">(Renagel, Renvela)</span>
                <span class="drug-class-badge">Phosphate Binder</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-absorbable polymer binds dietary phosphate in GI tract ‚Üí prevents absorption ‚Üí reduces serum phosphate. Does not contain calcium or aluminum.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hyperphosphatemia in CKD (stage 3-5, dialysis)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Start:</strong> 800 mg PO TID with meals</p>
                        <p><strong>Titrate:</strong> Increase by 400-800 mg per meal q2 weeks to goal phosphate</p>
                        <p><strong>MUST take with meals</strong> (binds dietary phosphate)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>GI upset (nausea, constipation, diarrhea)</li>
                            <li>Large pill burden</li>
                            <li>May bind some medications</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Sevelamer is preferred over calcium-based binders in patients with hypercalcemia or vascular calcification. Also lowers LDL. Must be taken WITH meals to be effective.</div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= ADDITIONAL PSYCHIATRY ======================= -->
<div class="drug-category" id="psych-additional">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üß† Additional Psychiatry</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- OLANZAPINE -->
        <div class="drug-card" data-search="olanzapine zyprexa atypical antipsychotic agitation schizophrenia bipolar im metabolic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Olanzapine</span>
                <span class="drug-brand">(Zyprexa)</span>
                <span class="drug-class-badge">Atypical Antipsychotic</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Antagonist at D2 dopamine, 5-HT2A serotonin, H1 histamine, and muscarinic receptors. Thienobenzodiazepine structure (related to clozapine).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Acute agitation</strong> (IM formulation)</li>
                            <li>Schizophrenia</li>
                            <li>Bipolar disorder (mania, maintenance)</li>
                            <li>Chemotherapy-induced nausea (with other agents)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Acute agitation (IM)</td><td>5-10 mg IM, may repeat q2h (max 30 mg/day)</td></tr>
                            <tr><td>Agitation (ODT)</td><td>5-10 mg PO/SL</td></tr>
                            <tr><td>Schizophrenia/bipolar</td><td>5-20 mg PO daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Metabolic effects:</strong> Weight gain (significant), hyperglycemia, dyslipidemia</li>
                            <li>Sedation (prominent)</li>
                            <li>Orthostatic hypotension</li>
                            <li>Anticholinergic effects</li>
                            <li>Low EPS risk (lower than haloperidol)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Do NOT give IM olanzapine with parenteral benzodiazepines - increased risk of respiratory depression, hypotension, and death. Wait at least 1 hour between doses.</div>
                <div class="pearl-box">IM olanzapine is highly effective for acute agitation with lower EPS than haloperidol. ODT formulation dissolves rapidly - useful when pill hiding is a concern.</div>
            </div>
        </div>

        <!-- TRAZODONE -->
        <div class="drug-card" data-search="trazodone desyrel insomnia depression serotonin priapism">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Trazodone</span>
                <span class="drug-brand">(Desyrel)</span>
                <span class="drug-class-badge">SARI Antidepressant</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Serotonin antagonist and reuptake inhibitor (SARI). At low doses, primarily H1 and Œ±1 antagonist effects ‚Üí sedation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Insomnia</strong> (most common use - low dose)</li>
                            <li>Major depressive disorder (higher doses)</li>
                            <li>Anxiety</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Insomnia</td><td>25-100 mg PO qHS</td></tr>
                            <tr><td>Depression</td><td>150-400 mg daily (divided doses)</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Sedation (therapeutic for insomnia)</li>
                            <li>Orthostatic hypotension</li>
                            <li><strong>Priapism</strong> (rare but serious - warn male patients)</li>
                            <li>Morning hangover</li>
                            <li>Serotonin syndrome (with other serotonergics)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Trazodone is most commonly used for insomnia at 25-100 mg rather than as an antidepressant. Non-habit forming alternative to benzodiazepines and Z-drugs.</div>
            </div>
        </div>

        <!-- MIRTAZAPINE -->
        <div class="drug-card" data-search="mirtazapine remeron antidepressant appetite weight gain insomnia nausea">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Mirtazapine</span>
                <span class="drug-brand">(Remeron)</span>
                <span class="drug-class-badge">Tetracyclic Antidepressant</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Œ±2-adrenergic antagonist (increases NE/5-HT release) + 5-HT2/5-HT3 antagonist + potent H1 antagonist. Unique mechanism ‚Üí enhances noradrenergic and serotonergic transmission.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Major depressive disorder</li>
                            <li>Depression with insomnia, poor appetite, weight loss</li>
                            <li>Nausea/vomiting (5-HT3 antagonism)</li>
                            <li>Appetite stimulation in cancer/AIDS</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Start:</strong> 15 mg PO qHS</p>
                        <p><strong>Target:</strong> 15-45 mg daily</p>
                        <p>Take at bedtime (sedating)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Sedation</strong> (more at lower doses - H1 effect predominates)</li>
                            <li><strong>Weight gain, increased appetite</strong> (can be therapeutic)</li>
                            <li>Dry mouth</li>
                            <li>Rare: agranulocytosis</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Paradoxically, mirtazapine is MORE sedating at 15 mg than 30 mg (H1 blockade predominates at low doses; higher doses have more noradrenergic activation). Excellent choice for depressed patients with insomnia, poor appetite, or nausea.</div>
            </div>
        </div>

        <!-- MELATONIN -->
        <div class="drug-card" data-search="melatonin sleep insomnia circadian delirium prevention">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Melatonin</span>
                <span class="drug-brand">(Melatonin)</span>
                <span class="drug-class-badge">Sleep Aid / Supplement</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Endogenous hormone from pineal gland that regulates circadian rhythm. Binds MT1/MT2 receptors ‚Üí promotes sleep onset and circadian entrainment.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Insomnia (sleep onset)</li>
                            <li>Circadian rhythm disorders (jet lag, shift work)</li>
                            <li><strong>ICU delirium prevention</strong> (sleep hygiene bundle)</li>
                            <li>Sleep in elderly (preferred over benzodiazepines)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Sleep onset</td><td>0.5-5 mg PO 30 min before bed</td></tr>
                            <tr><td>ICU delirium prevention</td><td>3-5 mg PO qHS</td></tr>
                            <tr><td>Jet lag</td><td>0.5-5 mg at destination bedtime</td></tr>
                        </table>
                        <p>Lower doses (0.5-1 mg) may be as effective as higher doses</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Very safe profile - no dependence, no respiratory depression</li>
                            <li>Minimal side effects (headache, dizziness, morning grogginess)</li>
                            <li>Part of ICU sleep bundles for delirium prevention</li>
                            <li>More effective for sleep onset than sleep maintenance</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Melatonin is first-line for insomnia in hospitalized patients - safer than benzodiazepines especially in elderly. Part of ABCDEF bundle for ICU delirium prevention.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= VITAMINS / SUPPLEMENTS ======================= -->
<div class="drug-category" id="vitamins">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üíä Vitamins & Supplements</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- THIAMINE -->
        <div class="drug-card" data-search="thiamine vitamin b1 wernicke korsakoff encephalopathy alcohol deficiency">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Thiamine (Vitamin B1)</span>
                <span class="drug-brand">(Thiamine)</span>
                <span class="drug-class-badge">Vitamin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Role</div>
                    <div class="drug-section-content">Cofactor for pyruvate dehydrogenase, Œ±-ketoglutarate dehydrogenase, transketolase. Essential for carbohydrate metabolism and neural function.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Wernicke encephalopathy</strong> (confusion, ataxia, ophthalmoplegia)</li>
                            <li>Prophylaxis in alcohol use disorder</li>
                            <li>Refeeding syndrome prevention</li>
                            <li>Any malnourished patient receiving glucose</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Wernicke encephalopathy</td><td>500 mg IV TID √ó 2-3 days, then 250 mg IV daily √ó 3-5 days</td></tr>
                            <tr><td>Prophylaxis (alcohol)</td><td>100 mg IV/PO daily</td></tr>
                            <tr><td>Before glucose (at-risk)</td><td>100 mg IV √ó 1</td></tr>
                        </table>
                        <p>IV preferred (poor oral absorption in alcoholics)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>ALWAYS give thiamine BEFORE glucose</strong> in at-risk patients (alcoholics, malnourished)</li>
                            <li>Wernicke is underdiagnosed - classic triad present in only 16%</li>
                            <li>Wernicke ‚Üí Korsakoff (irreversible memory impairment) if untreated</li>
                            <li>Anaphylaxis rare but possible with IV</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Giving glucose without thiamine can precipitate or worsen Wernicke encephalopathy. Give thiamine BEFORE or WITH glucose in any at-risk patient.</div>
                <div class="pearl-box">If Wernicke is suspected, treat empirically - do not wait for levels. Use HIGH doses (500 mg TID) for treatment, not prophylactic doses (100 mg daily).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#wernicke" class="guide-link">IMCRG: Wernicke</a>
                    <a href="im_guidev3B20.html#alcohol-withdrawal" class="guide-link">IMCRG: Alcohol Withdrawal</a>
                </div>
            </div>
        </div>

        <!-- FOLATE -->
        <div class="drug-card" data-search="folic acid folate vitamin b9 anemia megaloblastic pregnancy methotrexate">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Folic Acid (Vitamin B9)</span>
                <span class="drug-brand">(Folic Acid)</span>
                <span class="drug-class-badge">Vitamin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Role</div>
                    <div class="drug-section-content">Essential for DNA synthesis and cell division. Cofactor in one-carbon metabolism.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Folate deficiency anemia (megaloblastic)</li>
                            <li>Methotrexate toxicity reduction</li>
                            <li>Pregnancy (neural tube defect prevention)</li>
                            <li>Alcoholism (prophylaxis)</li>
                            <li>Hemolytic anemia, dialysis (increased requirements)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Deficiency treatment</td><td>1-5 mg PO daily √ó 1-4 months</td></tr>
                            <tr><td>With methotrexate</td><td>1 mg PO daily (or 5 mg weekly)</td></tr>
                            <tr><td>Pregnancy prevention</td><td>0.4-0.8 mg PO daily</td></tr>
                            <tr><td>Dialysis</td><td>1 mg PO daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Always check B12 before treating folate deficiency</strong> - folate can mask B12 deficiency while neurologic damage progresses</li>
                            <li>Leucovorin (folinic acid) is "active" form for methotrexate rescue</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Folate supplementation can correct anemia of B12 deficiency while allowing neurologic damage to progress. Always check B12 level before treating folate deficiency.</div>
                <div class="pearl-box">Folic acid with methotrexate reduces GI and hematologic toxicity without reducing efficacy. Give on different day than MTX or daily is fine.</div>
            </div>
        </div>

        <!-- VITAMIN B12 -->
        <div class="drug-card" data-search="cyanocobalamin vitamin b12 cobalamin anemia pernicious megaloblastic neurologic subacute combined">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Cyanocobalamin (Vitamin B12)</span>
                <span class="drug-brand">(Cyanocobalamin)</span>
                <span class="drug-class-badge">Vitamin</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Role</div>
                    <div class="drug-section-content">Cofactor for methionine synthase and methylmalonyl-CoA mutase. Essential for DNA synthesis, myelin formation, and neurologic function.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>B12 deficiency anemia (pernicious anemia, malabsorption)</li>
                            <li>Neurologic manifestations (subacute combined degeneration)</li>
                            <li>After gastric bypass</li>
                            <li>Long-term metformin or PPI use</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Situation</th><th>Dose</th></tr>
                            <tr><td>Severe deficiency</td><td>1000 mcg IM daily √ó 7 days, then weekly √ó 4, then monthly</td></tr>
                            <tr><td>Neurologic symptoms</td><td>1000 mcg IM daily √ó 7 days (may need longer)</td></tr>
                            <tr><td>Oral replacement</td><td>1000-2000 mcg PO daily (if no IF/absorption issue)</td></tr>
                            <tr><td>Maintenance</td><td>1000 mcg IM monthly OR 1000 mcg PO daily</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Neurologic damage may be irreversible if treatment delayed</li>
                            <li>Oral high-dose (1000-2000 mcg) can work even without intrinsic factor (passive absorption ~1%)</li>
                            <li>Check MMA and homocysteine if B12 borderline (200-400)</li>
                            <li>Monitor potassium during initial treatment (rapid cell production can cause hypokalemia)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">B12 deficiency causes neurologic damage (subacute combined degeneration) that may be irreversible. Treat urgently with IM B12. Anemia responds quickly; neurologic recovery takes months and may be incomplete.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#b12-deficiency" class="guide-link">IMCRG: B12 Deficiency</a>
                </div>
            </div>
        </div>

    </div>
</div>


<!-- ======================= POTASSIUM MANAGEMENT ======================= -->
<div class="drug-category" id="k-binders">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚öóÔ∏è Potassium Binders</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- SODIUM ZIRCONIUM CYCLOSILICATE -->
        <div class="drug-card" data-search="sodium zirconium cyclosilicate lokelma hyperkalemia potassium binder">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Sodium Zirconium Cyclosilicate</span>
                <span class="drug-brand">(Lokelma)</span>
                <span class="drug-class-badge">Potassium Binder</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Inorganic crystal that selectively traps potassium in GI tract in exchange for sodium and hydrogen ions. Works throughout entire GI tract.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hyperkalemia (acute and chronic)</li>
                            <li>Maintenance therapy to allow continued RAASi use</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Phase</th><th>Dose</th></tr>
                            <tr><td>Acute (correction)</td><td>10 g PO TID √ó 48 hours</td></tr>
                            <tr><td>Maintenance</td><td>5-10 g PO daily</td></tr>
                        </table>
                        <p>Mix with water; can take with or without food</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Edema (sodium load)</li>
                            <li>Hypokalemia (with overuse)</li>
                            <li>Constipation</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Lokelma works faster than patiromer (1-2 hours vs 7+ hours). Can be used for acute hyperkalemia in ED. Enables patients to stay on ACEi/ARB/MRA despite hyperkalemia tendency.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#hyperkalemia" class="guide-link">Nephro: Hyperkalemia</a>
                </div>
            </div>
        </div>

        <!-- PATIROMER -->
        <div class="drug-card" data-search="patiromer veltassa hyperkalemia potassium binder chronic">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Patiromer</span>
                <span class="drug-brand">(Veltassa)</span>
                <span class="drug-class-badge">Potassium Binder</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-absorbed polymer that binds potassium in colon in exchange for calcium. Works primarily in distal colon.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Chronic hyperkalemia</li>
                            <li>NOT for acute/emergency hyperkalemia (slow onset)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>Start:</strong> 8.4 g PO daily with food</p>
                        <p><strong>Titrate:</strong> Adjust by 8.4 g weekly to max 25.2 g daily</p>
                        <p>Separate from other medications by 3 hours</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Constipation (most common)</li>
                            <li>Hypomagnesemia</li>
                            <li>GI upset</li>
                            <li>Drug interactions (binds many medications)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Patiromer binds many oral medications. Separate administration by at least 3 hours. NOT for acute hyperkalemia - takes 7+ hours to work.</div>
                <div class="pearl-box">Patiromer is for chronic management only - too slow for acute hyperkalemia. Allows patients to continue RAASi therapy. Monitor magnesium levels.</div>
            </div>
        </div>

        <!-- SODIUM POLYSTYRENE SULFONATE -->
        <div class="drug-card" data-search="sodium polystyrene sulfonate kayexalate sps hyperkalemia potassium binder colonic necrosis">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Sodium Polystyrene Sulfonate</span>
                <span class="drug-brand">(Kayexalate, SPS)</span>
                <span class="drug-class-badge">Potassium Binder (Legacy)</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Cation exchange resin that exchanges sodium for potassium in colon. Efficacy is questionable and onset is slow.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Route</th><th>Dose</th></tr>
                            <tr><td>Oral</td><td>15-30 g PO q6h (with sorbitol or in water)</td></tr>
                            <tr><td>Rectal</td><td>30-50 g in retention enema</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Major Concerns</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Colonic necrosis</strong> (especially with sorbitol - FDA warning)</li>
                            <li>Questionable efficacy (poor evidence)</li>
                            <li>Slow onset (hours to days)</li>
                            <li>Sodium load</li>
                            <li>Constipation, fecal impaction</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Risk of intestinal necrosis, especially when given with sorbitol. Cases of fatal GI injury reported. Avoid sorbitol-containing preparations.</div>
                <div class="warning-box">Kayexalate has fallen out of favor due to safety concerns and questionable efficacy. Newer agents (Lokelma, Veltassa) are preferred when available.</div>
                <div class="pearl-box">Many institutions have restricted or removed Kayexalate. If used, avoid sorbitol and use in water. Newer K+ binders (Lokelma, patiromer) are safer and more effective.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= PHOSPHATE REPLACEMENT ======================= -->
<div class="drug-category" id="phosphate">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚öóÔ∏è Phosphate Replacement</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- PHOSPHATE -->
        <div class="drug-card" data-search="phosphate sodium potassium phosphorus hypophosphatemia refeeding dka replacement">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Sodium/Potassium Phosphate</span>
                <span class="drug-brand">(Various)</span>
                <span class="drug-class-badge">Electrolyte</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Hypophosphatemia (moderate to severe)</li>
                            <li>Refeeding syndrome</li>
                            <li>DKA (when phosphate <1.0)</li>
                            <li>TPN supplementation</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Phosphate Level</th><th>Dose</th></tr>
                            <tr><td>1.25-2.0 mg/dL (mild)</td><td>0.08-0.16 mmol/kg IV over 6h</td></tr>
                            <tr><td>1.0-1.24 mg/dL (moderate)</td><td>0.16-0.32 mmol/kg IV over 6h</td></tr>
                            <tr><td><1.0 mg/dL (severe)</td><td>0.32-0.64 mmol/kg IV over 6-12h</td></tr>
                        </table>
                        <p><strong>Choose Na-Phos vs K-Phos based on potassium level</strong></p>
                        <p>Max rate: 7 mmol/hr (0.4-0.5 mmol/kg over 6h)</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Potassium phosphate:</strong> 4.4 mEq K+ per 3 mmol phosphate - account for K+ load</li>
                            <li><strong>Sodium phosphate:</strong> Use if hyperkalemia or K+ repletion not needed</li>
                            <li>Risk of hypocalcemia, metastatic calcification with rapid infusion</li>
                            <li>Avoid in hypercalcemia, renal failure</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">IV phosphate must be infused slowly (over 6+ hours). Rapid infusion can cause hypocalcemia, arrhythmias, and soft tissue calcification. Use caution in renal impairment.</div>
                <div class="pearl-box">In DKA: Routine phosphate replacement not recommended unless <1.0 mg/dL or symptomatic. Phosphate will often correct with insulin therapy alone. K-Phos can serve dual purpose of K+ and PO4 repletion.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="nephrology_study_guide1.html#phosphate" class="guide-link">Nephro: Electrolytes</a>
                    <a href="im_guidev3B20.html#dka" class="guide-link">IMCRG: DKA</a>
                </div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= REVERSAL AGENTS ======================= -->
<div class="drug-category" id="reversal">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>‚Ü©Ô∏è Reversal Agents</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- IDARUCIZUMAB -->
        <div class="drug-card" data-search="idarucizumab praxbind dabigatran reversal pradaxa bleeding">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Idarucizumab</span>
                <span class="drug-brand">(Praxbind)</span>
                <span class="drug-class-badge">Dabigatran Reversal</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Humanized monoclonal antibody fragment that binds dabigatran with 350√ó higher affinity than thrombin ‚Üí immediate, complete reversal.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Life-threatening or uncontrolled bleeding on dabigatran</li>
                            <li>Emergency surgery/procedures on dabigatran</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <p><strong>5 g IV</strong> (two 2.5 g vials) as bolus or infusion over 5-10 min</p>
                        <p>Immediate onset; effect lasts 24 hours</p>
                        <p>Can repeat dose if needed</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Specific for dabigatran ONLY - does not reverse other DOACs</li>
                            <li>Very expensive (~$3,500)</li>
                            <li>Can resume anticoagulation 24 hours after administration</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Idarucizumab provides immediate, complete reversal of dabigatran. For factor Xa inhibitors (apixaban, rivaroxaban), use andexanet alfa or 4-factor PCC if unavailable.</div>
            </div>
        </div>

        <!-- ANDEXANET ALFA -->
        <div class="drug-card" data-search="andexanet alfa andexxa factor xa reversal apixaban rivaroxaban bleeding">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Andexanet Alfa</span>
                <span class="drug-brand">(Andexxa)</span>
                <span class="drug-class-badge">Factor Xa Inhibitor Reversal</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Recombinant modified factor Xa that acts as a decoy ‚Üí binds and sequesters factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and LMWH.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Life-threatening bleeding on apixaban or rivaroxaban</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Drug/Timing</th><th>Regimen</th></tr>
                            <tr><td>Apixaban ‚â§5 mg or rivaroxaban ‚â§10 mg (or >8h since dose)</td><td>Low dose: 400 mg bolus, then 480 mg over 2h</td></tr>
                            <tr><td>Apixaban >5 mg or rivaroxaban >10 mg (and <8h since dose)</td><td>High dose: 800 mg bolus, then 960 mg over 2h</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Very expensive</strong> (~$25,000-50,000)</li>
                            <li>Thrombotic events reported (10-18%)</li>
                            <li>Effect wears off after infusion ends</li>
                            <li>4-factor PCC is alternative if andexanet unavailable</li>
                        </ul>
                    </div>
                </div>
                <div class="black-box">Thrombotic events including stroke, MI, DVT, PE reported. Use only for life-threatening bleeding. Resume anticoagulation as soon as appropriate.</div>
                <div class="pearl-box">Andexanet is very expensive and availability limited. 4-factor PCC (25-50 units/kg) is a reasonable alternative for factor Xa inhibitor reversal if andexanet unavailable.</div>
            </div>
        </div>

        <!-- SUGAMMADEX -->
        <div class="drug-card" data-search="sugammadex bridion rocuronium vecuronium reversal neuromuscular blockade">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Sugammadex</span>
                <span class="drug-brand">(Bridion)</span>
                <span class="drug-class-badge">NMB Reversal</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Cyclodextrin that encapsulates rocuronium and vecuronium ‚Üí forms inactive complex ‚Üí rapidly reverses neuromuscular blockade.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Reversal of rocuronium or vecuronium-induced paralysis</li>
                            <li>Immediate reversal needed (can't intubate, can't ventilate)</li>
                            <li>Deep blockade reversal</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Depth of Block</th><th>Dose</th></tr>
                            <tr><td>Moderate (TOF 1-2 twitches)</td><td>2 mg/kg IV</td></tr>
                            <tr><td>Deep (PTC 1-2)</td><td>4 mg/kg IV</td></tr>
                            <tr><td>Immediate (after RSI dose rocuronium)</td><td>16 mg/kg IV</td></tr>
                        </table>
                        <p>Reversal in 1-3 minutes</p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Only reverses rocuronium and vecuronium (aminosteroids)</li>
                            <li>Does NOT reverse succinylcholine, cisatracurium, atracurium</li>
                            <li>May reduce efficacy of hormonal contraceptives</li>
                            <li>Expensive (~$100-200 per dose)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Sugammadex at 16 mg/kg can immediately reverse even RSI-dose rocuronium - enables rocuronium to replace succinylcholine for RSI with option for complete reversal if needed.</div>
            </div>
        </div>

    </div>
</div>

<!-- ======================= MISCELLANEOUS ======================= -->
<div class="drug-category" id="misc">
    <div class="category-header" onclick="toggleCategory(this)">
        <h2>üì¶ Miscellaneous</h2>
        <span class="toggle">‚ñº</span>
    </div>
    <div class="category-content">

        <!-- GLUCAGON -->
        <div class="drug-card" data-search="glucagon hypoglycemia beta blocker calcium channel blocker overdose">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Glucagon</span>
                <span class="drug-brand">(GlucaGen)</span>
                <span class="drug-class-badge">Hormone / Antidote</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Stimulates hepatic glycogenolysis ‚Üí raises blood glucose. Also has positive inotropic/chronotropic effects via non-catecholamine pathway (bypasses Œ≤-receptors).</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Hypoglycemia</strong> (when IV access unavailable)</li>
                            <li><strong>Œ≤-blocker overdose</strong> (bypasses blocked receptors)</li>
                            <li><strong>Calcium channel blocker overdose</strong></li>
                            <li>Food/esophageal impaction (smooth muscle relaxation)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Hypoglycemia</td><td>1 mg IM/SubQ/IV √ó 1</td></tr>
                            <tr><td>Œ≤-blocker/CCB overdose</td><td>3-10 mg IV bolus, then 3-5 mg/hr infusion</td></tr>
                            <tr><td>Esophageal impaction</td><td>1 mg IV √ó 1</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Nausea, vomiting (common)</li>
                            <li>Hyperglycemia</li>
                            <li>Hypokalemia</li>
                            <li>Ineffective if glycogen depleted (starvation, chronic alcohol)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">For Œ≤-blocker OD: Glucagon works via non-Œ≤-receptor pathway. May need very high doses (5-10 mg bolus) and continuous infusion. Also consider high-dose insulin euglycemia therapy (HIE).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#hypoglycemia" class="guide-link">IMCRG: Hypoglycemia</a>
                </div>
            </div>
        </div>

        <!-- DIPHENHYDRAMINE -->
        <div class="drug-card" data-search="diphenhydramine benadryl antihistamine h1 allergic reaction dystonia sedation">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Diphenhydramine</span>
                <span class="drug-brand">(Benadryl)</span>
                <span class="drug-class-badge">H1 Antihistamine</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">First-generation H1 antihistamine with significant anticholinergic properties. Crosses blood-brain barrier ‚Üí sedation.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>Allergic reactions (urticaria, pruritus)</li>
                            <li>Anaphylaxis (adjunct to epinephrine)</li>
                            <li><strong>Acute dystonia</strong> (from antipsychotics/metoclopramide)</li>
                            <li>EPS prophylaxis (with prochlorperazine)</li>
                            <li>Insomnia (OTC use)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td>Allergic reaction</td><td>25-50 mg IV/IM/PO q6h</td></tr>
                            <tr><td>Acute dystonia</td><td>50 mg IV/IM √ó 1</td></tr>
                            <tr><td>EPS prophylaxis</td><td>25-50 mg IV with antipsychotic</td></tr>
                            <tr><td>Insomnia</td><td>25-50 mg PO qHS</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Side Effects</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Sedation</strong> (significant)</li>
                            <li>Anticholinergic effects (dry mouth, urinary retention, confusion)</li>
                            <li><strong>Avoid in elderly</strong> (Beers criteria - delirium risk)</li>
                            <li>QTc prolongation (rare)</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">Avoid in elderly patients - high anticholinergic burden increases delirium risk. Use non-sedating antihistamines (cetirizine, loratadine) when possible.</div>
                <div class="pearl-box">For acute dystonia: IV diphenhydramine 50 mg works within minutes. Also useful as adjunct to prochlorperazine for migraine (prevents dystonia). Part of "B52" cocktail for agitation.</div>
            </div>
        </div>

        <!-- EPINEPHRINE -->
        <div class="drug-card" data-search="epinephrine adrenaline epipen anaphylaxis cardiac arrest alpha beta vasopressor">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Epinephrine</span>
                <span class="drug-brand">(Adrenalin, EpiPen)</span>
                <span class="drug-class-badge">Catecholamine</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Mechanism</div>
                    <div class="drug-section-content">Non-selective Œ± and Œ≤ agonist. Œ±1: vasoconstriction; Œ≤1: inotropy, chronotropy; Œ≤2: bronchodilation, vasodilation. Effects are dose-dependent.</div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Anaphylaxis</strong> (first-line, life-saving)</li>
                            <li><strong>Cardiac arrest</strong> (ACLS)</li>
                            <li>Severe asthma/bronchospasm</li>
                            <li>Shock (vasopressor)</li>
                            <li>Croup (nebulized)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Dose</th></tr>
                            <tr><td><strong>Anaphylaxis</strong></td><td>0.3-0.5 mg (0.3-0.5 mL of 1:1000) IM anterolateral thigh, repeat q5-15min</td></tr>
                            <tr><td>Cardiac arrest</td><td>1 mg (10 mL of 1:10,000) IV q3-5min</td></tr>
                            <tr><td>Shock (infusion)</td><td>0.01-0.5 mcg/kg/min IV</td></tr>
                            <tr><td>Severe asthma</td><td>0.3-0.5 mg IM or 0.1-0.5 mg IV slow</td></tr>
                        </table>
                        <p><strong>1:1000 = 1 mg/mL (IM)</strong>; <strong>1:10,000 = 0.1 mg/mL (IV)</strong></p>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Anaphylaxis:</strong> IM is preferred (faster, more reliable than SubQ)</li>
                            <li>Do NOT delay epinephrine for anaphylaxis - antihistamines are adjuncts only</li>
                            <li>Tachycardia, arrhythmias, hypertension at high doses</li>
                            <li>Tissue necrosis with extravasation</li>
                        </ul>
                    </div>
                </div>
                <div class="warning-box">For anaphylaxis: Give IM epinephrine IMMEDIATELY. There is NO contraindication to epinephrine in anaphylaxis. Antihistamines and steroids are adjuncts, not replacements.</div>
                <div class="pearl-box">IM injection into anterolateral thigh provides fastest absorption. Can repeat q5-15min. If refractory anaphylaxis, consider IV epinephrine infusion (start 0.1 mcg/kg/min).</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#anaphylaxis" class="guide-link">IMCRG: Anaphylaxis</a>
                </div>
            </div>
        </div>

        <!-- SODIUM CHLORIDE/FLUIDS -->
        <div class="drug-card" data-search="normal saline ns lactated ringers lr fluids crystalloid resuscitation">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">IV Fluids (NS, LR)</span>
                <span class="drug-brand">(0.9% NaCl, Lactated Ringer's)</span>
                <span class="drug-class-badge">Crystalloid</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">üìä Composition</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Component</th><th>0.9% NS</th><th>LR</th><th>Plasma</th></tr>
                            <tr><td>Na+ (mEq/L)</td><td>154</td><td>130</td><td>140</td></tr>
                            <tr><td>Cl- (mEq/L)</td><td>154</td><td>109</td><td>100</td></tr>
                            <tr><td>K+ (mEq/L)</td><td>0</td><td>4</td><td>4</td></tr>
                            <tr><td>Ca2+ (mEq/L)</td><td>0</td><td>3</td><td>5</td></tr>
                            <tr><td>Lactate (mEq/L)</td><td>0</td><td>28</td><td>0</td></tr>
                            <tr><td>pH</td><td>5.5</td><td>6.5</td><td>7.4</td></tr>
                            <tr><td>Osmolarity</td><td>308</td><td>273</td><td>290</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Fluid Selection</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>LR/Plasmalyte preferred:</strong> Sepsis, DKA (after initial NS), general resuscitation (SMART trial)</li>
                            <li><strong>NS preferred:</strong> Hyponatremia, hypochloremic alkalosis, with blood products, brain injury</li>
                            <li><strong>Avoid LR:</strong> Hyperkalemia (contains K+), with ceftriaxone (Ca2+ precipitation)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Rate</th></tr>
                            <tr><td>Maintenance (70 kg)</td><td>~100 mL/hr (4-2-1 rule: 40+40+20)</td></tr>
                            <tr><td>Resuscitation bolus</td><td>500-1000 mL over 15-30 min</td></tr>
                            <tr><td>Sepsis (initial)</td><td>30 mL/kg within 3 hours</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Considerations</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>NS:</strong> Can cause hyperchloremic non-anion gap metabolic acidosis</li>
                            <li><strong>LR:</strong> Contains lactate (converted to bicarbonate) - safe in lactic acidosis</li>
                            <li>Only ~25% of crystalloid stays intravascular</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">SMART trial: Balanced crystalloids (LR) reduced death, new renal replacement, and persistent renal dysfunction vs NS in critically ill. LR is generally preferred unless specific indication for NS.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#sepsis" class="guide-link">IMCRG: Sepsis</a>
                    <a href="nephrology_study_guide1.html#fluids" class="guide-link">Nephro: Fluids</a>
                </div>
            </div>
        </div>

        <!-- ALBUMIN -->
        <div class="drug-card" data-search="albumin 5% 25% colloid sbp cirrhosis paracentesis resuscitation">
            <div class="drug-header" onclick="toggleDrug(this)">
                <span class="drug-name">Albumin</span>
                <span class="drug-brand">(Albuminar, Flexbumin)</span>
                <span class="drug-class-badge">Colloid</span>
                <span class="drug-toggle">‚ñ∂</span>
            </div>
            <div class="drug-body">
                <div class="drug-section">
                    <div class="drug-section-title">‚öôÔ∏è Properties</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>5% albumin:</strong> Iso-oncotic, volume expander (1:1 volume expansion)</li>
                            <li><strong>25% albumin:</strong> Hyperoncotic, draws fluid into intravascular space</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üéØ Indications</div>
                    <div class="drug-section-content">
                        <ul>
                            <li><strong>Large volume paracentesis</strong> (>5L): 6-8 g albumin per liter removed</li>
                            <li><strong>Spontaneous bacterial peritonitis</strong>: 1.5 g/kg on day 1, 1 g/kg on day 3</li>
                            <li><strong>Hepatorenal syndrome</strong>: With vasoconstrictors (midodrine/octreotide or terlipressin)</li>
                            <li>Volume resuscitation (limited evidence vs crystalloid)</li>
                        </ul>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">üíâ Dosing</div>
                    <div class="drug-section-content">
                        <table class="dosing-table">
                            <tr><th>Indication</th><th>Formulation</th><th>Dose</th></tr>
                            <tr><td>Large volume paracentesis</td><td>25%</td><td>6-8 g per liter removed (if >5L)</td></tr>
                            <tr><td>SBP (day 1)</td><td>25%</td><td>1.5 g/kg IV</td></tr>
                            <tr><td>SBP (day 3)</td><td>25%</td><td>1 g/kg IV</td></tr>
                            <tr><td>HRS</td><td>25%</td><td>1 g/kg/day (max 100 g/day)</td></tr>
                            <tr><td>Volume expansion</td><td>5%</td><td>250-500 mL</td></tr>
                        </table>
                    </div>
                </div>
                <div class="drug-section">
                    <div class="drug-section-title">‚ö†Ô∏è Key Points</div>
                    <div class="drug-section-content">
                        <ul>
                            <li>No benefit over crystalloid for general resuscitation (SAFE trial)</li>
                            <li>Clear benefit in cirrhotic indications (SBP, LVP, HRS)</li>
                            <li>Expensive (~$50-200 per bottle)</li>
                            <li>Avoid in TBI (SAFE subgroup: worse outcomes)</li>
                        </ul>
                    </div>
                </div>
                <div class="pearl-box">Albumin is clearly beneficial in cirrhosis: Reduces mortality in SBP, prevents post-paracentesis circulatory dysfunction, and is part of HRS treatment. No clear benefit over crystalloid in other settings.</div>
                <div class="cross-links">
                    <div class="cross-links-title">üìé Referenced in:</div>
                    <a href="im_guidev3B20.html#sbp" class="guide-link">IMCRG: SBP</a>
                    <a href="im_guidev3B20.html#cirrhosis" class="guide-link">IMCRG: Cirrhosis</a>
                </div>
            </div>
        </div>

    </div>
</div>

<div class="footer">
    <p><strong>Comprehensive Drug Reference Guide</strong></p>
    <p>Extracted from: Internal Medicine CRG, Nephrology, Rheumatology, and Infectious Disease Study Guides</p>
    <p>Version 1.0 | Created December 2024 | For educational purposes</p>
    <a href="#toc" class="back-to-top">‚Üë Back to Top</a>
</div>

</div><!-- end container -->

<script>
// Toggle category expand/collapse
function toggleCategory(header) {
    const content = header.nextElementSibling;
    header.classList.toggle('collapsed');
    content.classList.toggle('collapsed');
}

// Toggle individual drug card
function toggleDrug(header) {
    const body = header.nextElementSibling;
    const toggle = header.querySelector('.drug-toggle');
    body.classList.toggle('expanded');
    toggle.textContent = body.classList.contains('expanded') ? '‚ñº' : '‚ñ∂';
}

// Search functionality
document.addEventListener('DOMContentLoaded', function() {
    const searchInput = document.getElementById('drugSearch');
    const searchClear = document.getElementById('searchClear');
    const searchResults = document.getElementById('searchResults');
    const drugCards = document.querySelectorAll('.drug-card');
    const categories = document.querySelectorAll('.drug-category');
    
    searchInput.addEventListener('input', function() {
        const query = this.value.toLowerCase().trim();
        let visibleCount = 0;
        
        if (query === '') {
            // Show all
            drugCards.forEach(card => {
                card.classList.remove('hidden');
            });
            categories.forEach(cat => {
                cat.style.display = 'block';
            });
            searchClear.style.display = 'none';
            searchResults.textContent = '';
            return;
        }
        
        searchClear.style.display = 'flex';
        
        // Filter drugs
        drugCards.forEach(card => {
            const searchData = card.getAttribute('data-search') || '';
            const drugName = card.querySelector('.drug-name')?.textContent || '';
            const drugBrand = card.querySelector('.drug-brand')?.textContent || '';
            const fullText = (searchData + ' ' + drugName + ' ' + drugBrand).toLowerCase();
            
            if (fullText.includes(query)) {
                card.classList.remove('hidden');
                visibleCount++;
            } else {
                card.classList.add('hidden');
            }
        });
        
        // Hide categories with no visible drugs
        categories.forEach(cat => {
            const visibleDrugs = cat.querySelectorAll('.drug-card:not(.hidden)');
            if (visibleDrugs.length === 0) {
                cat.style.display = 'none';
            } else {
                cat.style.display = 'block';
                // Expand category if collapsed
                const header = cat.querySelector('.category-header');
                const content = cat.querySelector('.category-content');
                if (content.classList.contains('collapsed')) {
                    header.classList.remove('collapsed');
                    content.classList.remove('collapsed');
                }
            }
        });
        
        searchResults.textContent = `Found ${visibleCount} medications`;
    });
    
    searchClear.addEventListener('click', function() {
        searchInput.value = '';
        searchInput.dispatchEvent(new Event('input'));
        searchInput.focus();
    });
});

// Toggle navigation sections (specialty and category)
document.querySelectorAll('.nav-section .nav-title').forEach(title => {
    title.addEventListener('click', function() {
        this.parentElement.classList.toggle('collapsed');
    });
});
</script>

</body>
</html>
